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Thesis Summary 
It is well established that inflammation is associated with many non-communicable 
diseases and that when there is a failure in the resolution process acute inflammation 
becomes chronic with many undesired consequences. Treatment of chronic 
inflammation with pharmacological anti-inflammatory drugs can have detrimental 
effects on the body and can lead to an immunocompromised state. It is therefore 
prudent to consider whether other interventions can combat chronic inflammation. 
It is possible that omega-3 polyunsaturated fatty acids (w-3 PUFAs) eicosapentaenoic 
acid (EPA) and docosahexaenoic acid (DHA), high levels of which are found in fatty 
fish, can influence the inflammatory process in a beneficial way and promote the 
resolution of inflammation thus facilitating a return to homeostasis. The mechanisms 
through which this might be achieved are not fully understood but the answer may lie 
within the epigenetic changes that are provoked by the presence of the fatty acids in 
the diet. 
Epigenetics is a rapidly developing field of study which investigates heritable chemical 
modifications to the genome which are independent of the DNA sequence. These 
chemical changes are vital for normal cellular development, cellular processes, and 
cell-specific gene expression profiles; and if w-3 PUFAs (EPA and DHA) could 
influence them, they could provide a target for therapeutic interventions.  
Research to date has demonstrated that w-3 PUFA (EPA and DHA) supplementation 
is associated with changes to markers of inflammation and changes in gene 
expression. Few studies have researched the effect of dietary w-3 PUFA (EPA and 
DHA) supplementation on the epigenome and none have focused specifically on the 
inflammatory pathways associated with chronic inflammation in adult humans. The 
doctoral research reported in this thesis aims to elucidate the interaction between 
dietary fatty acids and the epigenome particularly as regards inflammation and its 
resolution. 
Focusing on one epigenetic marker, DNA methylation, this work has employed a 
hypothesis driven targeted approach with candidate genes selected after a review of 
relevant literature. Custom designed pyrosequencing assays were developed to 
  II 
facilitate the measurement of DNA methylation at specific cytosine bases in identified 
biologically relevant stretches of DNA.  
We performed a cross sectional study to investigate the relationship between 
methylation levels of the gene which encodes tumor necrosis factor alpha (TNFα), and 
levels of fatty acids within the blood. It was found that many of the fatty acids included 
in the study were not correlated with methylation levels of TNF but some significant 
correlations were discovered. By analysing the results by sex it was also discovered 
that some correlations are sex-specific. Specifically, for the males within the study, 
significant correlations were observed between TNF methylation and w-3 PUFA DHA, 
as well as w-6 PUFA arachidonic acid (AA).  
The relationship between blood fatty acid levels and DNA methylation of cytokine 
genes was further investigated using a four-week ω-3 PUFA (EPA and DHA) 
supplementation intervention. The genes included in this study were TNF, interleukin 
6 (IL6) and interleukin 1 beta (IL1B). Peripheral blood mononuclear cells were isolated 
from blood samples before and after supplementation and these were analysed for 
fatty acid levels in the cell membranes in order to explore the timeframe over which 
incorporation occurred. Despite seeing an increase in w-3 PUFAs EPA and DHA in 
PBMCs, there were no changes in methylation of the candidate genes over the 
intervention period and therefore postulated that this might be because an 
inflammatory stimulus was absent in this cohort of healthy males. 
In the final study of this thesis methylation of candidate genes at biologically relevant 
sites cytokines and RNA expression were measured before and after an inflammatory 
stimuli, and either side of  fatty acid supplementation. In this randomised double blind, 
repeated measures supplementation study the inflammation stimulus was provided by 
eccentric exercise and one group was supplemented with ω-3 PUFA (EPA and DHA) 
and the other with olive oil. Baseline measurements, made before the inflammatory 
stimulus or supplementation, showed that methylation levels of TNF were negatively 
associated with the expression of TNF mRNA, however there was no association with 
TNFα cytokine levels. There was a negative relationship between TNF and IL1B 
methylation levels at baseline. 
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The inflammatory stimulus induced a decrease in TNF and IL6 methylation levels and 
an increase of serum cytokines coded by these genes. In contrast, an increase in 
methylation in the measured region of IL1B was observed. The results clearly 
demonstrated the effect of a repeated bout of exercise in which decreased 
inflammation (cytokines and muscle damage markers) is observed after the second 
bout. There was no difference in the decrease as a consequence of the dietary 
supplementation.  
In conclusion it was found that as a result of the cross-sectional study, that some but 
not all fatty acids in the blood affect the methylation levels of certain CpG sites in 
exon1 of TNF. Positive and negative associations were observed, with many of the 
associations being sex specific. In the second study it was established that a four-
week period of dietary w-3 PUFA (EPA and DHA) supplementation does not 
significantly change the methylation levels of TNF, IL6 or IL1B and, in the final study, 
muscle damage was induced through eccentric exercise and this effected a transient 
epigenetic change, but that fatty acid supplementation had no significant effect over 
the period of the study. Although DNA methylation of TNF, IL6 and IL1B at the sites 
studied is not altered by a change in blood fatty acids over a short period this may not 
be the case over longer periods of intervention and this, together with exploration of 
the interaction with other environmental factors, such as muscle induced inflammatory 
stimulus, present opportunities for future research. 
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Chapter 1 Introduction  
1.1 The Human Genome Project and Epigenetics 
For many years it was commonly accepted that sequencing the human genome would 
establish the origins of numerous diseases and genetic disorders as well as providing 
a means for curing them. However this perception was not realised, because after 
years of research and billions of dollars of funding, the Human Genome Project 
provided the script for the human genome but not the great leap in understanding that 
was sometimes anticipated (Wade, 2010; Non and Thayer, 2015). This has led to there 
being many more questions than answers and the key to answering them may lie in 
the rapidly expanding fields of epigenetics and epigenomics.  
Epigenetics as a term was introduced in the 1940’s by Conrad Waddington 
(Waddington, 1942, reprinted in 2012). It originally referred to the study of how cells 
with the same genetic code could differentiate into the vast array of different cell types 
within an organism, connecting the genotype with the phenotype. Over time usage of 
the term has changed and today the field of epigenetics, which literally means “above 
genetics”, investigates chemical changes to DNA that do not alter the gene sequence 
itself (Holliday, 2006; Bernstein, Meissner and Lander, 2007; Huang, Jiang and Zhang, 
2014). Epigenetics focuses upon how and when chemical modifications alter a specific 
gene’s expression, whilst epigenomics considers the overall effect of many epigenetic 
changes throughout the whole genome (Fazzari and Greally, 2004). 
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Figure 1-1 Epigenetic chromatin modifications, reproduced with permission from Mukherjee, Twyman and Vilcinskas, (2015)  
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The chemical changes with which epigenetics concerns itself are illustrated in Figure 
1-1 and include DNA methylation, histone modifications, chromatin remodelling and 
non-coding ribonucleic acids (RNAs; Jenuwein, 2001; Bird, 2002; Goll and Bestor, 
2005; Mattick and Makunin, 2006; Barski et al., 2007; Berger, 2007; Kouzarides, 
2007). These epigenetic changes are vital for, and part of, normal cellular 
development, cellular processes, and cell-specific gene expression profiles 
(Bernstein, Meissner and Lander, 2007; Jones and Baylin, 2007). Epigenetic 
modifications of the DNA alter regulate transcription through changes in the 
accessibility of the gene’s transcriptional regions, such as the promotor (Liu, Jin and 
Zhou, 2015). The modifications alter the chromatin structure to either be open and 
accessible, or closed and condensed. The ability of a transcription factor to bind to a 
particular gene promotor is the culmination of epigenetic events including histone 
modifications, nucleosome position, nuclear localisation and DNA methylation status 
which allow for accessible chromatin (Liu, Jin and Zhou, 2015).  
Epigenetic modifications are often stable in adults and can pass from one generation 
to another (Reik, 2007), giving rise to the concept of epigenetic memory (D’Urso and 
Brickner, 2014). This epigenetic stability helps maintain cell identity and provides 
genomic integrity. However, epigenetic responses are not always stable; sometimes 
they are short-lived and are reversed allowing the cell to adapt to the environment 
(Ivashkiv, 2013). The majority of epigenetic modifications occur during development 
(Santos and Dean, 2004), during this period it is essential for mammalian development 
(Smith and Meissner, 2013). After fertilisation of the egg, the DNA methylation of the 
paternal genome after fertilisation is rapidly demethylated, followed by a passive 
demethylated of the maternal genome, this occurs prior to the methylation being re-
written in order to assist in cell-linage decisions (Smallwood and Kelsey, 2012). There 
are exceptions of these epigenetic changes during development, which do not 
demonstrate the same demethylation, these are imprinted genes; these genes are 
expressed from either the maternal or paternal allele and maintain their DNA 
methylation status during the epigenetic reprogramming of early development.  
Through epigenetic modifications of the genome allow the cell to adapt and respond 
to the environment, however sometimes the changes are not beneficial, and such 
changes, together with errors in epigenetic modifications can result in disease (Portela 
  23 
and Esteller, 2010; Park, Friso and Choi, 2012; Brunet and Berger, 2014; Benayoun, 
Pollina and Brunet, 2015). In such cases an understanding of the aberrant epigenetic 
changes and its causes can provide a target for therapeutic interventions (Lu et al., 
2006; Kelly, De Carvalho and Jones, 2010).  
Much of the current understanding of the regulation of gene expression comes from 
studies of DNA methylation, which is an important epigenetic marker for regulation of 
gene expression (Morgan et al., 2017). It has been shown that gene methylation levels 
are implicated in disease and inflammation (Jin and Liu, 2018). Measurement of 
methylation levels is relatively easy and small changes to status over relatively short 
sections of DNA can have a big impact upon gene expression (Piperi et al., 2008). 
The fact that DNA methylation is such a widespread epigenetic modification, the 
impact varying levels of methylation have on gene expression and the ability to 
accurately measure those levels, combine to make methylation analysis such an 
important research tool and it is the one that is utilised in this research. 
In recent years there has been an exponential increase in epigenetic research and 
knowledge, and as a consequence the interactions between diverse environmental 
factors are beginning to be pieced together, the genome and the epigenome to provide 
some understanding of the potential implications for health and disease (Bollati and 
Baccarelli, 2010; Muka et al., 2016). One such key environmental factor to which 
humans are exposed from pre-conception to death is nutrition, which before birth is 
provided by the mother, and afterwards by diet.  
1.2 The diet and nutri-epigenomics 
Nutri-epigenomics seeks to delineate the interactions between the diet and the 
genome through epigenetic mechanisms (Anderson, Sant and Dolinoy, 2012; Zhang, 
2015). The ability of the epigenome to adapt to environmental factors, including diet, 
is referred to as “plasticity” and this alters across the lifespan of an organism (Gallou-
Kabani et al., 2007). Thus, there are periods during which the epigenome is more 
responsive to change (Kanherkar, Bhatia-dey and Csoka, 2014), for example 
increased plasticity occurs in pre-natal and neonatal phases (Reik, 2007; Foley et al., 
2008), when cell differentiation and specialisation is taking place. Environmental 
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factors, such as nutrition, therefore have more influence during these periods of 
development (Gluckman et al., 2008). Sometimes the epigenetic consequences can 
be quite dramatic, for example when genetically identical larvae of the honeybee are 
fed royal jelly, the DNA methylation patterns are altered, resulting in differentiation into 
a Queen bee rather than a worker bee (Kucharski et al., 2008). In mammals, 
malnutrition of methyl donors vitamin B12 and choline during gestation can lead to 
epigenetic dysregulation within the offspring, giving rise to obesity and influencing 
disease in later life (Waterland and Jirtle, 2003). 
The Developmental Origins of Health and Disease hypothesis explains how 
abnormalities within the developmental environment can affect the epigenome and 
lead to metabolic disease later in life (Gluckman and Hanson, 2004a). It is understood, 
for example, that maternal stress (Oberlander et al., 2008), birth weight (Burdge, 
Lillycrop and Jackson, 2009) and foetal malnutrition (Steegers-Theunissen et al., 
2009) can all impact upon the developmental environment, and that the consequential 
modifications to the epigenome can endure throughout the lifespan and that some are 
even passed onto future generations (Burdge et al., 2007). Key nutrients can protect 
against the detrimental effect of other environmental factors; for example, it has been 
shown that supplementation with omega-3 (ω-3) fatty acids eicosapentaenoic acid 
(EPA) and docosahexaenoic acid (DHA) during gestation has a protective effect 
against demethylation caused by the negative behaviour of smoking during pregnancy 
(Lee et al., 2013). 
Since the epigenome is especially responsive to change during gestation, the 
provision of a favourable developmental environment, including maternal diet, should 
be beneficial to the wellbeing of offspring and future generations. However, if diet in 
early life has an epigenetic consequence then it is reasonable to conclude that  diet in 
general, i.e. throughout a person’s lifespan, could also have such consequences. This 
is an important consideration because aberrant alterations to epigenetic regulation are 
implicated in many chronic diseases including cancer, chronic obstructive pulmonary 
disease, cardiovascular disease (CVD), obesity, neurological disorders, and type 2 
diabetes, to name a few (Portela and Esteller, 2010; Park, Friso and Choi, 2012; 
Brunet and Berger, 2014; Benayoun, Pollina and Brunet, 2015). If it can be determined 
whether, and to what extent, diet is involved in the epigenetic changes that are 
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associated with these diseases would it be possible to develop an “epigenetically 
healthy” diet to reduce their negative impact? 
Convincing individuals to maintain an “epigenetically healthy diet” in order to benefit 
their long-term health and that of their children and grandchildren might not be easily 
achieved for many reasons, one of which is that long term lifestyle changes do not 
offer an individual an immediate beneficial effect. However the epigenetic changes 
brought about by royal jelly in the honeybee larvae are an example of when even short 
term changes to diet can have significant consequence, therefore research into the 
short-term effects of diet on the epigenome may present opportunities which 
individuals would find attractive and to which they may be persuaded to adopt, 
particularly if it could be demonstrated that they would personally benefit. 
Personalised medicine and interventions are increasingly commonplace and seen as 
a way to both improve health care and lower costs (Vogenberg, Isaacson Barash and 
Pursel, 2010). For example, pharmacogenomics uses the genome of an individual in 
order to establish if they are responders or non-responders to particular drugs and to 
establish what dosage is appropriate (NIH, 2018). There has also been an increase in 
the use of genetic testing to identify targeted populations and interventions that will 
reduce the burden of disease in later life (The Academy of Medical Sciences, 2015). 
Consequently, there is building evidence to suggest that epigenetic signatures could 
also be used to personalise interventions and predict response status (Campión et al., 
2009).  
As research reveals more information about changes in the epigenome, it provides 
new therapeutic targets for interventions. Drugs have been developed to target 
epigenetic regulating enzymes, such as DNA methyltransferases (DNMT), histone 
deacetylase (HDAC) and histone acetyltransferase (HAT) inhibitors in order to reverse 
the changes to the epigenome. There is huge potential for epigenetic drugs, as 
discussed in Clinical Epigenetics (Altucci and Rots, 2016), however, there is a long 
way to go before the impact of such drugs is truly understood, particularly as regards 
the wider alterations to the epigenome. Perhaps nutritional interventions or dietary 
supplementation could provide a safer and more cost-effective approach to prevent or 
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reset aberrant epigenetic changes by influencing the natural epigenetic programming 
within cells. 
Whilst nutritional interventions may be seen as less invasive and safer than ‘epigenetic 
drugs’, it is still important to understand how they work and whether they really do 
provide the benefits that are frequently suggested. This means that interactions at a 
molecular level need to be fully understood so that their full consequences can be 
understood, and future research can determine how a rewarding benefit for public 
health can be achieved.  
1.3 Scope of this research 
There has been increasing evidence on the health benefits of fish oil supplements. 
The ‘active ingredients’ of fish oil supplements are the w-3 fatty acids EPA and DHA 
(Calder, 2008, 2012a). This thesis aims to consider the interactions between w-3 fatty 
acids and DNA methylation in order to understand how w-3 fatty acids alter cytokine 
gene expression and provide a greater understanding of fatty acid involvement in 
inflammation.   
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Chapter 2 Background and Literature Review 
2.1 What is inflammation? 
Inflammation has been recognised since the 1st century AD when Cornelius Celsus 
documented four main signs associated with it; redness, swelling, heat and pain 
(Rocha e Silva, 1978). Since the middle of the 20th century, there has been increased 
research into the inflammatory process leading to our current understanding that these 
clinical signs are the manifestation of a complex cascade of events which can be 
considered at molecular, cellular and physiological levels (Scott, 2004).  
This research is concerned with acute inflammation arising from induced damage to 
muscles and whether the inflammatory response can be influenced by the dietary 
intake of ω-3 PUFAs. It is therefore appropriate to discuss the process of inflammation 
at molecular and cellular levels since this informs the decisions made here regarding 
measurement of the induced inflammatory response. Thus, the following explanation 
seeks to provide background to the type of inflammatory response that this study is 
concerned with and does not consider inflammation mechanisms specific to immune 
related disorders. 
Acute inflammation is the initial response to various types of trauma, one of which is 
mechanical loading (Scott, 2004). The inflammatory response is mediated and 
regulated by the interactions of many cell types for example monocytes, 
macrophages and lymphocytes. During an acute inflammatory response, chemical 
mediators are released from activated cells and trigger the inflammatory response, 
these chemical mediators include cytokines, chemokines, eicosanoids and reactive 
oxygen species. As an example, monocytes within the circulation are surveillance 
and antigen presenting cells which give rise to macrophages when entering tissue. 
When responding to a stimulus, activated monocytes and macrophages are a source 
of eicosanoids, and a variety of cytokines including IL6, TNFa and IL1b. These 
proinflammatory cytokines and chemokines activate macrophages and neutrophils 
which in turn activate leukocytes to infiltrate the site of the trauma and attract 
neutrophils to the site through a chemotaxis gradient.  
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The acute inflammatory response is self-regulating through the activation of negative 
feedback mechanisms. However, when this tightly controlled process becomes 
unregulated this can result in chronic, systemic inflammation characterised by 
activated inflammatory cells and elevated inflammatory markers. There are increased 
concentrations of inflammatory cytokines such as IL6, TNFa and IL1b, which can 
cause damage to tissues throughout the body. Chronic diseases such as rheumatoid 
arthritis and inflammatory bowel disease are key examples of when this happens.  
Fatty acids play key roles within the inflammatory process. These roles include direct 
action through fatty acid receptors on the cell surface and within the cell, incorporation 
into the cell membrane and as precursors to other molecules including eicosanoids 
and prostaglandins. The interactions between fatty acids and the inflammatory 
process are discussed in more detail below, however first we must understand what 
fatty acids are. 
2.2 What are fatty acids? 
Whilst a full consideration of what fatty acids are, their properties and chemistry is 
beyond the scope of this thesis a basic understanding of what these molecules are 
will help put this research in context. 
Fatty acids are amphipathic small molecules which are formed by a hydrocarbon chain 
that has a methyl group at one end and a carboxylic acid group at the other (Fahy et 
al., 2005; Rustan and Drevon, 2005). Alterations in the length and structure of the 
hydrocarbon chain results in the different types of fatty acids which have varying 
properties (Gunstone, 1996).  
When the hydrocarbon chain (“backbone”) of a fatty acid does not contain any double 
bonds the carbon atoms are fully saturated with hydrogen it is known as a saturated 
fatty acid (SFA). Saturated fatty acids have the general formula CH3(CH2)nCOOH. For 
example, steric acid (also known as Octadecanoic acid) is a long chain SFA found as 
a major component in cocoa butter and has the formula CH3(CH2)16COOH, illustrated 
in Figure 2-1. 
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Figure 2-1 Chemical structure of Stearic acid, a saturated fatty acid (SFA) 
 
SFAs are relatively stable, have a lower reactivity, and their melting points tend to be 
higher than the more complicated fatty acids discussed below which include one or 
more double bonds in the carbon backbone. See Table 2-1. They are therefore 
relatively inert, and those with longer carbon backbones are oxidised at a slower rate 
than those with shorter chains (Leyton, Drury and Crawford, 1987). For example lauric 
acid, a 12 carbon saturated fatty acid more highly oxidised than the 18 carbon long 
stearic acid (DeLany et al., 2000). 
Table 2-1 Melting points of saturated fatty acids, data from Lide (2007) 
  Number of carbons Melting point (°C) 
13:0 (Tridecanoic acid) 13 41.5 
14:0 (Myristic acid) 14 54.2 
15:0 (Pentadecanoic acid) 15 52.3 
16:0 (Palmitic acid) 16 62.5 
18:0 (Stearic acid) 18 69.3 
20:0 (Arachidic acid) 20 76.5 
21:0 (Heneicosylic acid) 21 73.5 
22:0 (Behenic acid) 22 81.5 
When the hydrocarbon backbone includes a single double bond, a kink in the chain is 
formed. A fatty acid which includes such a double bond is known as a 
monounsaturated fatty acid (MUFA). Monounsaturated fatty acids have the general 
formula CH3(CH2)n–CH=CH–(CH2)n–COOH. The length of the carbon chain and the 
position of the double bond vary between different MUFAs. There are two orientations 
of the functional groups around the double bond. When the functional groups are on 
the same side of the double bond the molecule has a cis formation, and when they 
are on opposite sides the molecule has a trans formation. Oleic acid (also known as 
Cis-9-Octadecenoic acid) is a MUFA having the formula 
CH3(CH2)7CH=CH(CH2)7COOH, illustrated in Figure 2-2. The double bond causes 
MUFAs to have a lower melting point than SFAs, which is further reduced when the 
double bond is in the cis formation as opposed to the trans form (Gunstone, 1996).  
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Figure 2-2 Chemical structure of Oleic acid, an omega-9 monounsaturated fatty acid 
(w-9 MUFA) 
The addition of further double bonds to the hydrocarbon backbone results in 
polyunsaturated fatty acids (PUFAs). The location of the first double bond from the 
methyl end of the chain in both MUFAs and PUFAs leads to their designation by 
omega (ω) number. Naturally occurring fatty acids are generally in the cis orientation 
and typically the first double bond is positioned at the third (ω-3), sixth (ω-6) or ninth 
(ω-9) carbon from the methyl end of the hydrocarbon chain (Ratnayake and Galli, 
2009). The ω-3 PUFA EPA and the ω-3 PUFA DHA, both of which are constituents of 
fish oil dietary supplements, are illustrated in Figure 2-3. Eicosapentaenoic acid has a 
20-carbon atom chain and 5 cis double bonds. Docosahexaenoic acid has a 22-carbon 
atom chain and 6 cis double bonds.  
A)  B)
   
Figure 2-3 Chemical structure of A) eicosapentaenoic acid (EPA) and B) 
docosahexaenoic acid (DHA), omega-3 polyunsaturated fatty acids (w-3 
PUFA) found in fish oil supplements. 
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2.2.1 Biological significance of fatty acids: focus on PUFAs 
Fatty acids play key roles within the body, including: energy transport and storage, 
components of cell membranes, thermal, electrical and mechanical insulation, and 
assisting in cell signalling (e.g. lipid mediators and gene regulation; Arab, 2003; 
Rustan and Drevon, 2005; Ratnayake and Galli, 2009).  
Many of the biologically important fatty acids can be synthesised within the body but 
this is not universally true, and some must form part of an individual’s diet, and are 
designated as essential dietary fatty acids. Dietary fatty acids were first found to be 
essential to health in the late 1920’s when it was demonstrated that feeding a rat a fat-
deficient diet led to disease and ultimately to their death. However the addition of a 
few drops of fat to a diseased rats diet returned it to health (Burr and Burr, 1929). 
Further research by Burr & Burr (1930) demonstrated that it was two unsaturated fatty 
acids, ω-6 PUFA linoleic acid (LA) and ω-3 PUFA alpha-linolenic acid (ALA), that are 
essential to mammals in their diet. It transpires that mammals are unable to synthesise 
these two fatty acids because they lack the enzymes 12-desaturase and 15-
desaturase required to desaturate fatty acids at the ω-3 and the ω-6 positions, 
whereas plants do have these enzymes (Calder, 2004). Therefore, mammals rely on 
these essential fatty acids to have entered the food chain from plants. The ω-6 PUFA 
LA is in fact the most abundant of the PUFAs within the human diet (Calder and 
Grimble, 2002), and is found in vegetable oils including, for example sunflower oil, 
corn oil and soybean oil. Comparatively, dietary ω-3 PUFA ALA, which is found for 
example in flaxseed, soybeans and walnuts, is 5-10 fold less abundant (Mozaffarian, 
2012). 
The relative abundance, i.e. the ratio of ω-6 LA:ω-3 ALA, in the diet is of interest 
because this research is concerned with genes associated with the inflammatory 
response. Omega-3 fatty acids have been shown to be associated with an anti-
inflammatory (pro-resolving) response, whilst ω-6 fatty acids have been shown to be 
associated with an inflammatory response (pro-inflammatory; Calder, 2012). It is also 
worth noting at this point that human beings evolved on a diet containing a ω-6:ω-3 
ratio of approximately 1:1 (Simopoulos, 2006), whereas today’s western diet contains 
a ratio of LA:ALA that varies across Europe ranging from 1:4.3 in females from 
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Denmark to 1:28.8 in males from the Netherlands (Burdge and Calder, 2005). Thus, 
human beings evolved with a diet in which pro-inflammatory and pro-resolving fatty 
acids were in balance, but humans now consume a diet in which pro-inflammatory ω-
6 fatty acids predominate (Simopoulos, 2009). The human diet has therefore changed 
remarkably from that consumed over the evolutionary period and now there is also 
considerable variation in the consumption of essential fatty acids according to the 
geographic location of the consumer. 
The dietary importance of the essential fatty acids LA and ALA arises because they 
are precursors to longer highly unsaturated and biologically relevant PUFAs, their 
metabolism is depicted in Figure 2-4. Firstly, the w-6 PUFA arachidonic acid (AA) and 
the w-3 PUFA eicosapentaenoic acid (EPA) are synthesised from LA and ALA 
respectively. EPA is further elongated to form DPA and then further desaturated to 
form DHA. 
Although EPA and DHA are not essential fatty acids in the diet because the body can 
convert ALA to them, the conversion process is poor and the major source of EPA and 
DHA comes from the diet (Plourde and Cunnane, 2007). The inability of the body to 
efficiently synthesis these “conditionally” essential fatty acids and the consequential 
reliance on dietary intake, means that dietary choices can alter the availability of these 
acids in the body (Plourde and Cunnane, 2007). 
Elongation of the fatty acid carbon chain is achieved by fatty acid enlongases and 
desaturation with the insertion of double bonds by Δ6-desaturase and Δ5-desaturase 
(Benatti et al., 2004). The Δ6-desaturase and Δ5-desaturase enzymes are encoded 
by the genes FADS2 “fatty acid desaturase 2” and FADS1 “fatty acid desaturase 1” 
respectively. The steps in the fatty acid metabolic pathway that these enzymes 
catalyse are rate limiting (Marquardt et al., 2000; Nakamura and Nara, 2004). In 
addition, both in vivo and in vitro studies have shown that LA and ALA compete within 
the same pathway for the Δ6-desaturase, with the ω-3 PUFA ALA suppressing the ω-
6-PUFA metabolism (Mohrhauer et al., 1967; Holman, 1998; Jump and Clarke, 1999). 
The endogenous process of desaturation and elongation of the ω-6 and ω-3 PUFAs 
occurs predominantly in the liver, but also in other tissues (Hughes and Dhiman, 
2002).   
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Figure 2-4 Omega 3 and Omega 6 Polyunsaturated Fatty Acid metabolism. The Δ6-
desaturase and Δ5-desaturase enzymes are encoded by the genes FADS2 
“fatty acid desaturase 2” and FADS1 “fatty acid desaturase 1”. Eicosanoids 
and Docosanoids are key mediators and regulators of inflammation. Figure 
adapted from Glaser, Heinrich and Koletzko (2010). 
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Prior to the ground-breaking work of Burr and Burr in the early 20th Century, it was 
thought that fatty acids were just a source of calorific energy and thus interchangeable 
with carbohydrates (Smith and Mukhopadhyay, 2012). Whilst it is true that fatty acids 
do provide an important source of energy, which can be stored in adipose tissue and 
skeletal muscle, and which can be transported around the body in the blood, it is now 
known that they also have important and sometimes complex roles (Rustan and 
Drevon, 2005). The work carried out by the Burrs’ demonstrated that linolenic acid 
played a physiological role in rats (Burr and Burr, 1929, 1930)  and later work, such 
as that of Holman, demonstrated that it also plays a physiological role in humans 
(Holman, Johnson and Hatch, 1982). Indeed, the work of Holman showed that in 
humans a deficiency of linolenic acid had wide ranging debilitating effects, including 
numbness, paresthesia, weakness, inability to walk, pain in the legs and blurring of 
vision.  
The wide-ranging effects observed by Holman reflect the varied and complex roles 
that fatty acids play in the body. Over time the biological significance of fatty acids and 
the way in which they act has been the subject of a considerable amount of research. 
For example, the skin abnormalities observed in the rats studied by the Burr’s have 
been the subject of further research and the mechanisms for these observations have 
now been proposed; one example is the enzymic oxygenation of ceramides which aid 
in the function of the epidermal barrier (Zheng et al., 2011). Fatty acids have also been 
found to influence diseases, sa demonstrated by the long chain ω-3 PUFA’s influence 
on susecptibilty to cardiovascular disease through the beneficial influence of a range 
of risk factors associated with atherosclerosis, including a reduced production of 
inflammatory eicosanoids (Calder, 2004). Further evidence includes the cytoprotective 
capacity of long chain ω-3 PUFA’s contribute to anti-angiogenic and neuroprotective 
mechanisms within the eye (SanGiovanni and Chew, 2005). The pro-physiological 
effect of ω-3 fatty acids has also been studied in relation to cancer and chronic illness 
(Colomer et al., 2007). However, the physiological importance of fatty acids does not 
just extend to beneficial instances, since, for example, chronically elevated levels of 
plasma free fatty acids have adverse consequences and have been linked with the 
onset of peripheral and hepatic insulin resistance (Oh et al., 2018; Spiller, Blüher and 
Hoffmann, 2018).  
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Fatty acids are major structural components of cells membranes, which are primarily 
formed from glycerophospholipids (commonly referred to as phospholipids) such as 
diacylglycerol and phosphatidic acid. Phospholipids are composed of a glycerol head 
and fatty acid backbone (Ratnayake and Galli, 2009). It is the amphipathic nature of 
these phospholipids which allow them to form cell membranes. Furthermore, the 
physical nature of the membrane is altered by the type of fatty acid that is incorporated 
into it (Stubbs and Smith, 1984). For example, if the proportion of unsaturated fatty 
acid incorporated within the cell membrane is increased, the fluidity of the membrane 
is itself increased (Abbott et al., 2012). The type of fatty acid incorporated in the 
membrane also affects the lipid-protein interactions and the function of the membrane 
(Singer and Nicolson, 1972). Fatty acids, such as ω-3 PUFAs alter the composition of 
the membrane by increasing clustering of lipids rafts, resulting in the formation of large 
raft domains (Turk and Chapkin, 2013). Large lipid rafts can suppress the cell 
activation by impairing cell signalling (Chapkin et al., 2008; Kim et al., 2008), ultimately 
affecting cell function through suppression of downstream pathways, for examples 
those involved in inflammation. 
While dietary SFAs have very little influence on cell membrane SFA content, as shown 
in rats; increasing the amount of dietary ω-3 PUFAs in the diet has been shown to 
increase the amounts of both ω-3 PUFAs EPA and DHA in the membrane 
phospholipids of both rats and humans (Yaqoob et al., 2000; Kew et al., 2004; Abbott 
et al., 2012). Assessment of the ω-3 PUFA incorporation into red blood cells (RBCs) 
(Al-Hilai et al., 2013; Amarasekera et al., 2014; Albert et al., 2015; Lind et al., 2015) 
or plasma (Bouwens et al., 2009; Block et al., 2013; Abdolahi et al., 2014; Augustine 
et al., 2014) are therefore used to assess dietary PUFA intake. Foods rich in ω-3 
PUFAs, such as salmon, leads to increased incorporation and modification of the cell 
phospholipid membrane (Raatz et al., 2016). Displacement of the ω-6 PUFA AA form 
the membrane by ω-3 PUFAs EPA and DHA (Calder, 2015), occurs in a dose-
dependent response manner (Trebble et al., 2003). The composition of the cell 
membrane is altered in different ways by EPA and DHA separately (Mason et al., 
2016) and incorporation into the membrane can be modulated by genetic factors, for 
example a variant in the FADS1 gene (Takkunen et al., 2016).  
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Once in the cell membrane, EPA and DHA compete with AA to be metabolised to lipid 
derived mediators, by cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome 
P monooxygenases 450 (CYP450; Arita, 2012; Wang et al., 2012). Compared to the 
eicosanoids derived from the ω-6 PUFA AA which are potent inflammatory mediators, 
those derived from the ω-3 PUFAs are more anti-inflammatory in nature. Genetic 
polymorphisms COX and LOX genes have been linked to cancer, Alzheimer disease 
and myocardial infarction (Zhang et al., 2015; Mashima and Okuyama, 2015) and are 
linked to the activity of the lipid mediator pathways (Tyurina et al., 2014).  
It is now understood that many different fatty acids are involved in a whole range of 
physiological processes and that their consumption, metabolism and synthesis are 
critical to life (Rustan and Drevon, 2005). Their involvement is now known to extend 
well beyond the traditionally understood role of providing a source of energy and the 
roles of fatty acids are of significant throughout the body and influence both health and 
disease. 
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2.3 PUFAs, disease and inflammation 
The composition of fats within the diet has previously been scrutinised for their health 
benefits (Calder, 2006; Ruxton et al., 2007; Khorsan et al., 2014; Elagizi et al., 2018). 
Populations with a diet rich in ω-3 PUFAs EPA and DHA have been shown to have a 
lower incidence of chronic non-communicable diseases (Simopoulos, 1999). The 
Mediterranean Diet for example, high in PUFAs and MUFAs, has been demonstrated 
to have beneficial effects on individuals with cardiovascular disease (CVD) by 
reducing the associated risk factors in comparison to the levels associated with a low-
fat diet (Estruch et al., 2006). 
Considerable research has been undertaken in an attempt to establish whether it is  
the dietary ω-6 LA:ω-3 ALA ratio that has an impact upon disease manifestation in 
humans. Simopoulos (2002) concluded that a lower ratio reduced the risk of many 
chronic diseases. However, a cross-sectional study completed as part of the Tehran 
lipid and glucose study in Iran concluded that there was no association between the 
dietary ω-6/ω-3 PUFA ratio and metabolic syndrome (MetS; Mirmiran et al., 2012).  
Other researchers have found that intake of ω-6 PUFAs did not influence the beneficial 
effect of increased ω-3 PUFAs intake on the risk of CVD and chronic heart disease 
(CHD; Mozaffarian et al., 2005; Fontes et al., 2015). Mirmiran et al. (2012) found an 
inverse association between both ω-3 PUFA ALA and ω-6 PUFAs with MetS, the 
highest consumptions having lowest prevalence. In this study, no significant 
associations were found however between ω-3 EPA or ω-3 DHA and MetS. However, 
dietary intake of the ω-6 and ω-3 PUFAs was assessed using a food-frequency 
questionnaire (FFQ). This approach to data collection is inherently flawed because 
they rely on subject recall and it is difficult to achieve quantifiably precise records and 
they are not suitable when seeking to establish epigenetic relationships in detail. 
Evidence that ω-3 PUFAs, such as EPA and DHA, can modulate inflammation has 
come from in vitro work (Endres et al., 1989; Trebble et al., 2003; Verlengia et al., 
2004), animal models (Yaqoob and Calder, 1995; Al-Khalifa et al., 2012; Olson et al., 
2013; Richard et al., 2016) and human studies (Endres et al., 1989; Tartibian, Maleki 
and Abbasi, 2011; Itariu et al., 2012); although the latter evidence is weaker as a 
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consequence of more complex environmental factors. The mechanisms through which 
ω-3 PUFAs promote an anti-inflammatory environment within the body are 
multifaceted and complex (Calder, 2015), and are illustrated in Figure 2-5.  
Inflammatory diseases are often characterised with chronic activation of NFkB 
pathway (Lawrence, 2009). In its inactive form, NFkB is stored in the cytoplasm 
covalently bonded to its inhibitory subunit IkB (Jacobs and Harrison, 1998). After 
activation, IkB is phosphorylated by IKKs and this allows for the translocation of NFkB 
to the nucleus (Israel, 2010). ω-3 PUFAs have been shown reduce activation of NFkB 
by multiple mechanisms. Ligand bound PPARy can interact with NFkB by preventing 
its translocation to the nucleus (Calder, 2012b). EPA has also been shown to inhibit 
the translocation of NFkB subunits to the nucleus directly. Zhao et al., (2004) showed 
THP-1 cells treated with EPA had decreased translocation of the p65 subunit to the 
nucleus following LPS stimulation; pre-stimulation with EPA did not alter cytoplasm 
p65 and p50 content. EPA treatment resulted in lower NFkB activity after LPS 
stimulation and reduced TNFα mRNA expression and cytokine production (Zhao et 
al., 2004). EPA treatment also supressed the phosphorylation of IkB-a in the 
cytoplasm, indicating that degradation of IkB-a and translocation of NFkB to the 
nucleus may be prevented by EPA through decreased phosphorylation of IkBa. 
Reduced activation of NFkB by ω-3 PUFAs in response to inflammation ultimately 
results in reduced expression of its target genes, such as cytokines. Treatment in vivo 
with EPA and DHA can modulate the expression of multiple inflammatory genes within 
the NFkB pathway (Allam-Ndoul et al., 2016). In vitro models have demonstrated that 
treatment with EPA and/or DHA reduces cytokine production after stimulation with 
LPS.  
Treatment of cells ex vivo with an inflammatory stimulus, for example LPS, and 
measurement cytokine production, can be used to measure the effect of in vivo 
supplementation with ω-3 PUFAs on the inflammatory response. Decreased 
production of TNFa, TNFR2, IL6, IL-1b, IL2, IFNg and CRP have been observed when 
cells are stimulated ex vivo after ω-3 PUFA supplementation (Verlengia et al., 2004). 
Some studies have examined the effect of EPA and DHA separately, DHA is shown 
to have a greater inhibitory effect on TNFa, IL-1b IL6, (Weldon et al., 2007). Gene 
expression for TNFa, IL1b and IL6 were measured and were consistent with the 
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cytokine data (Weldon et al., 2007). Whereas, EPA decreases production of IL2 and 
IFNg to a greater extent than DHA (Verlengia et al., 2004). The dosage of 
supplementation has also been shown to have an effect; three doses of ω-3 PUFAs 
over 12 weeks in males resulted in a 'U-shaped' dose-response curve with maximum 
inhibitory effects TNFα and IL6 production at 1g/day compared to the 0.3 and 2g/day 
(Trebble et al., 2003). 
Modulation of inflammatory gene expression also occurs through transcription factors. 
Once the ω-3 PUFAs are incorporated in the cell membrane they can be released into 
the cell and can interact with these transcription factors, such as PPAR, in the 
regulation of gene expression. Activation of PPAR occurs when ligands, including ω-
3 PUFAs and eicosanoids, are non-covalently bonded to them. PPARg and PPARa 
are the most understood of the PPAR isoforms (Tyagi et al., 2011). Of interest here, 
PPARg is expressed in inflammatory cells and has an anti-inflammatory action. In a 
cancer cell line, treatment with EPA and DHA have shown to increase expression of 
PPARg (Rovito et al., 2013). DHA interacts with PPARg resulting in reduced cytokine 
production after stimulation (Li et al., 2005). PPARg is also involved in regulating 
metabolism in adipocytes with downstream effects promoting insulin sensitivity and 
blood triglyceride concentrations (Poynter and Daynes, 1998; Dunning et al., 2014; 
Chiazza and Collino, 2016). Expression of PPARg is modulated by DNA methylation 
within its promotor (Fujiki et al., 2009). In a case-control study of T2DM patients, DNA 
methylation was significantly different in genes involved in inflammation, among other 
pathways; differential methylation was also shown in T2DM candidate genes, 
including PPARG (Nilsson et al., 2014). 
Alterations to the fluidity of the cell membrane, through changes in fatty acid 
composition, has an impact on the function of proteins within the membrane, cell 
signalling and gene expression. Specific genes have been found to be differentially 
expressed by alterations in ω-3 PUFA levels. The membrane glycoprotein which 
promotes inflammation in monocytes and macrophages, CD36 “cluster of 
differentiation 36”, has been found to be differentially expressed as the result of ω-3 
PUFA supplementation. CD36 is a membrane glycoprotein expressed on the surface 
of many cells that are active in fatty acid metabolism, such as adipocytes, muscle cells, 
platelets, monocytes, heart and intestine cells (Kuriki et al., 2002). The CD36 protein 
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functions include the uptake of long-chain PUFAs, regulation of angiogenesis, 
scavenger in innate immunity, and has a key role in foam cell formation (Febbraio, 
Hajjar and Silverstein, 2001). In human skeletal muscle and macrophages, high levels 
of CD36 have been correlated with insulin resistance (Bonen et al., 2004; Liang et al., 
2004). However, this correlation may be due to the up-regulation of CD36 that occurs 
in response to high fat feeding (Greenwalt, Scheck and Rhinehart-Jones, 1995) and 
diabetes (Greenwalt, Scheck and Rhinehart-Jones, 1995; Van Nieuwenhoven, Van 
der Vusse and Glatz, 1996) as a consequence of the increase fatty acid utilisation, 
demonstrated in cell culture with long-chain fatty acid treatment (Sfeir et al., 1997). 
In a rat model of MetS using spontaneously hypertensive rats (SH-rats), in which 
expression levels of CD36 are undetectable in adipocyte plasma membranes, a diet 
rich in ω-3 PUFAs was shown to increase CD36 mRNA expression to comparable 
levels to those of Kyoto-Wistar rats (KW-rats) on a control diet (Alexander Aguilera et 
al., 2006). Metabolic parameters of the SH-rats were increased compared to the KW-
rats prior to diet changes; they had increased blood pressure, serum insulin, FFAs and 
triglyceride levels. After the diet intervention, the SH-rats fed ω-3 PUFAs had 
significantly lower serum insulin, FFAs, triglycerides, total cholesterol, HDL, LDL, and 
total lipids than the SH-rats on a canola-corn control diet, giving a metabolic profile 
similar to the KW-rats. Serum glucose measurements were not found to be different 
across the three groups. This study is an example of one gene which has altered 
expression levels following the addition of ω-3 PUFA to the diet.  
Agreement with these results has been shown in cell culture, increased CD36 mRNA 
expression as the result of separate EPA and DHA treatment has also been shown in 
THP-1 macrophages, in a dose-dependent manner (Vallvé et al., 2002). However, 
when expression of CD36 was measured by assessing mRNA levels in PBMCs 
isolated from healthy human males and females who’s diet had been supplemented 
with combined EPA (1.8g/day) and DHA (0.4g/day) for 26 weeks; a decrease in CD36 
mRNA expression was observed (Bouwens et al., 2009). Using a micro-array, the 
expression of 900 genes uniquely changed as a result of the ω-3 PUFA 
supplementation compared to a placebo. A decrease in expression of genes involved 
in inflammatory pathways was observed. However, no changes in plasma C-Reactive 
protein (CPR), a measure of inflammation, were seen in this cohort and no other 
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measures of inflammation were investigated. The study also found a decrease in the 
expression of PDK4, LTA4H, ADFP, CD14 and HIF1a (Bouwens et al., 2009).  
Another cell membrane bound protein important in the anti-inflammatory effects of ω-
3 PUFAs is G-Protein-Coupled receptor 120 (GPR120). GPR120 functions as a 
receptor for unsaturated long chain free fatty acids. EPA and DHA have been found 
to exert their potent anti-inflammatory effects through GPR120 (Oh et al., 2010). It was 
shown that GPR120 knockout mice did not show inhibition of inflammation from ω-3  
supplementation, whereas the wild-type mice had reduced inflammation and 
enhanced insulin sensitivity as a result of the supplementation. Two non-synonymous 
variants of GPR120 have been found to be associated with diabetes; Ichimura et al. 
(2012) also found that in GPR120 knockout mice fed on a high fat diet showed 
increased body weight compared to the wild-type mice fed on the same diet. 
Evidence suggests that one of the ways in which ω-3 PUFAs exert these effects is 
through changes in gene expression as a result of varied transcription factor activation 
(Bouwens et al., 2009; Rudkowska et al., 2013), however, they may also be a 
consequence of changes in epigenetic mechanisms, such as DNA methylation. 
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Figure 2-5 Mechanisms Omega 3 polyunsaturated fatty acids (ω-3 PUFAs) action to promote an anti-inflammatory environment. G-coupled protein 
receptor 120 (GPR120); nuclear factor kappa B (NFkB); omega 6 polyunsaturated fatty acids (ω-6 PUFAs); Specialised pro-resolving 
mediators (SPMs); toll like receptor 4 (TRL4).)  
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2.4 What is DNA Methylation? 
DNA methylation is the most accessible and widely studied epigenetic mark (Lam et 
al., 2012) and has been shown to vary with nutrition, disease and age (Choi and Friso, 
2010; Gomes et al., 2012; Bacalini et al., 2014; Joyce et al., 2015). DNA methylation 
occurs when a methyl group is covalently attached to the fifth position of the pyrimidine 
ring to give 5mC, Figure 2-6, and it is most commonly found on a cytosine (C) 
positioned next to a guanine (G; Jones and Takai, 2001), however methylation of 
adenine (A) is also observed in bacterial, plant and recently in mammalian DNA (Wu 
et al., 2016; Xiao et al., 2018). Within embryonic stem cells, a quarter of the 
methylation occurs at non-CG sites (Lister et al., 2009), suggesting that there are 
different mechanisms for DNA methylation during development that do not endure into 
adulthood.  
Methylation does not alter the underlying genetic code, and whilst it is a reversible 
process, it can also be passed through cell divisions (Kim et al., 2010). DNA 
methylation is required for normal cell function, and it is also important because it can 
regulate gene expression, it is key to genomic imprinting, X-chromosome inactivation 
and repression of transposable elements (Bird, 2002).  
In most cases, the result of DNA methylation is the silencing of genes by the inhibition 
of gene transcription, effectively deactivating the promoter region of the gene (Breiling 
and Lyko, 2015). It is thought that the methyl group inhibits transcriptional factor 
binding, interacts with methyl binding proteins and also alters the DNA shape by the 
methyl group protruding into the major groove of the DNA double helix and narrowing 
the minor grove (Lazarovici et al., 2013). Therefore, the methylation level of DNA 
impacts upon the accessibility of the DNA, and in particular the gene promotors and 
regulatory regions. The addition of a methyl group results in transcriptional repression 
whilst the removal of a methyl group results in transcriptional activation.  
Within the human genome, there are approximately 29 million CpG sites with 60-80% 
of these sites contain a methylation cytosine (Lister et al., 2009). Regions of the 
genome that are enriched for CpG dinucleotides are termed CpG islands. These 
islands occur in various locations across the genome, 48% in promotors, 27% in 
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intergenic regions and 25% in gene bodies (Gao and Das, 2014). Most DNA 
methylation occurs in CpG sites that are dispersed across the genome, whereas CpG 
islands are predominantly unmethylated (Gao and Das, 2014).  
The regulation of DNA methylation is completed by the DNA methyltransferase 
(DNMT) family of enzymes, where the methyl group is transferred from S-adenyl 
methionine (SAM) to the fifth carbon on the cytosine ring. Each enzyme plays a 
specific role: new methylation (de novo) transferred to the unmodified DNA is 
catalysed by DNMT3a, DNMT3b and cofactor DNMTL; DNA methylation patterns are 
maintained during DNA replication by DNMT1 (Prokhortchouk and Defossez, 2008). 
DNMT2 is not involved in DNA methylation but rather methylation of transfer 
ribonucleic acid (tRNA) (Goll et al., 2006). The roles of the DNMT enzymes are 
reviewed in further detail by Gros et al. (2012) and Moore et al. (2013). 
DNA methylation levels within the genome are cell- and tissue-specific, with changes 
observed during the human lifespan (Wilson et al., 1987; Gilbert, 2009; Jones, 
Goodman and Kobor, 2015). Dysregulation of 5-methylcytosine (5mC) has been 
associated with diseases including cancer and cardiovascular disease (Ehrlich, 2002; 
Jones and Baylin, 2007; Muka et al., 2016).  
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Figure 2-6 A) The chemical structure of cytosine and two of its modified forms, 5-
methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC). R group 
indicates connection to the DNA strand backbone; B) Cytosines positioned 
next to guanines (CG) can have a methyl group (CH3) covalently attached 
to the fifth carbon atom by DNA methyltransferase (DNMT) family of 
enzymes in the presence of co-factor S-adenosyl methionine (SAM) to give 
5mC. DNA methylation in the form of 5-methylcytosine (5mC) can be 
actively reversed to unmodified cytosine (C) by the ten-eleven translocation 
(TET) family of enzymes, resulting cytosine modifications include 5hmC. 
Figure adapted from Chen and Riggs (2011)  
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2.5 Fatty Acids and Epigenetics 
In this thesis the research is concerned with the interactions between fatty acids and 
DNA methylation. The following review of the literature aims to summarise the current 
knowledge of this relationship and identify where further research is required. The 
search strategy for the literature review involved combining the terms for DNA 
methylation (e.g. DNA methylation and CpG) with terms relating to fatty acids (e.g. 
saturated fatty acid, monounsaturated fatty acid polyunsaturated fatty acid, EPA and 
DHA). The online database PubMed was last searched using these terms on the 22nd 
May 2018. Articles were included in this review if they investigated the interactions 
between DNA methylation and fatty acids within humans and are summarised in Table 
2-2.  
2.5.1 Epigenome wide associations studies 
Epigenome wide associations studies (EWAS), which despite the name, focus mainly 
on the specific epigenetic marker DNA methylation, have provided preliminary 
evidence linking ω-3 PUFA consumption with differential DNA methylation.  
The Yup’ik people from Alaska provide a unique opportunity to study a population 
where there is a wide range in consumption of fish. Their traditional diet is rich in fish 
but this is changing with westernisation (Bersamin et al., 2008), permitting stratification 
of this population into high and low ω-3 PUFA intake groups. One prominent EWAS 
of the Yup’ik (n = 185) utilised biochemical analysis to investigate associations 
between ω-3 PUFA status and DNA methylation; associations were observed at 
biologically relevant targets, including genes involved in T-cell homeostasis 
(Aslibekyan et al., 2014). Positive relationships were observed in seventy eight 
percent of the associations with ω-3 PUFA status (Aslibekyan et al., 2014). Genomic 
instability occurs with hypomethylation (Chen et al., 1998), and therefore the increased 
methylation observed with high ω-3 PUFA status may be beneficial to the genomic 
stability.  
In a study of a cohort of Greek preadolescents (n = 69), associations were found 
between dietary fats and DNA methylation, including sites within pathways linked to 
inflammation; nuclear factor kappa B (NFkB), peroxisome proliferator-activated 
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receptor alpha (PPARa), leptin and interleukin 6 (IL6) (Voisin et al., 2015). This study 
measured dietary fat intake using FFQs. Although their results were consistent with 
the finding of Aslibekyan et al. (2014), in their study of the Yup’ik people, it is worth 
noting that in general, whilst FFQs provide an estimation of fatty acid intake, they do 
not provide a direct measurement of biologically available ω-3 PUFAs in the target 
tissue. It is the fatty acids within the target tissue that contributes to the environment 
of the cell, thus influencing the epigenetic control of the genome, rather than the diet 
itself. 
The study of the Yup’ik cohort also found that individuals with higher ω-3 PUFA status 
had significantly lower levels of plasma triglyceride (TG), increased high density 
lipoproteins (HDL), and higher but not significant levels of low density lipoproteins 
(LDL) and total cholesterol (Aslibekyan et al., 2014). Consistent with previous 
supplementation studies (Harris, 1997; Das, 2000) and dietary salmon consumption 
(Raatz et al., 2016). It has been demonstrated that there is an association between 
blood lipids (TG, HDL and LDL) and DNA methylation of the genes encoding six key 
regulators of lipid metabolism (Dekkers et al., 2016), and therefore the DNA 
methylation associations observed in the studies discussed above may not be due to 
ω-3 PUFAs in the diet, but rather differences in blood lipid profiles, or a combination 
of both. One method of addressing this issue is the utilisation of closely controlled 
intervention studies. 
As briefly discussed in Chapter 1, the impact of nutrition during early life is of interest 
due to the plasticity of the epigenome during development and the links to diseases in 
later life (Gluckman and Hanson, 2004b; Gluckman et al., 2008).  
Global methylation analysis pre- and post-intervention can be used to investigate the 
impact of ω-3 PUFA supplementation on differentially methylated regions (DMRs) 
throughout the genome. The first two intervention studies that are considerd took 
slightly different approaches, the first supplemented mothers with 3.7g/day EPA+DHA 
(n = 36) or placebo (n = 34, placebo details not provided) from 20 weeks of gestation 
to delivery (Amarasekera et al., 2014). Whereas, the second study supplemented 9-
month-old infants with either 1.6g/day EPA+DHA (n = 6) or a placebo 3.1g/day LA (n 
= 6, LA in the form of sunflower oil); (Lind et al., 2015). Neither investigation found a 
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significant difference in DNA methylation between those taking the ω-3 PUFA and 
those taking the placebo after adjusting for multiple testing (Amarasekera et al., 2014; 
Lind et al., 2015). In contrast, however, a third more recent large randomised control 
trial (RCT) supplementing mothers during gestation with 1.5g/day ω-3 PUFA (0.8g/day 
DHA + 0.1g/day EPA, n = 190) or 1.5g/day vegetable oil placebo (n = 179), found that 
there were significant DMRs, including those relating to immune function, between the 
two experimental groups (van Dijk et al., 2016). 
The apparent differences in results between the first two studies and the third warrant 
consideration. Cohort size in the first two studies was small as compared to the larger 
third study. It is possible that the differences in methylation are so small that significant 
results only become apparent in a larger sample size. In addition, a confounding factor 
might also be that the relationship between methylation and supplementation are sex 
specific and could, at least in part, cancel each other out. In fact it is known that there 
are significant differences in the way males and females metabolise and store ω-3 
PUFAs (Burdge and Wootton, 2002; Burdge, Jones and Wootton, 2002; Lohner et al., 
2013). It has also been shown that there are differences in global methylation levels 
between the sexes (Zhang, Cardarelli, et al., 2011); which is consistent with the clear 
effect observed between sexes in the third study where there was higher number of 
differentially methylated regions (DMRs) in males compared to females (van Dijk et 
al., 2016). It is therefore important to appreciate that when using small sample sizes 
for ω-3 PUFA and DNA methylation studies, a lack of separation of the sexes may 
result in critical results being overlooked. 
Notably, the majority of studies presented thus far have utilised Illumina Infinium 
HumanMethylation450 BeadChip ArraysTM (450k arrays). This technology measures 
DNA methylation at over 450,000 individual CpG sites throughout the genome, and 
although a powerful tool in explorative work in determining DMRs, there are limitations 
to the use of 450k array data, including multiple testing, the generation of artefactual 
data and the need for complicated normalisation (Dedeurwaerder et al., 2014). 
Therefore, targeted analysis of specific CpG sites through a candidate gene approach 
should be completed to confirm the 450k array findings and provide additional 
information about methylation at specific and relevant sections of DNA. 
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2.5.2 LINE1 as an estimation of Global Methylation 
It has been estimated that repetitive transposable elements account for 45% of the 
genome (Lander et al., 2001) and it is estimated that these transposable elements 
contain one third of the genome’s DNA methylation (Kochanek, Renz and Doerfler, 
1993; Schmid, 1998). Measuring the levels of DNA methylation in repetitive elements, 
such as long interspersed nucleotide elements (LINEs), can therefore provide a proxy 
for global DNA methylation (Zhu et al., 2012).  
The high level of methylation in these elements represses their transcription (Kemp 
and Longworth, 2015). Associations between LINE1 methylation and lifestyle factors, 
including physical activity and nutrition have been found (Zhang, Cardarelli, et al., 
2011; Zhang, Morabia, et al., 2011; Agodi et al., 2015; Garcia-Lacarte et al., 2016; 
Marques-Rocha et al., 2016) and have also been shown to be associated with both 
disease (Schulz, Steinhoff and Florl, 2006; Baccarelli et al., 2010; Joyce et al., 2016) 
and ageing (Bollati et al., 2009; Jintaridth and Mutirangura, 2010).  
DNA methylation of LINE1 in cord blood mononuclear cells (CBMCs) was measured 
from mothers who received 0.4g/day DHA (n = 131) or placebo (n = 130, olive oil) 
during gestation (Lee et al., 2013). Neither this study or the third RCT above found 
any differences in LINE1 methylation between supplementation and control groups 
(Lee et al., 2013; van Dijk et al., 2016). However, Lee et al. (2013) did find an 
interaction between smoking status and DHA supplementation; CBMCs of mothers 
who smoked and took DHA supplements during gestation had significantly higher 
LINE1 methylation levels than the CBMCs of mothers who smoked and took the 
control supplement. These results suggest that there is a complex interaction between 
multiple environmental stimuli and the epigenome.  
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2.5.3 Candidate Targets 
Whilst LINE1 analysis provides information about DNA methylation status across the 
genome, it does not provide the level of detail that is required to fully understand what 
is happening at a gene level. In order to investigate the gene environment interaction 
in more detail it is necessary to study methylation of specific regions within genes that 
are thought to be relevant to transcriptional activity. 
In addition to LINE1 methylation, Lee et al. (2013) investigated specific genes and 
found no significant differences in methylation of TNF “tumor necrosis factor”, IL13 
“interleukin 13”, GATA3 “GATA binding protein 3”, STAT3 “signal transducer and 
activator of transcription”, IL10 “interleukin 10” and FOXP3 “forkhead box P3”. 
However, the promotor methylation was lower, although not significantly, for IFNG 
“interferon gamma” in CBMC from participants supplemented with DHA (Lee et al., 
2013). This study was novel in that the supplementation only contained DHA. It would 
have been interesting to see if they had also included a separate EPA supplement 
group in order to establish whether there are differing effects on the epigenome. 
Unfortunately the comparison between EPA and DHA is often lacking in in vivo human 
studies potentially because of the increased cost of multiple intervention groups and 
a greater availability of mixed ω-3 PUFA supplements commercially. Despite this, in 
vitro studies do provide evidence of differing effects of EPA and DHA on inflammation 
(Gorjão et al., 2009; Mickleborough et al., 2009).  
In terms of genes relevant to the inflammatory process, two have been investigated 
briefly in cross-sectional association studies. The methylation status of an individual 
CpG site within IL6 was found to be negatively associated with ω-3 DHA and total ω-
3 fatty acids (Ma et al., 2016). The relationship was dependent on the genotype of a 
nearby single nucleotide polymorphisms (SNPs; Ma et al., 2016). Anthropometric 
measurements, blood lipids and levels of ω-6 fatty acids, all contribute to explaining 
the variance in methylation status of TNF, an inflammatory cytokine encoding gene 
(Hermsdorff et al., 2013); similar associations have been observed in the clock 
circadian regulator genes: CLOCK, BMAL1 and PER2 (Milagro et al., 2012). 
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We have already noted that fatty acids are important structural components of cell 
membranes (Section 2.2.1). Consumption of foods rich in ω-3 PUFAs, such as 
salmon, results in increased incorporation and modification of cell phospholipid 
membrane (Raatz et al., 2016). Composition of the membrane is altered by clustering 
of lipids rafts containing the ω-3 PUFAs, resulting in the formation of large raft domains 
(Turk and Chapkin, 2013). As shown in murine obesity models (Kim et al., 2008) and 
HeLa cells (Chapkin et al., 2008) large lipid rafts can suppress the cell activation by 
impaired signalling, ultimately affecting cell function through suppression of 
downstream pathways, including those involved in inflammation.  
Leptin, a protein involved in energy balance, is localised to these lipid rafts and its 
expression is reduced by ω-3 PUFAs (Reseland et al., 2001; Klok, Jakobsdottir and 
Drent, 2007). This reduction in expression may be a result of epigenetic control of the 
gene. Indeed epigenetic control of the LEP “leptin” gene has been demonstrated in a 
murine model (Shen et al., 2014). However, when using a murine model candidate 
gene approach to investigate the effect of ω-3 PUFA supplementation on epigenetic 
control, no effect on LEP, LEPR “leptin receptor” or POMC “pro-opiomelanocortin” 
promotor methylation was found (Fan et al., 2011). In humans, cross-sectional 
evidence indicates differential methylation in the leptin pathway genes with varying ω-
3 PUFA status (Voisin et al., 2015). Whether or not supplementation of the human diet 
would alter methylation status of these genes remains to be seen, but if it does then 
the results would be contrary to those found in the murine model.  
Another protein found in cell membranes, CD36 , also has its expression altered by 
fatty acid treatment in vitro (Vallvé et al., 2002) and in animal models (Alexander 
Aguilera et al., 2006). This membrane glycoprotein promotes inflammation in 
monocytes and macrophages. In addition it binds long chain fatty acids to facilitate 
their transport into the cell (Silverstein and Febbraio, 2009). In humans, the 
methylation of CD36 promotor was significantly reduced by a the low-calorie diet, and 
this reduction was attenuated by ω-3 PUFA supplementation (Amaral et al., 2014).  
However, decreases in DNA methylation of other genes investigated within the same 
study, CD14 “cluster of differentiation 14” and PDK4 “pyruvate dehydrogenase kinase 
4” were shown to be only significant as a result of the low-calorie diet and were not 
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attenuated by the ω-3 PUFA supplementation. Gene expression was not measured in 
this study. When the effect of ω-3 PUFA supplementation has been investigated on 
the expression of these genes in peripheral blood mononuclear cells (PBMCs), a 
decreased expression of CD36, CD14 and PDK4 was observed (Bouwens et al., 
2009). It is possible that the low calorie diet impacted on the DNA methylation to a 
greater extent than the ω-3 PUFAs, which only attenuated the decrease in methylation 
of CD36 once adjusted for baseline body weight. This study illustrates the difficulty in 
understanding the relationships between ω-3 PUFAs and methylation when there are 
confounding factors, such as multiple interventions. 
In fact the study carried out by Amaral et al. (2014) included an additional confounding 
factor because the participants were asked not to consume seafood and to follow a 
detailed diet plan during the intervention period to minimise variability. However, this 
study was carried out in Spanish females. The Spanish diet is high in shellfish/fish, on 
average 88.6g/person/day are consumed (Varela-Moreiras et al., 2013), and therefore 
the researchers may have simply replaced the ω-3 PUFAs that the participants 
obtained from their habitual diets with the supplementation. No biochemical 
measurements for EPA and DHA were provided in this paper (Amaral et al., 2014), 
however, earlier work from the same researchers for this cohort described the EPA 
and DHA increased after the intervention (Parra et al., 2008). In order to be certain 
about the effects of supplementation it is important to include measurement of ω-3 
PUFA in the tissue used for epigenetic analysis both before and after the intervention 
in order to confirm changes to the ω-3 PUFA status of the cells investigated.  
Endogenous metabolism of PUFAs occurs within a cell. The initial step in the 
metabolic pathway takes places in the endoplasmic reticulum, where LA and ALA 
undergo elongation by fatty acid enlongase (ELOVL) and desaturation by Δ6-
desaturase and Δ5-desaturase (Benatti et al., 2004). The Δ6-desaturase and Δ5-
desaturase enzymes, encoded by the FADS2 and FADS1 genes respectively, are rate 
limiting steps in this metabolic pathway (Marquardt et al., 2000; Nakamura and Nara, 
2004). Genetic polymorphisms of these genes and others related to PUFA metabolism 
can significantly alter the levels of PUFAs within the body (Glaser, Heinrich and 
Koletzko, 2010) and differential methylation is likely to have a similar effect. 
Associations between methylation of genes encoding fatty acid metabolism enzymes 
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and fatty acids levels have been found in multiple cohorts; these relationships were 
found to be altered by the genotype of relevant SNPs (Cui et al., 2016; Rahbar et al., 
2018). Furthermore, the methylation of FADS1 is altered by a low calorie diet with a 
small interaction with ω-3 PUFA supplementation (Amaral et al., 2014). When 
investigated alone, with a higher dose of ω-3 PUFA supplementation, no significant 
changes in methylation were observed in FADS1 or the elongation gene ELOVL2 
(Hoile et al., 2014). However, the methylation of two other fatty acid metabolism genes, 
FADS2 and ELOVL5, increased with supplementation; with a larger number of CpG 
sites changing methylation in females than males and a negative relationship between 
the DNA methylation and the gene messenger RNA (mRNA) levels was observed 
(Hoile et al., 2014).  
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Table 2-2 Summary of literature investigating fatty acids, with a particular focus on DNA methylation, in human participants. See 
abbreviation list on page XV. 
Reference Cohort Study type /  
Intervention 
Fatty acid Tissue / Targets Results 
Amarasekera 
et al., (2014) 
Mother-infant 
pairs (n=70, 31-
32 yrs) who were 
atopic and had 
clinical allergy 
 
[Male (n=37) and 
female (n=33) 
Infants] 
DB RCT 
 
~18 weeks 
supplementation (20 
weeks’ gestation to 
birth) with Fish oil 
(n=36; 3700mg/day) or 
control (n=34; olive oil); 
RBC fatty acid 
profile  
 
(maternal and 
cord blood) 
CD4+ T-cells from 
cord blood 
 
Infinium 450 array 
No significant associations found with ω-3 PUFA levels 
after multiple testing. A dose-response was observed in the 
top ranked unadjusted CpG sites and the total ω-3 fatty 
acid levels. 
Arpón et al., 
(2017) 
Male (n=18, 55-
60 yrs) and 
female (n=18, 60-
80 yrs) healthy 
adults 
RCT 
 
5 years Mediterranean 
diet with olive oil 
(n=12) or with nuts 
(n=12) or control diet 
(n=12; advice to 
reduce fats) 
No measurement Buffy Coat  
 
Infinium 450 array 
Specific CpG sites showed differential methylation after five 
years of MedDiet with additional fats from either nuts or 
olive oil compared to control diet. Pathways analysis 
showed differential methylation in genes relating to 
metabolism, inflammation, intracellular signals and diabetes 
phenomena. Methylation of a CpG site within CPT1B gene 
was associated with PUFA uptake 
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Reference Cohort Study type /  
Intervention 
Fatty acid Tissue / Targets Results 
Aslibekyan et 
al., (2014) 
Male (n=91) and 
Females (n=94) 
young adults of 
Yup’ik descent 
Cross-sectional, 
extreme phenotype 
 
High and Low ω-3 
PUFA status 
RBC ω-3 PUFA 
status (nitrogen 
stable isotope 
ratio (d15N)) 
  
Whole blood 
 
Infinium 450 array 
A total of 27 disease related sites significantly correlated 
with ω-3 PUFA (not after adjusting for multiple testing); 78% 
of significant associations were increased methylation. 
Inflammatory related methylated CpG sites associated with 
d15N included CCL17, FAS, EIF2AK4. A significant 
difference in age between the two groups. 
Cui et al., 
(2016) 
Male Prostate 
Cancer patients 
(n=60, 55-64 yrs) 
Cross-sectional Prostate tumour 
fatty acid profile 
Prostate tumour 
 
FADS cluster 
(cg27386236) 
Methylation of cg27386326 negatively associated with 
Arachidonic acid, along with ratio ARA+ADA to LA 
(indicating ω-6 biosynthesis). Genotype of rs174537 
significantly interacts with fatty acids (stearic, oleic, linoleic, 
DGLA, ARA, Adrenic, DPA, DHA and ω-6:ω-3 ratio). 
do Amaral et 
al., (2014) 
Overweight 
females (n=12, 
20-40 yrs) 
DB RCT  
 
8 weeks calorie 
restriction (30%) with 
supplementation of ω-3 
PUFAs (n=7; 
>1300mg/day) or 
Control (n=5; ω-3 
PUFAs  <260mg/day) 
Blood lipid profile 
(total cholesterol, 
LDL, HDL, TAG) 
  
PBMC 
 
CD36, CD14, 
FADS1, PDK4 and 
FFAR3 
Weight loss similar between groups. Diet reduced DNA 
methylation of CD36 (CpG+477, -11.8% control & -7.3% ω-
3 PUFA), no influence of fish oil unless baseline body 
weight was controlled for in which case methylation was 
lower in ω-3 PUFA group. Small increase in CD14 
methylation (CpG +765+733, +0.3% control & +0.6% ω-3 
PUFA). Significant, but small changes in promotor 
methylation PDK4 (CpG -222-50) and FADS1 (CpG -25-22-
20); methylation percentage of PDK4 and FADS1 reduced 
in control group and increased in fish oil group. No data on 
gene expression. Leptin significantly changed with weight 
loss, no interaction and no fish oil significance. No 
significant change in blood lipid profiles. 
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Reference Cohort Study type /  
Intervention 
Fatty acid Tissue / Targets Results 
Hermsdorff 
et al., (2013) 
Female healthy 
young adults 
(n=40, 18-28 yrs) 
Cross-sectional, 
extreme phenotype 
 
High and Low truncal 
fat 
Blood lipid profile 
(total cholesterol, 
LDL, HDL, TAG); 
 
Semi-
quantitative food 
frequency 
questionnaire 
(136 food-items) 
Buffy coat 
 
TNF 
Higher inflammation (TNFα and CRP) in high truncal fat 
women. Methylation status of 2 CpG sites within the exon 1 
TNF gene significantly different between low and high 
truncal fat. Methylation of one and average of both sites 
negatively correlates with plasma TNFα; with truncal fat 
positively correlates with plasma TNFα. Central adiposity 
indicator (truncal fat), metabolic features (HDL-c and 
insulin), plasma TNFα, and dietary fat intake (ω-6 fatty acid) 
all contribute to explaining 48% of the variation in 
methylation state of one CpG site in TNF. 
Hoile et al., 
(2014) 
 
Cohort 1 
 
Australia 
Male (n=16) and 
Female (n=13) 
Chronic kidney 
disease patients 
(47-64 yrs) 
DB RCT 
 
8 weeks 
supplementation with 
ω-3 PUFA (n=14, EPA 
1800mg, DPA 200mg, 
DHA 1500mg/day) or 
Olive oil (n=15, 
4000mg/day) 
No measurement PBMC 
 
FADS1, FADS2, 
ELOVL2, ELOVL5 
Both ω-9 PUFA and ω-6 PUFA supplementation induced 
changes to methylation status of four FADS2 CpG site and 
one ELOV5 CPG site that were both sex specific and 
specific to the PUFA supplemented. These sites were 
negatively associated with FADS2 and ELOV5 mRNA 
expression. 
Hoile et al., 
(2014) 
 
Cohort 2 
 
England 
Male (n=8) and 
Female (n=12) 
healthy adults 
(22-34 yrs) 
Supplement 
 
12 weeks 
supplementation of ω-3 
PUFA (n=20, EPA 
1100mg, DPA 100mg, 
DHA 800mg/day) 
No measurement Whole blood 
 
FADS1, FADS2, 
ELOVL2, ELOVL5 
Results for all bar two of the CpG sites were replicated from 
cohort 1 ω-3 PUFA group. 
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Reference Cohort Study type /  
Intervention 
Fatty acid Tissue / Targets Results 
Karimi et al., 
(2017) 
Male (n=32) and 
Female (n=31) 
Mild to moderate 
Alzheimer’s 
patients  
 
(73±9 yrs) 
DB RCT 
 
6 months 
supplementation of ω-3 
PUFA (n=30, EPA 
600mg, DHA 
1700mg/day) or 
Placebo (n=33, Corn 
oil 1000mg, linoleic 
acid 600mg/day) 
Plasma fatty acid 
profile 
Buffy coat 
 
LINE1 
Significant decrease in LINE1 methylation with ω-3 PUFA 
supplementation, observed in both males and females. 
Significant differences to the placebo group observed after 
six months supplementation, the placebo increasing 
methylation of LINE1. 
Lee et al., 
(2013) 
Mother-infant 
pairs (n=261, 18-
35 yrs) who were 
atopic and had 
clinical allergy.  
 
[Male (n=133) 
and female 
(n=128) Infants] 
DB RCT 
 
14-18 weeks 
supplementation (18-
22 weeks’ gestation to 
birth) with 400mg/day 
DHA (n=131) or control 
(olive oil, n=130) 
No measurement CBMC 
 
IFNG, TNF, IL13, 
GATA3, STAT3, 
IL10, FOXP3 & 
LINE1 
No difference in LINE1 methylation between the ω-3 PUFA 
and control groups, the interaction between smoking status 
of mothers and ω-3 PUFAs was significant, with higher 
methylation in the ω-3 PUFA smoking mothers group 
(n=26). IFNG promotor methylation was lower (not 
significantly) in the ω-3 PUFA group. No effect was 
observed in TNF, IL13, GATA3, STAT3, IL10 and FOXP3. 
ω-3 PUFA supplementation altered the ratio of methylation 
levels between IFNG and IL13 (Th1-Th2 specific genes). 
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Reference Cohort Study type /  
Intervention 
Fatty acid Tissue / Targets Results 
Lee et al., 
(2014) 
Mother-infant 
pairs (n=261, 18-
35 yrs) who were 
atopic and had 
clinical allergy.  
 
[Male (n=133) 
and female 
(n=128) Infants] 
DB RCT 
 
14-18 weeks 
supplementation (18-
22 weeks’ gestation to 
birth) with 400mg/day 
DHA (n=131) or control 
(corn & soy oil, n=130) 
No measurement CBMC 
 
IGF2 & H19 
Modulation of methylation status of IGF2 and H19 DMRs by 
DHA supplementation, dependent on pre-pregnancy 
maternal BMI. Interactions between maternal BMI and IGF2 
DMR, and H19 DMR methylation. Increased methylation of 
IGF2 in preterm infants who received DHA 
supplementation. 
 
(Note: discrepancy in description of control oil for same 
cohort as Lee et al., (2013) above) 
Lind et al., 
(2015) 
Male (n=6) and 
Female (n=6) full 
term infants  
 
(9 mths) 
DB CT 
 
9 months 
supplementation of ω-3 
PUFAs (n=6, 1600mg 
EPA+DHA) or 
sunflower oil (n=6, 
3100mg) 
RBC fatty acid 
profile 
Buffy coat 
 
Infinium 450 array 
ω-3 PUFA group had lower ex vivo production of IL6 than 
the control group (p=0.08). No discrimination in DNA 
methylation between the two interventions after adjusting 
for multiple testing. 43 CpG sites had a >10% difference in 
absolute methylation, including sites in transcription factors 
(GATA4, TBPL2), nucleic acid binding proteins (RBM9, 
CDYL) and metabolic genes (ACOT13, KCNV1, NR3C1). 
Ma et al., 
(2016) 
Male (n=459) and 
Female (n=389) 
adults 
Cross-sectional RBC fatty acid 
profile 
CD4+ T-cells 
 
IL6 (cg01770232, 
cg26061582) 
Higher methylation of cg01770232 associated with higher 
IL6 gene expression and higher plasma IL6. Negative 
association between total ω-3 PUFAs and cg01770232 
methylation (dependent on rs2961298 genotype), as well as 
plasma IL6. 
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Reference Cohort Study type /  
Intervention 
Fatty acid Tissue / Targets Results 
McMorrow et 
al., (2018) 
Male and Female 
overweight and 
obese 
adolescents 
(n=70, 13-18 yrs) 
DB RCT(crossover) 
 
8 weeks 
supplementation of 
AINS [LC ω-3 PUFA 
(1000mg EPA and 
1000mg DHA), 567mg 
vitamin C, 390mg α-
tocopherol, 416mg 
green tea extract (45% 
epigallocatechin ω-3-
gallate) and 16.5mg 
lycopene.] or Placebo 
(oleic sunflower oil and 
microcrystalline 
cellulose), 6 weeks 
washout, 8 weeks 
opposite supplement 
Blood lipid profile 
(total cholesterol, 
LDL, HDL, TAG) 
  
Buffy coat 
 
Infinium 450 array 
Significant association between adiponectin and 
methylation of 487 CpG sites following AINS 
supplementation. Pathway analysis identified positive 
associations with pathways including metabolic gene, 
genes involved in developmental biology and gene express, 
as well as an inverse relationship with genes involved in 
signal transduction and the immune system. 
Milagro et al., 
(2012) 
Female adults 
(n=60, 23-53 yrs) 
 
[normal weight 
(n=20), 
overweight/obese 
(n=20) and 
morbidly obese 
(n=20)] 
Methylation only 
measured at baseline 
 
16-week Weight 
reduction intervention 
Blood lipid profile 
(total cholesterol, 
LDL, HDL, TAG) 
PBMC 
 
CLOCK-R1, 
CLOCK-R2, BMAL1 
and PER2 
(measured at 
baseline only) 
The methylation of CLOCK showed associations with the 
intake of MUFA and PUFAs. Associations with methylation 
of CpG sites located in clock genes (CLOCK, BMAL1 and 
PER2) with obesity, MetS and weight loss. 
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Reference Cohort Study type /  
Intervention 
Fatty acid Tissue / Targets Results 
Perfilyev et 
al. (2017) 
Male (n=22) and 
Female (n=9) 
healthy adults 
(20-38yrs) 
DB RCT 
 
7 weeks of overfeeding 
(high calorie muffins) 
containing either: 
Blood lipid profile 
(total cholesterol, 
LDL, HDL, TAG) 
Adipose tissue 
 
Illumina 450K array 
Mean methylation of 1797 genes (including FTO, IL6, INSR, 
NEGR1, POMC) was changed by PUFA overfeeding 
compared to 125 genes by SFA overfeeding. When data 
combined for PUFA and SFA, mean methylation of 1444 
genes was changed by overfeeding, including FABP1, 
FABP2, MC2R, MC3R, PPARGC1A and TNF. The PUFA 
diet did not significantly alter gene expression, compared to 
the SFA which altered the expression of 28 transcripts. 
Rahbar et al., 
(2018) 
 
Cohort 1 
Male (n=31) and 
Female (n=58) 
healthy adults 
(21-65 yrs) 
Cross-sectional Serum fatty acid 
profile 
Leukocytes 
 
FADS1, FADS2 
FADS2 methylation an indicator of circulating ω-6 PUFA. 
DNA methylation in the FADS2 promotor were inversely 
related to DGLA levels. Positive association between 
FADS2 methylation and AA/DGLA ratio. Allele specific 
methylation with rs174537 and FADS2 methylation. 
Rahbar et al., 
(2018) 
 
Cohort 2 
Male (n=13) and 
Female (n=19) 
healthy adults 
(21-65 yrs) 
Cross-sectional Plasma fatty acid 
profile  
CD4+ Cells and 
Saliva 
 
FADS1, FADS2 
Consistent findings as cohort 1 for CD4+ cells methylation 
of FADS2 and inverse relationship with DGLA levels. 
Positive association between FADS2 methylation and 
AA/DGLA ratio. No associations observed in saliva 
methylation and circulating fatty acids. 
Tremblay et 
al., (2017) 
Male (n=18) and 
Female (n=18) 
overweight and 
obese adults 
(34.7 ± 8.8 yrs) 
Supplement 
 
6 weeks 
supplementation with 
3000mg ω-3 PUFA 
(1900-2200mg EPA, 
1100mg DHA) 
Plasma fatty acid 
profile; Blood 
lipid profile (total 
cholesterol, 
VLDL, LDL, 
HDL, TAG) 
  
Whole blood 
 
Illumina 450K array 
Post supplementation, 308 CpG sites, relating to 231 
genes, were differentially methylated, 93% (286 CpG sites) 
were hypermethylated post supplementation. Total of 55 
overrepresented pathways altered post supplementation, 
including 16 that were related to inflammatory and immune 
response, lipid metabolism, type 2 diabetes, and 
cardiovascular signalling. 
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Reference Cohort Study type /  
Intervention 
Fatty acid Tissue / Targets Results 
van Dijk et 
al., (2016) 
Mother-infant 
pairs (n= 991, 
~30 yrs) who 
were healthy 
 
[Male (n=502) 
and female 
(n=489) Infants] 
DB RCT 
 
18+ week 
supplementation 
 
(<21 weeks’ gestation 
to birth) with 1500mg 
ω- PUFA (800mg DHA 
and 100mg EPA) or 
1500mg vegetable oil 
(rapeseed, sunflower, 
and palm) 
Plasma DHA Neonates: Dried 
blood spots 
Age 5 yrs: Whole 
blood 
 
LINE1, (n=991 
neonates, n=663 
age 5 yrs) 
 
Infinium 450 array 
(n=369 neonates, 
n=65 age 5 yrs) 
LINE1 methylation higher in males than females. No 
significant difference in LINE1 methylation between 
intervention groups at birth or 5 years. After DHA 
supplementation compared to the control group there were 
21 differentially methylated regions, predominantly lower 
methylation, genes included ones involved in lipid exchange 
between membranes (ESYT3), plasma membrane function 
(SLC12A6), appetite regulation (CCK), immune function 
(RAET1L and LTB) and neurodevelopment/brain function 
(SLC12A6, TRAK1, LPHN3 and RFPL2). Limited overlap 
with significant DMRs at birth and 5 years. 
Voisin et al., 
(2015) 
Male (n=22) and 
Female (n=47) 
Greek 
preadolescents 
[Normal-weight 
(n=34), Obese 
(n=35)] 
Cross-sectional Dietary intake via 
24hr recall for 2 
weekdays and 1 
weekend day 
Whole blood 
 
Infinium 450 array 
34 pathways significant for PUFA/SFA diet content 
including adipogenesis, PPARy, leptin and IL6 pathways. 
Five pathways significant for (MUFA+PUFA)/SFA diet 
content including ones linked to NFkB. 
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The literature review performed here highlights the varied nature of the studies 
investigating ω-3 PUFAs and DNA methylation performed to date. The lack of 
consistency of the study designs makes it difficult to interpret the relationship and 
indicate points to consider when conducting the research being undertaken in this 
thesis. 
Firstly, there is not yet a consensus on the dosage level of ω-3 PUFAs required to 
produce an anti-inflammatory effect in humans. In a review by Calder (2015), it is 
suggested that a dose between 1.35g/day and 2.7g/day of EPA is required. In addition, 
there is a dose response relationship between ω-3 PUFAs and the effect on cytokine 
levels (Caughey et al., 1996), it is possible that there will also be a dose-response 
relationship in epigenetic control of inflammation.  
There is also no consensus on the timeframe required for epigenetic changes to occur. 
The largest incorporation of ω-3 PUFAs into erythrocyte membranes occurs within the 
first 4 weeks of supplementation and it is not known if the epigenetic changes occur 
within the same timeframe. 
Most studies measure fatty acid content of RBCs or plasma, with fewer measuring the 
incorporation into PBMCs which are used as the source of DNA in many of the 
methylation studies. In addition, none of the studies consider methylation alongside 
fatty acid incorporation into PBMCs. 
Finally, the majority of intervention studies investigating epigenetic changes do not 
account for the impact of the intervention on the cell population from which the DNA 
was extracted. This results in multiple complications; firstly, if the influence of ω-3 
PUFAs is specific to one cell type it may not be observed if the cells are not separated 
prior to analysis. Secondly, changes may be falsely observed or masked with 
variations in cell populations. Differentiation into the cell subtypes found within blood 
requires changes within the epigenetic signatures, and therefore the observed 
changes in percentage methylation for an individual CpG may be the result of a 
change in the cell population rather than a result of the intervention. Data can be 
normalised to account for the proportion of different cells (Hoile et al., 2014; Lind et 
al., 2015).  
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2.6 Conclusion 
Associations between fatty acids and DNA methylation have been demonstrated, with 
further evidence that supplementation with fatty acids, such as ω-3 PUFAs, affect 
methylation levels of certain genes some of which are involved in inflammation. A more 
targeted approach to the effects of ω-3 PUFAs, and use of well controlled 
supplementation studies could elucidate a mechanism through which ω-3 PUFAs alter 
the DNA methylation within the inflammatory landscape. 
Having regard to the importance of ω-3 and ω-6 PUFAs in health and disease and the 
recent studies that have observed differences in DNA methylation dependent on 
PUFA levels, the general aims of this research are to: 
• Characterise the relationship between methylation of a candidate cytokine gene 
and the fatty acid composition in blood; 
• Identify if changing the fatty acid composition of PBMCs can alter the 
methylation signatures of selected cytokine genes;  
• Investigate whether the supplementation of ω-3 PUFAs reduces the 
inflammation caused by eccentric exercise induced muscle damage through 
alteration of the methylation status of the cytokine genes. 
The null hypotheses tested within this thesis: 
• The is no relationship between methylation of a candidate cytokine gene and 
the fatty acid composition in blood; 
• Changing the fatty acid composition of PBMCs does not alter the methylation 
signatures of selected cytokine genes;  
• Supplementation of ω-3 PUFAs does not reduce the inflammation caused by 
eccentric exercise induced muscle damage through alteration of the 
methylation status of the cytokine genes. 
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Chapter 3 Method Development: 
Quantification of DNA Methylation 
3.1 Introduction 
The genetic analysis of DNA sequences has come a long way since 1977 when 
Frederick Sanger first published details of gel-based enzymatic termination 
sequencing (Sanger, Nicklen and Coulson, 1977), which today is known as Sanger 
Sequencing and was the work horse of the Human Genome Project referred to in the 
introduction of this thesis. Since the advent of Sanger sequencing and the subsequent 
developments in sequencing and molecular biology technologies (Heather and Chain, 
2016), give scientists the ability to analyse the epigenetic code of cells more easily, at 
less cost and in greater depth than ever before.  
This chapter explains how DNA methylation will be measured in this research and 
provides details of the design and validation of assays used later in the thesis. 
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3.2 Measuring DNA methylation 
3.2.1 Method selection 
DNA methylation was first discovered in 1948 (Hotchkiss, 1948), since then there has 
been an evolution in the methods that can be used to measure this epigenetic mark. 
Measurement of cytosine methylation levels involves either the use of methylation-
specific restriction enzymes, bisulphite conversion of DNA, or enrichment with 
methylation targeting enzymes. Methodologies fall into two categories, epigenome -
wide or locus-specific.  
Levels of methylation across the genome can be measured in a non-locus specific 
manner by global methylation analysis techniques which include luminometric 
methylation assay (LUMA), enzyme-linked immunosorbent assays (ELISAs), high 
performance liquid chromatography (HPLC), repetitive element DNA methylation 
analysis (e.g. LINE1) (Kurdyukov and Bullock, 2016). However, these techniques do 
not provide information on the levels of methylation at certain loci. This may lead to 
losing key information on the methylation patterns in certain loci of interest. 
Measurement techniques which allow for the identification of methylation at individual 
loci include bisulphite whole genome sequencing (BS-WGS), which provides details 
of methylation levels across the whole genome; or regional levels can be measured 
via pyrosequencing. Epigenome-wide methylation analysis determines global 
methylation levels, examples of such methods include high performance liquid 
chromatography (HPLC) and bisulphite whole genome sequencing (BS-WGS); the 
latter of which also provides detail on the location of the methylation marks. There are 
methods, such as array based chips, which give levels of methylation from loci spread 
across the genome, representing approximately 2% of the sites that could be 
methyalted. 
Methods which do not allow for measurement of methylation at individual loci can be 
difficult to link changes to biologically significant outcomes, however, the cost of the 
global methylation methods of £5 per sample is significantly cheaper than the genome 
wide loci specific methods. The use of Illumina Infinium HumanMethylation450 
BeadChip ArraysTM (approx. £250/sample) and BS-WGS (approx. £3,600/sample) do, 
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however, provide information on individual CpG sites. These methods are often used 
to scan the genome for novel DMRs. However, in addition to their high cost, they 
require large amounts of input DNA and even then, significant results found using the 
450k array should be validated using sequencing-based methods. Microarrays, such 
as the 450k array, are susceptible to batch effects and require comprehensive 
analytical techniques to correct for this. In addition, due to the requirement to have two 
different probes types on the same array, to be able to still measure methylation in 
areas of high CpG density, data processing can be problematic as a result of the 
differences in the performance of the probes (Pidsley et al., 2013).  
An alternative to epigenome-wide methylation analysis, which can be used when a 
candidate gene has been identified, is the measurement of methylation levels of 
smaller regions of DNA. The methylation of these smaller regions can be quantified 
after bisulphite conversion using polymerase chain reaction (PCR)-based methods, 
which include methylation sensitive PCR (MSP), MethyLight (utilising real-time PCR), 
methylation-specific high-resolution melting and bisulphite pyrosequencing.  
Methylation sensitive PCR permits screening of methylation at a specific site; 
however, it is not quantitative. Real-time PCR methods do allow quantitative 
measurement at specific sites and utilise primer sets designed to amplify methylated 
or unmethylated regions; however, this will only allow for the detection of completely 
methylated or unmethylated sites within the target region.  
Having regard to the advantages and disadvantages of the various available methods, 
including budgetary constraints, and having considered the number of samples that 
would have to be analysed during the course of the proposed research the decision 
was made to use a PCR-based method for analysing DNA methylation at specific 
identified CpG sites of interest. 
Methylation levels of CpG sites within a specific region can be assessed by using the 
primer extension sequencing method, pyrosequencing. Pyrosequencing uses 
bisulphite-converted amplified DNA and provides sequence data over short DNA 
stretches. Methylation can be quantified by calculating the ratio of unconverted 
cytosine to converted thymine at the CpG loci (see below for further details on 
bisulphite conversion). Benefits of the pyrosequencing method include the inclusion of 
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an internal bisulphite conversion control and the ability to measure individual 
methylation values of CpG sites in the short stretch of DNA sequenced. As the length 
of DNA sequenced is relatively short, less than 60 base pairs (bp), this limits the 
number of CpG sites that can be assessed in one assay.  
 Bisulphite conversion 
In order to assess the DNA methylation of a target CpG site when using PCR-based 
methods, the DNA must first undergo bisulphite conversion.  
Without bisulphite conversion, during PCR amplification, methylated cytosines are 
replaced by unmethylated cytosine (He and Cole, 2015), and therefore the methylation 
is lost after the first cycle of PCR.  
Bisulphite conversion is the deamination of unmethylated cytosine to uracil. This 
reaction does not occur if the cytosine is methylated. Hence after bisulphite conversion 
the only cytosine remaining in the DNA is methylated cytosine. During PCR these 
methylated cytosines are converted to unmethylated cytosine and the uracil is 
converted to thymine. This preserves the methylation information of the original DNA 
sequence after PCR amplification (Grunau, Clark and Rosenthal, 2001). 
The original method for bisulphite conversion was proposed by Frommer et al. (1992). 
Briefly, precipitated DNA is incubated with sodium bisulphite hydroquinone at pH5 & 
50oC for 16 or 40 hours, after which remaining bisulphite is removed via dialysis and 
the resulting solution is neutralized, desalted and re-suspended in storage solution 
and is ready for PCR (Frommer et al., 1992). The harsh conditions of this original 
method have been shown to degrade the DNA during treatment. New commercial kits 
are not as problematic as several chemical improvements have been made to the 
reaction and therefore there is improved recovery. Hernández et al. (2013) compares 
the commercially available kits. The most commonly used kits in research are 
EpiTectTM Bisulphite kit produced by Qiagen (Qiagen N.V. and its subsidiaries), or EZ 
DNA methylation GoldTM kit produced by Zymo Research.  
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3.2.2 Tissue Selection 
In DNA methylation research, the tissue of interest must be carefully chosen as more 
variability is observed between tissues from the same individual, than within tissue 
between individuals (Kochanek et al., 1990). The ability to obtain tissue from 
metabolically relevant tissues within humans, such as muscle, liver and adipose tissue 
can be problematic in healthy individuals that have not required surgery. One key 
tissue used in genetics research, due to the less invasive collection method, is whole 
blood. This source of DNA is most beneficial when looking for genetic polymorphisms. 
Other cells used for this line of work include buccal epithelial cells and hair. However, 
it is not going to be relevant to use hair follicles or buccal swabs for many epigenetic 
studies where epigenetic signatures are specific to cell type. For example, when 
considering the role of DNA methylation in gene regulation, there is greater variance 
between tissues in the same individual than that observed between individuals within 
a single tissue (Eckhardt et al., 2006; Byun et al., 2009; Davies et al., 2012). 
Consideration must also be given for samples derived from multiple cell types that 
have the potential for different methylation patterns (Siegmund and Laird, 2002; Wu 
et al., 2011). The implication when designing a research study investigating epigenetic 
modifications is that the samples studied must be from the same tissue and chosen 
so that any changes that are observed in DNA methylation in a specific cell type are 
biologically relevant to the research question. In addition to epigenetic signatures 
depending on the type of cell, they are also influenced by the metabolic processes 
within the cell and the environment the cell is exposed to.  
In regards to inflammation, within the blood are white blood cells that are important in 
systemic function and inflammation (Afman and Müller, 2012). These cells contain 
DNA that can be easily extracted from small volumes of blood. PBMCs isolated from 
blood are a heterogeneous mix of white blood cells and therefore will have varying 
epigenetic profiles. It is also important to consider that the blood composition, 
leukocyte composition of the whole blood was found to correlate with DNA methylation 
(Lam et al., 2012), an issue that may influence associations between environmental 
factors and DNA methylation when using blood samples. Therefore, composition of 
whole blood should be determined for each individual and used in statistical models 
to correct the methylation values or complete the DNA methylation analysis on specific 
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blood cells types. Differences in DNA methylation in PBMCs have also been 
associated with demographic factors such as sex, age and ethnicity (Lam et al., 2012). 
In this thesis all blood samples have had the cell composition analysed on a Beckman 
Coulter Counter (Beckman, USA) to allow for appropriate adjustments to be made for 
the methylation values. In this thesis, the method presented by Jones et al., (2015) 
has been used to adjust DNA methylation values to account for the white blood cell 
composition. This method uses a sum of the mean methylation for the site and the 
unstandardised residual from a linear regression between DNA methylation 
(dependent variable) and the individual white blood cell counts (independent 
variables) to give an adjusted methylation value.  
3.3 Target Identification and Justification 
The overarching aim of this research is to investigate how ω-3 PUFAs and other fatty 
acids within the blood interact with inflammation, thus a critical component of this work 
was the identification of target genes and specific CpG sites within them. The current 
research into the interaction between fatty acids and DNA methylation, described in 
Chapter 1, has particularly focused on fatty acid metabolism genes and genome-wide 
methylation analysis. The methylation genome-wide association studies (meth-
GWAS) research has identified gene pathways enriched for DMRs which are linked to 
fatty acids and include pathways involved in initiating and regulating inflammation. 
Therefore, the decision was made to investigate genes that have been associated with 
fatty acids or where their transcripts have been altered by fatty acid consumption.  
Inflammatory diseases are often characterised with chronic activation of NFκB 
transcription factor and release of inflammatory cytokines (Epstein, Barnes and Karin, 
1997) and therefore an important target for changes in DNA methylation by ω-3 
PUFAs. Associations between dietary fats and DNA methylation in the NFκB pathway, 
measured using the 450k array, were observed in the Greek preadolescent cross-
sectional cohort (Voisin et al., 2015), and therefore may provide valuable targets within 
intervention studies. The transcription factor NFκB is a protein complex encoded by 
multiple genes including NFKB1 and NFKB2. Furthermore, methylation of these genes 
have been associated with dietary intake of milk post-exercise and to exercise 
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interventions (Y. Zhang et al., 2015; Masuki et al., 2017). These two genes warrant 
further investigation as to their interactions with fatty acids. 
Considering the cytokines within the NFκB pathways, the inflammatory cytokine tumor 
necrosis factor alpha (TNFa), encoded by the TNF gene, primarily mediates the acute-
phase response in the inflammatory process (Sullivan et al., 2007). TNFα is 
associated with a wide range of inflammatory disorders, and therefore is regularly a 
therapeutic target with anti-TNFα drugs (Bazzani et al., 2009). When a macrophage 
cell line has been stimulated with LPS in vitro, TNFα secretion is decreased by the 
treatment of ω-3 PUFAs EPA and DHA (Mullen, Loscher and Roche, 2010). EPA 
treatment does not affect the stability of TNF mRNA in cytoplasm and therefore 
reductions in TNF mRNA as a result of EPA treatment is likely to be the result of 
decreased formation rather than degradation of the cytokine (Zhao et al., 2004). The 
influence of ω-3 PUFAs on TNF expression may be the result of alterations in 
epigenetic mechanisms such as DNA methylation. Epigenetic regulation plays an 
important role in the control of TNF expression (Kochanek et al., 1991; Takei et al., 
1996; Sullivan et al., 2007). In a cell line that does not produce TNFα in response to 
LPS or phorbol myristate acetate (PMA), the promotor and exon-1 of TNF had higher 
methylation levels than TNFα expressing cells (THP-1 macrophages) which had a 
demethylated promotor and exon-1 (Sullivan et al., 2007). Specifically, TNF has been 
shown to be hypomethylated in Crohn’s disease patients (Nimmo et al., 2012), and 
that CpG methylation interacts with histone methylation to silence TNF expression 
during endotoxin tolerance (Gazzar et al., 2008). Although some previous research 
has not observed associations between DNA methylation of TNF and fatty acids (Lee 
et al., 2013; Bollati et al., 2014); other research has found environmental factors, 
including diet and fatty acids, that do have relationships with TNF methylation 
(Campión et al., 2009; Hermsdorff et al., 2013; Bollati et al., 2014; Gómez-Uriz et al., 
2014). For this reason, it is worth considering cytokine genes as potential targets for 
further investigation. 
The expression of IL6 is also decreased after the treatment of ω-3 Fatty acids 
(Cawood et al., 2010). There is previous evidence for the regulation of gene 
expression through alterations in the methylation of the IL6 promotor (Poplutz et al., 
2014). The occurrence of DNA methylation of four CpG sites in the IL6 promoter is 
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significantly higher in cancer cell lines and associated with lower IL6 mRNA and 
methylation of the IL6 promoter was inversely related to mRNA levels (Tekpli et al., 
2013). In addition, when macrophages are stimulated with LPS, increased mRNA is 
associated with lower IL6 promotor methylation (Nile et al., 2008). Measures of 
adiposity have been found to associate with IL6 promotor methylation (Na et al., 2015). 
A cross sectional study comparing ω-3 PUFA in erythrocyte membranes with IL6 
methylation of a single CpG site within the IL6 gene found that DHA and total ω-3 fatty 
acid was negatively associated with the methylation level. Furthermore, methylation 
of this site was correlated with IL6 expression and plasma IL6 concentration (Ma et 
al., 2016). A separate CpG site in the same study found no relationship between IL6 
expression and plasma IL6 concentration (Ma et al., 2016), indicating the importance 
of site selection. In addition, this study used 450k array measurements of the 
methylation at each of these sites, demonstrating that although 450k arrays sample a 
high number of sites, it depends if those individual CpGs are biologically relevant to 
be altered or have associations with fatty acids.  
A third cytokine, for which evidence of alteration by of ω-3 PUFAs exists, is IL1β 
(Allam-Ndoul et al., 2016). There is also evidence of transcriptional regulation of this 
cytokine through methylation of the promotor (Hashimoto et al., 2009; Aoi et al., 2011; 
Tekpli et al., 2013). In cancer cells, CpG sites near the transcription start site (TSS) of 
IL1B “interleukin 1 beta” promoter were significantly more methylated and associated 
with lower IL1B mRNA levels (Tekpli et al., 2013). Methylation of the IL1B promoter 
was inversely related to mRNA levels in cultured human lung cells (Tekpli et al., 2013). 
Two CpG sites (-299 and -256bp from Exon 1) in the IL1B promoter were differentially 
methylated between control samples and cytokine-treated chondrocytes (Hashimoto 
et al., 2009). There is currently no evidence on the effects of ω-3 PUFAs on the 
methylation levels of IL1B and therefore will investigate this further in this thesis. 
The following genes were considered for assay design: NFKB1, NFKB2 (failed assay 
design), TNF, IL6 and IL1B.  
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3.4 Pyrosequencing Assay Design 
3.4.1 Assay Design 
Approximately half of all gene promotors contain CpG islands, the methylation of these 
islands interacts with other epigenetic controls such as histones to control the 
transcription of the gene (Deaton and Bird, 2011). Methylation in promotors and 
regions proximal to promotors which do not contain CpG islands has also been shown 
to regulate gene expression (Jones, 2012). This has been observed in inflammatory 
genes including NOS2 “nitric oxide synthase 2”, IL2 “interleukin 2”, IFNG, MMP13 
“Matrix Metallopeptidase 13”, IL1B , and TNF; (Northrop et al., 2006; Gazzar et al., 
2008; Berkley et al., 2013; Hashimoto et al., 2013; Williams et al., 2013; Gross et al., 
2014). Additionally, it is not only the DNA methylation that occurs in the promotor 
region near the TSS that plays an important role in regulation of gene expression, with 
evidence suggesting that 5mC in gene bodies and non-promotor regions plays an 
important role (Lou et al., 2014). Methylation in gene bodies alters the activity of the 
gene by preventing the binding of transcription proteins (Choy et al., 2010). There is 
also evidence that methyl-CpG-binding proteins bind to methylated DNA and recruit 
other proteins, such as histone deacetylases, which alter the chromatin structure 
which reduces transcription (Nan et al., 1998). However there are also recent reports 
that methylation can also promote transcription of a gene through the recruitment of 
protein complexes (Harris et al., 2018), thus aiding the fine tuning of gene expression 
through DNA methylation.  
Careful considerations must be taken when designing assays to measure the DNA 
methylation of candidate genes. In order to design assays that were within biologically 
relevant regions of each of the target genes, the current literature was used to pick 
regions of the genes which had either shown some associations with fatty acids (where 
available) or where there was previous evidence of transcriptional activation of the 
gene. The FASTA DNA sequence for each target gene was downloaded from 
Ensemble (EMBL-EBI) NCBI build 38 and the sequence for the target region within 
the gene was imported into the PyroMarkTM assay design software (Qiagen, 
Germany). The bisulphite conversion of the sequence is performed in silico by the 
assay design software. Manual selection of the target region within the bisulphite-
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converted target region was completed prior to running the software to generate 
potential primer sets. The PyroMarkTM software scored each of the assays generated 
out of 100. For each target region the highest scoring assay was assessed for 
suitability and manually adjusted if required. 
PCR Primers should have the following characteristics where possible (Chuang, 
Cheng and Yang, 2013): 
• Primer length between 20-32 nucleotides 
• No CpG sites within the binding region of the primer 
• The GC content <60% 
• Annealing temperature below 65oC 
• Sequences of homopolymers and repetitive sequences should be avoided 
• No self-complementarity or secondary structures 
• Amplification product should be <350bp 
The specificity of the PCR primer sets was assessed using online primer design tools:  
• Bisearch (http://bisearch.enzim.hu/?m=genompsearch) primer search function 
run the PCR in silico using the bisulphite converted DNA of the selected 
organism. This is used to identify the number of products that will be formed by 
the PCR primers. 
• PrimerBLAST (https://www.ncbi.nlm.nih.gov/tools/primer-blast/) checks the 
primers against the reference assembly for human genomic DNA, this is used 
to confirm that non-converted DNA will not be amplified by the primer sets.  
The assays designed are detailed in Table 3-1. 
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Table 3-1 Pyrosequencing assays 
Assay Primer Sequence 
Assay 
Score 
(PyroMark) 
Number of 
CpG sites 
covered 
Validation 
Accuracy 
(R2) 
Coefficient 
of Variation 
(%) 
Assay A Forward PCR  5’- biotin-TGTGAGGGGTATTTTTGATGT-3’ 
75 5 Failed 
  
N/A 
 
(TNF Promotor) Reverse PCR  5’-CCTTAATAAAAAAACCCATAAACTCATC-3’ N/A 
 Sequencing  5’-AAACCCATAAACTCATCTA-3’  
Assay B Forward PCR  5’-GGAAAGGATATTATGAGTATTGAAAGTATG-3’ 
100 4 Passed  
  
7.84 (TNF exon 1) Reverse PCR  5’-biotin-CTAAAACCCCCCTATCTTCTTAAA-3’ 0.9915 
 Sequencing  5’-ATTATGAGTATTGAAAGTATGAT-3’  
Assay C Forward PCR  5’-GGGAAGAGGGTTTTTGAATTAG-3’ 
92 6 Passed  
  
0.38 (IL6 -1099) Reverse PCR  5’-biotin-CTCCCTCTCCCTATAAATCTTAATTTAA-3’ 0.9939 
 Sequencing  5’-TTGAATTAGTTTGATTTAATAAGAA-3’  
Assay D Forward PCR  TGGGTTGAAGTAGGTGAAGAAA-3’ 
95 4 
Passed – very low 
methylation levels on 
samples 
  
N/A 
 
(IL6 -666) Reverse PCR  5’-biotin-ACTACCTAACCATCCTCAAATT-3’ N/A 
 Sequencing  AGGTGAAGAAAGTGG-3’  
Assay E Forward PCR  5’-ATGGAAGGGTAAGGAGTAGTAA-3’ 
89 2 Failed 
  
N/A 
 
(IL1B -299) Reverse PCR  5’-biotin-ATATCTTCCACTTTATCCCACATATAC-3’ N/A 
 Sequencing  5’-ATGTAAATATGTATTGTTTTTTTGA-3’  
Assay F Forward PCR  5’-GGGAGGTTGAGGTAGGAGAAT-3’ 
92 5 Passed  
  
0.97 
 
(IL1B -1063) Reverse PCR  5’-biotin-CACCCTCCTTTACCTCTTTAACAAATCTA-3’ 0.9934 
 Sequencing  5’-GGAGAATGGTGTGAA-3’  
Assay G Forward PCR  5’-GGTTGGTTGAGTTAGTTTAGAGTTAAA-3’ 
89 2 
Passed – very low 
methylation levels on 
samples 
  
N/A 
 
(NFKB1) Reverse PCR  5’-biotin-CTCAAAACCCAAAAAACCCCTTCTC-3’  N/A 
 Sequencing  5’-GTTAGTTTAGAGTTAAATTTTTAGT-3’  
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3.4.2 Tumor Necrosis Factor (TNF) Assay 
The primers were designed to amplify two regions within the gene encoding TNFα 
which had been demonstrated to either change with an inflammatory stimulus or 
associated with expression. The FASTA sequence (GRCh 38: 6: 31574967: 
31578936: 1) for the TNF gene was used to design the assays for two regions of the 
gene: promotor and exon 1, refer to Figure 3-2. Assay A was designed to measure the 
methylation of five CpG sites within the promotor of TNF (-170, -164, -162, -147 and -
120 bp from the TSS). The highest score for an assay in this region was 75; this was 
the result of a homopolymer sequence adjacent to the CpG sites that were being 
analysed. Assay B targeted four CpG sites within exon 1 of TNF (+197, +202, +214 
and +222 bp from the TSS), this assay scored the maximum with a score of 100. 
Bisearch confirmed that PCR product would be formed from the correct regions on the 
sense strand of chromosome 6. The primers were then run through PrimerBLAST, for 
Assay A (Promotor) there were no targets found within the reference assembly. Assay 
B (Exon 1) found two potential products, however it was considered that these 
products would not interfere with the assay due to the product length (>1000bp) and 
confirmed during validation of the assay via gel electrophoresis and assay 
performance.  
3.4.3 Interleukin 6 (IL6) Assay 
With regards to the IL6 gene, two regions were identified in the gene promotor which 
had associated with fatty acids and transcription of the gene. The FASTA sequence 
(GRCh38:7:22725284:22732602:1) was used for the IL6 assay design. Assay C was 
designed to cover the CpG site -1099 from the TSS and Assay D covered CpG site -
666 from the TSS. Both assays scored well on the assay design software with 95 and 
92 respectively. Using Bisearch, one PCR product was found for each of the assays 
designed and PrimerBLAST did not identify any products from non-bisulphite 
converted DNA, indicating only bisulphite converted DNA would amplify. 
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3.4.4 Interleukin 1 Beta (IL1B) Assay 
The FASTA sequence (GRCh38:2:112829151:112837503:-1) was used for the IL1B 
assay design. The IL1B assay was designed on the reverse strand of the gene with 
Assay E covering the CpG -299bp from the TSS and Assay F covering -1099bp from 
the TSS. These assays scored 89 and 92 respectively. 
3.4.5 Assay validation 
Once the assays had been designed for the regions of interest, the assays were 
ordered from the custom assay service provided by Qiagen. Validation of the assays 
was completed by using the PyroMark® PCR kit (Qiagen, Germany) in a Veriti® 
thermocycler (Applied Biosystems Inc., USA) for amplification of target DNA. The PCR 
product was sequenced with the PyroMark® Q48 Autoprep (Qiagen, Germany) using 
Advanced CpG Reagents (Qiagen, Germany) in accordance with the manufacturer’s 
protocols. 
The specificity of the primers to detect methylated and unmethylated cytosines was 
evaluated using EpiTect Control DNA (Qiagen, Germany), then mixed to varying 
methylation percentages. In addition, interaction between the primers for loop 
formation was examined using a specific set of control experiments:  
• PCR negative (no template DNA),  
• PCR negative (no template DNA, no sequencing primer),  
• Sequencing primer (no PCR product),  
• PCR product (non-converted template DNA). 
The performance of each assay was confirmed by running methylated and 
unmethylated bisulphite-converted DNA (Qiagen, Germany), a combination of the two 
bisulphite-converted DNA controls (50% methylated), unmethylated non-converted 
DNA (uncon) and negative no template control (NTC). Two additional reactions of 50% 
methylated control DNA were included to allow for a no sequencing primer (noseq) 
control. PCR product was visualised on a 2% agarose gel stained with SybrSafe, an 
example gel is shown in Figure 3-1.  
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Figure 3-1 Gel electrophoresis image of the IL1B validation. No template control (NTC) 
PCR-based methods of methylation analysis, such as pyrosequencing can be affected 
by PCR bias, because the methylated and unmethylated DNA amplify at different 
efficiencies. In order to check each of the designed assays for PCR biases, known 
quantities of methylated and unmethylated control DNA (Qiagen, Germay) were mixed 
at incremental percentages to produce standard curves.  
The bisulphite-converted DNA was amplified using custom designed assays with the 
PyroMark® PCR kit (Qiagen, Germany) in a Veriti® thermocycler (Applied Biosystems 
Inc., USA). PCR product was used for CpG quantification with the PyroMark® Q48 
Autoprep (Qiagen, Germany) using Advanced CpG Reagents (Qiagen, Germany) in 
accordance with the manufacturers protocol. The assay covered the methylation sites 
+197, +202, +214 and +222 bp from the transcription start site of TNF. The percentage 
methylation of the four CpG sites was calculated within the software (PyroMark® Q48 
Autoprep 2.4.1 Software, Qiagen, Germany) and the methylation percentages were 
exported for further analysis. 
Three assays passed validation and had methylation levels from blood samples of 
>5%, refer to Table 3-1. These assays TNF (Assay B), IL6 (Assay C) and IL1B (Assay 
F) are used throughout this thesis, the genomic location of these assays is shown in 
Figure 3-2, Figure 3-3 and Figure 3-4. 
. 
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Negative control 
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Figure 3-2 Genomic structure of TNF (MIM 191160; GRCh 38: 6: 31574967: 31578936: 1). Sequence shown for promotor and exon 
1 with Cytosine-Guanine dinucleotides (CpG) sites indicated. Assay A (red) covers five CpG sites CpG1 (-170), CpG2 (-
164), CpG3 (-162), CpG4 (-147) and CpG5 (-120) base pairs from the Transcription Start Site (TSS). Assay B (green) 
covers four CpG sites CpG1 (+197), CpG2 (+202), CpG3 (+214) and CpG4 (+222) base pairs from the TSS. Coding DNA 
Sequence (CDS). Exon 1 displayed in bold. 
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Figure 3-3 Genomic structure of IL1B (MIM 147720; 
GRCh38:2:112829151:112837503:-1). Sequence shown for promotor and 
exon 1 with Cytosine-Guanine dinucleotides (CpG) sites indicated. Assay 
F (red) covers five CpG sites CpG1 (-1063), CpG2 (-1056), CpG3 (-1039), 
CpG4 (-1033) and CpG5 (-1009) base pairs from the Transcription Start 
Site (TSS) Assay E (green) covers two CpG sites CpG1 (-299), and CpG2 
(-256) base pairs from the TSS. The start of Exon 1 displayed in bold. 
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Figure 3-4 Genomic structure of IL6 (MIM 147620; GRCh38:7:22725284:22732602:1). 
Sequence shown for promotor with Cytosine-Guanine dinucleotides (CpG) 
sites indicated. Assay D (red) covers four CpG sites CpG1 (-666), CpG2 (-
664), CpG3 (-628) and CpG4 (-610) base pairs from the Transcription Start 
Site (TSS) Assay C (green) covers six CpG sites CpG1 (-1099), CpG2 (-
1065), CpG3 (-1094), CpG4 (-1069), CpG5 (-1061) and CpG6 (-1057) base 
pairs from the TSS. Exons within the region are displayed in bold. 
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Chapter 4 Cross sectional analysis of TNF 
methylation and associations with blood 
fatty acid profile 1 
4.1 Introduction 
The global trend towards the Western diet has altered the quantity and composition of 
dietary fat (Popkin, 2006). This change is significant because evidence now indicates 
that consuming the right sort of fat is important (de Oliveira Otto et al., 2012). Dietary 
fatty acids, SFAs, MUFAs, w-3 PUFAs and w-6 PUFAs are reported as having differing 
effects upon health (Estruch et al., 2006; Lunn, 2007; Mozaffarian, Micha and Wallace, 
2010; Innes and Calder, 2018). Some of the reported effects are beneficial whilst 
others are detrimental. For example, research suggests that the replacement of SFAs 
with PUFAs is associated with lower incidence of CHD (Mozaffarian, Micha and 
Wallace, 2010). Furthermore, consuming MUFAs rather than SFAs has a protective 
effect for CHD, diabetes and cancer (Lunn, 2007). 
The nutritional components of diet, including fatty acids, ultimately contribute to cell 
environment. Cells respond to their environment through changes in epigenetic 
mechanisms, which include histone modifications, microRNAs, chromatin remodelling 
and DNA methylation (Joseph, Abey and Henderson, 2016). Some of these responses 
result in alterations to and errors within the epigenome and are implicated in diseases 
such as cancer, CHD, and inflammatory bowel disease (Jones and Baylin, 2007; 
Barnett et al., 2010; Muka et al., 2016). A common component of these diseases is 
chronic inflammation (Chen et al., 2018). Fatty acids are involved with the 
inflammatory process on multiple levels, including the production of eicosanoids, 
                                            
1 Adapted from Hussey B., Steel R., Taylor I.M., Gyimah B., Reynolds J., Lindley 
M.R., & Mastana S.S. (In review) DNA methylation of tumor necrosis factor (TNF) 
alpha gene is associated with specific blood fatty acid levels. Epigenetics. 
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alterations in cell signalling and interactions with gene expression, amongst others 
(Calder, 2012a). It is the epigenetic interaction of fatty acids, specifically with regards 
to DNA methylation, which will be examined using a cross sectional study design in 
this chapter.  
Interactions between fatty acids and methylation have been the subject of research 
utilising both cross-sectional loci-specific and meth-GWAS. Relationships between 
dietary fatty acids and biologically significant pathways related to inflammation have 
been observed (Hermsdorff et al., 2013; Aslibekyan et al., 2014; Haghighi et al., 2015; 
Voisin et al., 2015; Cui et al., 2016; Ma et al., 2016; Rahbar et al., 2018). In a meth-
GWAS study of an adolescent population, fatty acid ratios (including 
(MUFA+PUFA)/SFA and PUFA/SFA) in the diet showed significant associations with 
pathways linked to nuclear factor kappa B (NFkB), peroxisome proliferator-activated 
receptor alpha (PPARa), LEP and IL6 (Voisin et al., 2015). Using a 24-hour dietary 
recall, the authors were only capturing the short-term dietary effects of the fatty acids. 
By measuring the biochemical w-3 PUFA status of blood, a separate meth-GWAS 
study considered the longer-term dietary habits, incorporation into the blood and the 
endogenous production of fatty acids (Aslibekyan et al., 2014). This research of an 
Alaskan (Yup’ik) cohort found 27 significant DMRs when splitting the cohort by w-3 
PUFA status; DMRs were found in genes which are implicated in disease and 
inflammation including helicase-like transcription factor (HLTF), actin a 2 smooth 
muscle, fas cell surface death receptor (FAS), neuron navigator 1, chemokine ligand 
17, and aryl-hydrocarbon receptor repressor (Aslibekyan et al., 2014). Additionally, it 
was found that the majority of sites (78%) had increased methylation with higher w-3 
status, suggesting that increased levels of w-3 PUFA may improve epigenomic 
stability. 
In candidate gene approaches, associations have been investigated between dietary 
fatty acids and the DNA methylation of genes involved in fatty acid metabolism. The 
methylation of the FADS1, and FADS2 genes were investigated in three cohorts, 
where negative associations with w-6 PUFAs were observed in all cases (Cui et al., 
2016; Rahbar et al., 2018). The methylation of these genes, and fatty acid metabolism 
gene elongation of very long chain fatty acids protein 5 (ELOVL5), has been 
associated with clinical outcomes such as major depressive disorder (Haghighi et al., 
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2015). In addition, associations between PUFA’s and suicide risk were explained by 
ELOVL5 methylation (Haghighi et al., 2015). Genes involved with inflammation have 
briefly been studied. A CpG site within the IL6 gene showed a negative association 
with total w-3 PUFA, with dependency on a single nucleotide polymorphism within the 
same gene (Ma et al., 2016).  
The interactions that have been discussed so far, suggest that there is scope to 
investigate further the relationship between fatty acids and methylation focusing on 
genes associated with the inflammatory process. Chronic inflammatory diseases are 
often characterised by elevated levels of circulating inflammatory cytokines, such as 
TNFa. The research, which is the subject of this chapter, has specifically focused on 
the effect of methylation on this gene. 
TNFa is produced predominantly in monocytes and macrophages; it is an important 
mediator in inflammation and in the regulation of multiple other genes, including but 
not limited to: transcription factors, cytokines, growth factors, receptors, cell adhesion 
molecules and inflammatory mediators (Vilček and Lee, 1991; Locksley, Killeen and 
Lenardo, 2001; Bradley, 2008). Transcriptional control of the TNF gene occurs partly 
through epigenetic mechanisms (Sullivan et al., 2007; Gazzar et al., 2008; Campión 
et al., 2009; Falvo, Tsytsykova and Goldfeld, 2010; Cordero et al., 2011; Gowers et 
al., 2011). Furthermore, DNA methylation levels within the promotor and exon 1 
regions of the TNF gene are associated with plasma TNFa cytokine levels (Hermsdorff 
et al., 2013). The DNA methylation profile of TNF has been shown to be associated 
with diseases including Crohn’s disease, post-traumatic stress disorder and age-
related inflammation, as well as truncal fat and diet (Gazzar et al., 2008; Pieper et al., 
2008; Campión et al., 2009; Cordero et al., 2011; Gowers et al., 2011; Nimmo et al., 
2012). Using a targeted candidate gene approach, this research has sought to 
establish whether there is a relationship between blood fatty acid levels and the DNA 
methylation profile within the first exon of the TNF gene. 
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4.2 Method 
4.2.1 Participants 
Ethical clearance was granted from the Loughborough University Ethics Approvals 
(Human Participants) Sub-Committee (reference R16-P074) and all participants 
provided written informed consent. Adults (n=88, 18+ years) were recruited from the 
local community in the Loughborough Town area. Participants were free of blood 
borne viruses; there were no other exclusion criteria.  
4.2.2 Study visit 
Participants came to the National Centre for Sport and Exercise Medicine at 
Loughborough University for one visit. After obtaining written consent, anthropometric 
measurements of height and weight were recorded; two participants refused 
measurement of height and weight and therefore were not included in analysis 
requiring these variables. A finger prick capillary blood sample was collected into three 
300μL EDTA-coated microvette tubes (Microvette® CB 300 µl, K2 EDTA, Sarstedt, 
Germany) for blood cell count and DNA extraction. Four dried blood spots (DBS) were 
collected for fatty acid analysis.  
4.2.3 Fatty acid measurements 
DBSs were collected on Whatman cards (903 Protein saver, Sigma-Aldrich) pre-
treated with butylated hydroxytoluene (supplied by the Loughborough University 
Chemistry department) to stabilise the blood fatty acids for up to eight weeks at room 
temperature (Metherel et al., 2013). Each DBS was punched from the card, weighed 
and frozen at -80oC within eight weeks of collection. Gas chromatography mass 
spectrometry (GC-MS), carried out by Boakye Gyimah in the Loughborough University 
Chemistry department, was used to analyse the fatty acid composition of the DBS. 
Methyl esters were prepared using the method from Ichihara and Fukubayashi, 
(2010). Briefly, one of the 30mm2 punched samples was derivatised by acetyl chloride 
(99%, Sigma Aldrich) and methanol (HPLC grade, Fisher Scientific) at 70oC for 60 
minutes to produce fatty acid methyl esters (FAMEs) and reconstituted in 100µl 
hexane (HPLC grade, Fisher Scientific) containing 10µg/ml of internal standard 
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(methyl heptadecanoate, analytical standard 51633-1G, Sigma Aldrich). The sample 
was analysed by GC-MS, FAMEs were characterized by electron ionization in positive 
ion full scan mode. Fatty acid quantities were determined based on the relative 
abundance to the internal standard. Fatty acids are presented as their percentages of 
total fatty acids (%TFA.). 
4.2.4 DNA extraction and bisulphite conversion 
One aliquot of the capillary blood was used for a cell count (Beckman Coulter Counter, 
USA). Aliquots of capillary blood were frozen at -80oC until analysis. DNA was 
extracted from the capillary blood and bisulphite-converted using EpiTectTM Fast 
LyseAll Bisulphite conversion kit (Qiagen, Germany) using the manufacture’s protocol. 
Briefly, the blood sample was lysed, and proteins denatured, the resulting pellet was 
re-suspended in PBS and added directly into the bisulphite reaction. The DNA was 
sodium bisulphite-treated and subjected to two cycles of denaturing at 95oC for 5 
minutes and incubation 60oC for 20 minutes. Bisulphite-converted DNA was 
desulfonated and purified using MinElute spin columns provided. Successful bisulphite 
conversion was assessed using a bisulphite-converted DNA-specific dispensation 
during the pyrosequencing, as displayed on a pyrogram in Figure 4-1 highlighted in 
orange. 
 
Figure 4-1 Example pyrogram for TNF exon 1 assay covering Cytosine-Guanine 
dinucleotides (CpG) sites +197, +202, +214 and +222 from the transcription 
start site, highlighted grey. Dispensation 15, highlighted in orange, served 
as a bisulphite conversion control. 
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4.2.5 DNA methylation analysis 
The methylation of four CpG sites within Exon 1 of the TNF were measured using 
bisulphite pyrosequencing (PyroMark® Q48 Autoprep System, Qiagen, Germany).  
Primers, designed in Chapter 3, are provided in Table 4-1. The extracted bisulphite-
converted DNA was amplified using the PyroMark® PCR kit (Qiagen, Germany) in a 
Veriti® thermocycler (Applied Biosystems Inc., USA). PCR product was used for CpG 
quantification with the PyroMark® Q48 Autoprep (Qiagen, Germany) using Advanced 
CpG Reagents (Qiagen, Germany) in accordance with the manufacturers protocol. 
The assay covered the methylation sites +197, +202, +214 and +222 bp from the 
transcription start site of TNF. The percentage methylation of the four CpG sites was 
calculated within the software (PyroMark® Q48 Autoprep 2.4.1 Software, Qiagen, 
Germany) and the methylation percentages were exported for further analysis.  
 
 
Table 4-1: Pyrosequencing primers for TNF (MIM 191160) exon 1. The assay covers 
four methylation sites +197, +202, +214 and +222 base pairs from the 
transcription start site. 
Pyrosequencing Primer Sequence 
Forward PCR 
Primer  
5’-GGAAAGGATATTATGAGTATTGAAAGTATG-3’ 
Reverse PCR Primer  5’-biotin-CTAAAACCCCCCTATCTTCTTAAA-3’ 
Sequencing Primer  5’-ATTATGAGTATTGAAAGTATGAT-3’ 
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4.2.6 Statistical Analysis 
All statistical analysis was performed using IBM SPSS statistics software (SPSS 
version 23). The data distribution was assessed for normality by Shapiro-Wilk's test (p 
> 0.05). Group differences between sex were assessed using an independent sample 
t-test for normally distributed data and a Man Whitney-U test where appropriate. 
Differences between sex for categorical data were assessed using chi-square.  
A key consideration in DNA methylation studies is the composition of the white blood 
cells (WBCs) from which the DNA is extracted. The DNA methylation values are 
therefore presented raw and adjusted for the cell heterogeneity of the capillary blood. 
The method presented by Jones et al., (2015) was used to adjust DNA methylation 
values to account for the white blood cell composition. In brief, the adjusted figure is a 
sum of the mean methylation for the site and the unstandardised residual from a linear 
regression between DNA methylation (dependent variable) and the individual white 
blood cell counts (independent variables).  
Spearman’s correlation analysis was used to assess the relationship between the 
methylation (raw and adjusted) percentage of the four sites studied and the fatty acids 
identified within the blood. A p-value lower than 0.05 was considered significant. Using 
an expected b = 0.2 and r = 0.3, sample size required was 85. 
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4.3 Results 
Table 4-2: Demographic characteristics of the sample population 
 All participants Males Females   
(n=88) (n = 30) (n = 58) p 
Age (years)a. 25 (22-41) 30 (23-47) 24 (21-39) .210 
     
Height (cm)b,d. 170.3 ± 8.7 177.3 ± 6.7 166.6 ± 7.2 <.001 
Weight (kg)a,d. 70.2 (59.9-80.1) 80.6 (75.5-88.9) 63.3 (56.6-73.0) <.001 
BMI a,d. 23.9 (21.9-26.5) 24.9 (22.7-27.3) 22.9 (21.2-26.0) .071 
     
Current smoker (n, %)c. 7 (8.0%) 4 (13.3%) 3 (5.2%) .180 
Ever smoked (n, %)c. 24 (27.3%) 10 (33.3%) 14 (24.1%) .359 
     
Total white blood cells (109/L) a.e. 6.69 ± 1.40 6.19 ± 1.12 6.94 ± 1.47 .018 
Neutrophils (109/L) a.e. 3.95 ± 1.09 3.61 ± 0.90 4.13 ± 1.15 .039 
Lymphocyte (109/L) a.e. 1.99 ± 0.55 1.87 ± 0.33 2.06 ± 0.63 .132 
Monocytes (109/L) a.e. 0.48 ± 0.12 0.47 ± 0.11 0.48 ± 0.12 .928 
Eosinophils (109/L) a.e. 0.18 ± 0.11 0.15 ± 0.07 0.19 ± 0.12 .115 
Basophils (109/L) a.e. 0.06 ± 0.02 0.06 ± 0.02 0.06 ± 0.02 .808 
Large immature cells (109/L) a.e.. 0.04 ± 0.03 0.03 ± 0.02 0.04 ± 0.03 .181 
a. Data was non-normally distributed, and data presented as median (lower quartile-upper quartile); differences between 
groups assessed by Man-Whitney-U difference test. 
b. Data was normally distributed and presented as mean ± standard deviation; differences between groups assessed by 
independent samples t-test. 
c. Categorical data, differences between groups assessed by Pearson chi-square 
d. height and weight data missing for 2 female participants, (total n=86, female n=56) 
e. Blood cell count data was not available for 3 participants (total n=85, males n=29, females n=56) 
4.3.1 Sample demographic 
Eighty-eight adults (Male n=30 and Female n=58) were recruited, details of the sample 
demographic are shown in Table 4-2. The age ranged from 18 to 74 years and there 
was a positive skew towards younger individuals, the sample contained 4 individuals 
above the age of 60 years. A small number of individuals were current smokers (n=7) 
within the sample, with almost a third (n=24) had considered themselves smokers at 
some point during their life. Height and weight differed between the sex, with male 
participants significantly taller and heavier than the female participants. In addition, a 
significant difference in total white blood cell count and neutrophil cell count was 
observed between males and females, therefore adjustment of DNA methylation 
values for cell composition was calculated both as a whole sample and separately split 
by sex. 
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4.3.2 DNA methylation 
The average methylation of the four sites studied was 8.71%. DNA methylation was 
not significantly different between males and females, refer to Table 4-3. Moreover, 
this remained after adjustment for white blood cell composition (data not shown) 
despite the significant difference in white blood cell count between the sex. 
 
Table 4-3 DNA methylation percentages for four Cytosine-Guanine dinucleotides 
(CpG) sites (+197, +202, +214 and +222 base pairs from transcription start 
site) located within exon 1 of the TNF gene (encoding cytokine Tumor 
Necrosis Factor alpha, TNFα) 
DNA Methylation (%) 
 All  Males  Females   
 (n=88)  (n = 30)  (n = 58) p 
CpG 1 (+197) 8.8 ± 2.3 8.6 ± 2.0 8.9 ± 2.4 .511 
CpG 2 (+202) 6.5 ± 2.0 6.3 ± 2.1 6.6 ± 1.9 .568 
CpG 3 (+214) 7.3 ± 2.1 7.2 ± 2.3 7.3 ± 2.0 .679 
CpG 4 (+222) 12.3 ± 2.9 12.0 ± 3.2 12.4 ± 2.8 .520 
CpG average 8.7 ± 2.1 8.5 ± 2.3 8.8 ± 2.1 .532 
Data was normally distributed and presented as percentage methylation (%) mean ± standard deviation; differences between 
groups assessed by independent samples t-test. Cytosine-Guanine dinucleotides (CpG). 
 
4.3.3 Fatty acid profile of peripheral blood 
A total of 25 fatty acids were identified from the dried blood spots, presented in Table 
4-5 as a percentage of total fatty acid. A ratio of 3.04 was observed for w-6 to w-3 
PUFAs. There was no significant difference in fatty acid ratios between the sex, Table 
4-4. The ⍵-3 PUFA DPA was significantly different between sex (p=0.05); all other 
fatty acids identified did not show any difference between the sexes, Table 4-5. 
Table 4-4 Fatty acid ratios from dried blood spots 
 Fatty Acid Ratios All Males Females   (n=88) (n = 30) (n = 58) p 
MUFA / SFA 0.48 ± 0.08 0.47 ± 0.09 0.49 ± 0.08 0.199 
PUFA / SFA 0.65 ± 0.10 0.64 ± 0.08 0.66 ± 0.10 0.482 
(MUFA+PUFA) / SFA 1.13 ± 0.12 1.11 ± 0.12 1.15 ± 0.13 0.159 
w-6 PUFA / w-3 PUFA 3.04 ± 0.50 3.06 ± 0.56 3.02 ± 0.48 0.740 
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Table 4-5 Fatty acid profile of dried blood spots 
  All Males Females   
  (n=88) (n = 30) (n = 58) p 
Omega 3 Polyunsaturated Fatty Acids (⍵-3 PUFA) 
18:3w-3 (ALA, alpha-Linolenic acid) 5.3 ± 1.1 5.3 ± 1.1 5.3 ± 1.1 0.975 
20:5w-3 (EPA, Eicosapentaenoic acid) 0.6 ± 0.7 0.5 ± 0.2 0.6 ± 0.8 0.399 
22:5w-3 (DPA, Docosapentaenoic acid) 0.6 ± 0.2 0.6 ± 0.1 0.6 ± 0.2 0.050 
22:6w-3 (DHA, Docosahexaenoic acid) 1.3 ± 0.5 1.2 ± 0.5 1.3 ± 0.5 0.643 
TOTAL ⍵-3 PUFA 7.7 ± 1.5 7.6 ± 1.4 7.8 ± 1.6 0.728 
Omega 6 Polyunsaturated Fatty Acids (⍵-6 PUFA) 
18:2w-6 (LA, Linoleic acid) 13.8 ± 1.6 13.7 ± 1.6 13.9 ± 1.6 0.641 
18:3w-6 (GLA, "-Linolenic acid) 1.2 ± 0.4 1.1 ± 0.4 1.2 ± 0.5 0.328 
20:2w-6 (Eicosadienoic acid) 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 0.409 
20:3w-6 (DGLA, Dihomo-"-linolenic acid) 0.8 ± 0.2 0.8 ± 0.2 0.8 ± 0.3 0.850 
20:4w-6 (AA, Arachidonic acid) 6.4 ± 1.4 6.5 ± 1.5 6.3 ± 1.4 0.491 
22:4w-6 (Adrenic Acid) 0.4 ± 0.1 0.4 ± 0.1 0.4 ± 0.1 0.193 
22:2w-6 (Docosadienoic acid) 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.977 
TOTAL ⍵-6 PUFA 22.8 ± 2.8 22.8 ± 2.8 22.8 ± 2.6 0.986 
Monounsaturated Fatty Acids (MUFA) 
14:1w-5 (Myristoleic acid) 14.4 ± 2.1 14.1 ± 2.4 14.5 ± 2.0 0.319 
16:1w-7 (Palmitoleic acid) 1.1 ± 0.3 1.1 ± 0.2 1.1 ± 0.3 0.427 
17:1w-7 (Cis-10-Heptadecenoic acid) 2.4 ± 0.7 2.3 ± 0.9 2.5 ± 0.6 0.326 
22:1w-17 (5Z-docosenoic acid) 0.6 ± 0.1 0.6 ± 0.1 0.6 ± 0.1 0.687 
18:1w-9 (Oleic acid) 2.8 ± 1.0 2.9 ± 1.0 2.8 ± 1.0 0.812 
18:1w-9 (9-octadecenoic acid) 0.7 ± 0.4 0.7 ± 0.4 0.8 ± 0.40 0.559 
20:1w-9 (Gondoic acid) 0.4 ± 0.1 0.4 ± 0.1 0.4 ± 0.1 0.663 
TOTAL MUFA 22.5 ± 3.2 22.0 ± 3.5 22.7 ± 3.0 0.327 
Saturated Fatty Acids (SFA) 
13:0 (Tridecanoic acid) 0.1 ± 0.1 0.1 ± 0.0 0.1 ± 0.0 0.447 
14:0 (Myristic acid) 3.1 ± 1.2 3.3 ± 1.2 3.1 ± 1.2 0.528 
15:0 (Pentadecanoic acid) 0.9 ± 0.3 1.0 ± 0.3 0.9 ± 0.2 0.146 
16:0 (Palmitic acid) 22.8 ± 2.1 23.0 ± 2.0 22.7 ± 2.2 0.540 
18:0 (Stearic acid) 19.2 ± 1.4 19.4 ± 1.4 19.1 ± 1.4 0.235 
20:0 (Arachidic acid) 0.5 ± 0.3 0.5 ± 0.3 0.5 ± 0.3 0.391 
22:0 (Behenic acid) 0.4 ± 0.1 0.4 ± 0.1 0.4 ± 0.1 0.410 
TOTAL SFA 47.0 ± 2.8 47.6 ± 2.7 46.6 ± 2.9 0.188 
Data is presented as Percentage Total Fatty Acids (%TFA), mean ± standard deviation; differences between groups assessed 
by independent samples t-test. 
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4.3.4 Relationship between blood fatty acid and TNF DNA methylation 
The relationship between capillary blood fatty acid levels and DNA methylation of TNF 
(correlation) at the four sites studied in exon 1 is highly dependent upon the sex of the 
cohort. Consequently, examining the results of the cohort as a whole could lead to 
misleading conclusions and hence the following analysis considers the results 
according to sex. In addition, it was also found that levels of correlation depended 
upon whether methylation was adjusted for white blood cell composition (adjustment). 
As regards males, the w-3 PUFA DHA was positively correlated with CpG methylation 
of TNF at all the CpG sites studied. Post adjustment the correlation remained for CpG2 
and CpG4 but was no longer observed at CpG1 or CPG3. The w-6 PUFA arachidonic 
acid was also found to be positively correlated at all sites except CpG3 where no 
correlation was observed. Post-adjustment the observed correlations increased. The 
results for the male cohort also indicated positive correlation at CpG2 and CpG4 for 
SFA stearic acid. This correlation was no longer evident post adjustment. The male 
cohort had a negative correlation between the w-5 MUFA myristoleic acid across all 
sites pre-adjustment, correlation only remained at CpG2 post-adjustment.  
As regards females, no correlations were observed between w-3 PUFAs and CpG 
methylation pre-adjustment. Post-adjustment a negative correlation was observed at 
CpG1. A negative correlation was also observed in respect of the w-6 PUFA γ-linolenic 
acid (GLA) at CpG1 and CpG2 pre-adjustment. Post-adjustment the correlation only 
remained at CpG2. In contrast the w-6 PUFAs adrenic acid and eicosadienoic acid 
had a positive correlation. Both adrenic acid and eicosadienoic acid were positively 
correlated at CpG3 pre-adjustment. Post adjustment these correlations remained but 
eicosadienoic acid was also found to be positively correlated at CpG2 and CpG4. 
Additional positive correlations were measured for the MUFA 5Z-docosenoic acid at 
CpG4 pre-adjustment and for the SFA tridecanoic acid at CpG2 post-adjustment.  
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Figure 4-2 Spearman correlation coefficients heat map between the DNA methylation 
of four Cytosine-Guanine dinucleotides (CpG) sites located in exon 1 of the 
Tumor Necrosis Factor (TNF) gene and dried blood spot fatty acid levels 
measured as a percentage of total fatty acids. Data values shown in 
Appendix 1. 
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Omega 3 Polyunsaturated Fatty Acids (⍵-3 PUFA)
18:3⍵-3 (ALA, alpha-Linolenic acid)
20:5⍵-3 (EPA, Eicosapentaenoic acid)
22:5⍵-3 (DPA, Docosapentaenoic acid)
22:6⍵-3 (DHA, Docosahexaenoic acid)
TOTAL ⍵-3 PUFA
Omega 6 Polyunsaturated Fatty Acids (⍵-6 PUFA)
18:2⍵-6 (LA, Linoleic acid)
18:3⍵-6 (GLA, !-Linolenic acid)
20:2⍵-6 (Eicosadienoic acid)
20:3⍵-6 (DGLA, Dihomo-!-linolenic acid)
20:4⍵-6 (AA, Arachidonic acid)
22:4⍵-6 (Adrenic Acid)
22:2⍵-6 (Docosadienoic acid)
TOTAL ⍵-6 PUFA
Monounsaturated Fatty Acids (MUFA)
14:1⍵-5 (Myristoleic acid)
16:1⍵-7 (Palmitoleic acid)
17:1⍵-7 (Cis-10-Heptadecenoic acid)
18:1⍵-9 (Oleic acid)
18:1⍵-9 (9-octadecenoic acid)
20:1⍵-9 (Gondoic acid)
22:1⍵-17 (5Z-docosenoic acid)
TOTAL MUFA
Saturated Fatty Acids (SFA)
13:0 (Tridecanoic acid)
14:0 (Myristic acid)
15:0 (Pentadecanoic acid)
16:0 (Palmitic acid)
18:0 (Stearic acid)
20:0 (Arachidic acid)
22:0 (Behenic acid)
TOTAL SFA
Fatty Acid Ratios
MUFA / SFA
PUFA / SFA
(MUFA&PUFA) / SFA⍵-6 PUFA / ⍵-3 PUFA
Key:
- 0.6 + 0.6
Spearman's Rho correlation coefficient
Significant (p<0.05) Spearman's correlation coefficients between the four cytosine-guanine dinucleotide (CpG) sites (+197, +202, +214 and +222 base pairs from 
Transcription Start Site) of TNF gene and fatty acids detected in blood; average methylation of the four sites (CpGavg). Red indicates negative correlation, green 
indicates positive correclation and black indicates no significant correlation, see key. # CpG methylation percentage adjusted for white blood cell population. 
All Males Females
Raw (n=88) Adjusted# (n=85) Raw (n=30) Adjusted# (n=29) Raw (n=58) Adjusted# (n=56)
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4.4 Discussion 
The research reported here demonstrates that there are significant relationships 
between levels of specific blood fatty acids and DNA methylation of four CpG sites in 
exon 1 of the cytokine encoding gene TNF. Although methylation levels were not 
shown to be associated for most of the fatty acids measured, dependent upon the fatty 
acid group, some positive and some negative associations were observed. 
Significantly the magnitude and direction of associations were found to differ according 
to sex.  
The CpG sites investigated here have previously been shown to be associated with 
TNFa mRNA and circulating TNFa (Hermsdorff et al., 2013; Marques-Rocha et al., 
2016). The average methylation levels observed in the current study (8.7%) are 
comparable to those previously observed (Hermsdorff et al., 2013), with a similar 
profile where the fourth CpG site had slightly higher methylation (12.3%). DNA 
methylation is associated with the silencing of genes, specifically when the methylation 
occurs around the transcription start site and the first exon (Brenet et al., 2011), as 
well as in gene bodies and non-promotor regions (Lou et al., 2014). Multiple sites 
within the TNF gene have been shown to be associated with environmental stimuli 
and biomarkers for phenotypes (Gazzar et al., 2008; Pieper et al., 2008; Campión et 
al., 2009; Cordero et al., 2011; Gowers et al., 2011; Nimmo et al., 2012). Additionally, 
the methylation of these sites in particular have been shown to be potential biomarkers 
of the adiposity status of an individual (Marques-Rocha et al., 2016). Associations 
between the methylation status of these sites and TNFa mRNA, as well as cytokine 
levels, have been observed (Hermsdorff et al., 2013). Although gene expression was 
not measured in the current study, it can be hypothesise that the fatty acids with a 
positive relationship to methylation at these sites interact with TNF through altered 
DNA methylation patterns. This may provide an anti-inflammatory effect through 
reduced TNFa cytokine expression; and vice versa for those with a negative 
relationship. In this context, and the results presented in this research, methylation of 
TNF may play an important role in inflammation, specifically relating to obesity.  
We found that w-6 PUFA, AA was positively correlated with TNF methylation in males, 
whilst in females it was not correlated, but its elongated form Adrenic Acid was. This 
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is interesting given that these two fatty acids only differ in length by two carbon atoms. 
In addition to the positive associations observed with w-6 PUFAs, in males it was found 
that there was a positive relationship at all sites between w-3 PUFA DHA and TNF 
methylation. By contrast, females did not show any significant association with DHA 
until adjusted for WBC population, when CpG1 showed a significant negative 
correlation. The differences between the associations observed may be the result of 
the efficiency in which males and females metabolise fatty acids (Lohner et al., 2013). 
An alternative explanation could involve the metabolism of fatty acids to eicosanoids, 
which have also been shown to differ between males and females (Pace, Sautebin 
and Werz, 2017). It is also important to consider that the sex differences could be the 
result of differential regulation of TNF between males and females; previous research 
into TNF promotor methylation, in a weight loss response study, also demonstrated 
sex-specific results (Campión et al., 2009). 
One of the ways in which fatty acids have been found to modulate inflammation is 
through altered cytokine expression (Calder, 2003, 2012a; Rangel-Huerta et al., 
2012). w-3 PUFA supplementation and in vitro studies report decreased production of 
TNFa in LPS-stimulated cells when treated with DHA (Weldon et al., 2007). Despite 
w-6 PUFAs and their inflammatory mediators being predominantly pro-inflammatory 
(Calder, 2006), AA-derived eicosanoid 2-series prostaglandins also have a potent anti-
inflammatory effect through the inhibition of TNFa production (Miles, Allen and Calder, 
2002). As increased methylation of exon 1 is associated with lower levels of TNFa 
mRNA (Hermsdorff et al., 2013), this research suggests that higher levels of w-6 
PUFAs AA and Adrenic Acid as well as the w-3 PUFA DHA result in higher methylation 
of TNF, and this could explain a mechanism through which these fatty acids interact 
with inflammation. Further investigation of the associations found here may lead to a 
better understanding of this interaction and its mechanism. 
Work carried out by Hermsdorff et al. on the same CpG sites found an association with 
w-6 PUFA intake, however their research found the direction of the association to be 
the opposite to that observed here (Hermsdorff et al., 2013). It is possible that this 
discrepancy arises from the different methodologies used for the measurement of the 
w-6 PUFAs. Hermsdorff et al measured w-6 dietary intake, rather than the biochemical 
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measurement of blood fatty acids used here. Multiple factors impact upon the fats 
within blood including the proportion of other dietary fats and other dietary components 
(Katan, Zock and Mensink, 1994), endogenous synthesis of fatty acids and the 
individual’s genetic makeup (Porenta et al., 2013). These factors and the inherent 
disadvantages of FFQ (Prentice et al., 2011) compared to biochemical measurements 
may explain the differences in results. 
In comparison to the w-6 PUFA relationship that was observed, the MUFA myristoleic 
acid was found to have a weak negative correlation with TNF methylation at CpG2. 
Males had a significant negative association between TNF methylation and myristoleic 
acid, as well as total MUFA; no relationship was observed in the female cohort. MUFAs 
are generally considered the healthier option to SFAs (Schwingshackl and Hoffmann, 
2014), however negative association was observed between MUFA/SFA ratio and 
DNA methylation. No other fatty acid ratios showed significant relationships. The 
differing effects of w-6 PUFAs and MUFAs on the methylome have been shown in in 
vitro monocyte models. AA had a trend towards global hypermethylation and the 
MUFA Oleic acid (OA) had a (weaker) hypomethylating effect on the methylome. The 
changes observed were in biologically significant sites rather than random sporadic 
effects throughout the genome (Silva-Martínez et al., 2016).  
Consideration must be given to the design of this research. Firstly, the biological 
significance of measuring only four CpG sites must be considered. The four CpG sites 
are located close to NFKB transcription binding sites and therefore alterations in their 
methylation may impact gene transcription. Secondly, it is unclear if the absolute 
percentage differences observed in this data set are substantial enough to be 
biologically significant, and this warrants further investigation. Although previous 
research has demonstrated associations with TNF transcripts, by not measuring the 
levels in this research there is a limitation to the conclusions that can be drawn. In 
addition, measurement of other CpG sites within the TNF gene would provide further 
detail into the epigenetic control of this cytokine’s expression. However, due to the 
structure of the TNF gene there are complications in designing an assay to measure 
methylation within the promotor of TNF. The TNF promotor has multiple homologous 
stretches of sequence when the DNA is bisulphite-converted, there are few methods 
which allow for sequencing when this is the case.  
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There are methodological considerations for DNA sources used within epigenetic 
research due to the specificity of the epigenetic makeup of each individual cell. For 
example, there is a greater difference in methylation between tissues from the same 
individual than there are from the same tissue from multiple individuals (Byun et al., 
2009). In the current research blood was used as the DNA source, which is a tissue 
heterogenous in cell composition. Nevertheless, there are benefits in using blood as 
a source of DNA, firstly it is convenient to collect through a fingerprick sample, and 
secondly it contains WBCs which play key roles within the inflammatory process. To 
combat the heterogeneity of the cells and to minimise WBC composition as a 
confounding factor, the methylation results have been presented both as raw and as 
adjusted for WBC composition using a regression-based method (Jones et al., 2015). 
The relationships between the fatty acids and TNF methylation did not disappear once 
adjusted for WBC composition. 
Although individuals were not excluded based on their health status, participants were 
required to travel to the National Centre for Sport and Exercise Medicine in 
Loughborough for data and sample collection and consequently the cohort was 
generally healthy. Investigating the associations between TNF methylation and fatty 
acids in an unhealthy cohort could further elucidate the epigenetic effect of fatty acids 
with inflammation. Unlike the wide range of PUFA status that the Yup’ik study utilised, 
the cohort in this chapter displayed a small range in w-3 PUFAs. Additionally, the w-
6/w-3 PUFA ratio was low in comparison to that expected for a Western population 
(Simopoulos, 2016). Future research should investigate whether interventions could 
alter the methylation profile of the TNF gene to one that is associated with a healthier 
phenotype. For example, could altering the fatty acid composition of blood through 
dietary supplementation increase the methylation percentage of TNF to give a 
protective effect against prolonged inflammation, a characteristic of obesity and 
chronic disease? The methylation of TNF has previously been shown to decrease with 
age (Gowers et al., 2011), but this was not possible to measure in this cohort, which 
although having a wide age range, was skewed towards younger individuals.  
The increasing prevalence of non-communicable diseases places increased pressure 
on society, healthcare providers and governments worldwide (Naghavi et al., 2017). A 
common component of these diseases is chronic inflammation. It is of great 
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importance to consider whether health outcomes can be improved in order to alleviate 
some of this burden. The potential to make small changes to diet which could have a 
positive impact upon the reduction of chronic incapacitating diseases, including 
through interactions with the inflammatory process, is attractive, and a better 
understanding of epigenetic effects may be of assistance. In conclusion, this research 
indicates that the levels of certain blood fatty acids are associated with the epigenetic 
signatures, DNA methylation, of TNF exon 1.Further research into how fatty acids 
interact with the epigenetic control of cytokines may provide a therapeutic avenue for 
prevention of chronic inflammation. Additionally, the results here suggest that 
subsequent research must include the analysis of results separately between the 
sexes in order to not miss important findings that may be sex-specific. 
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Chapter 5  Does ω-3 PUFA supplementation 
alter the methylation status of genes 
encoding inflammatory cytokines TNFα, IL6 
and IL1b? 
5.1 Introduction 
The cross-sectional analysis reported in Chapter 4 demonstrated that there are 
associations between the amounts of fatty acids in blood and the degree to which four 
CpG sites within TNF are methylated. Increased methylation of these CpG sites has 
been associated with reduced TNF gene expression (Hermsdorff et al., 2013), and 
since this encodes for a cytokine which is pro-inflammatory, would be expected to 
reduce inflammation. Chronic inflammation is a concomitant of many debilitating 
chronic diseases including, for example, cancer, CVD, chronic obstructive pulmonary 
disease (COPD) and type 2 diabetes (Hotamisligil, 2006; Shoelson, 2006; van der 
Molen, 2010; Rook and Dalgleish, 2011). Currently nonsteroidal anti-inflammatory 
drugs (NSAIDs) are widely used to control inflammation but it has become increasingly 
evident that they may have unintended adverse effects. As a consequence, there is 
now increasing interest in controlling symptoms of chronic diseases, including 
inflammation, in a ‘more natural’ way. 
Against this background, and in the light of the associations reported in Chapter 4, it 
is relevant to ask whether supplementing the human diet with fatty acids could 
increase their levels in the blood and therefore influence the methylation level of the 
four CpG sites that were investigated. If this was the case, then it might be possible to 
reduce chronic inflammation, at least to some extent, by making relatively simple 
changes to diet. A better understanding of the epigenetic mechanism of the genome 
and the way in which environmental factors, including diet, control gene expression 
could provide a route to reducing dependency upon NSAIDs and alleviate the 
unintended consequences of their use. 
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Research into the effect of ω-3 PUFA supplementation has thus far investigated 
epigenome-wide methylation via 450k arrays (Amarasekera et al., 2014; Aslibekyan 
et al., 2014; Lind et al., 2015; Voisin et al., 2015; van Dijk et al., 2016; Arpón et al., 
2017; Perfilyev et al., 2017; Tremblay et al., 2017; McMorrow et al., 2018) or targeted 
specific genes, for example those encoding fatty acid metabolism enzymes, e.g. 
FADS1 and FADS2 (do Amaral et al., 2014; Hoile et al., 2014; Cui et al., 2016; Rahbar 
et al., 2018). The 450k array measures the methylation level of more than 450,000 
single CpG sites dispersed throughout the genome. Analysis of 450k array data is 
prone to multiple testing errors, as well as possible cross-reactivity and polymorphisms 
in CpG sites (Chen et al., 2013). However, they are useful in identifying DMRs that 
may have important biological functions, and their results can be used to identify 
enriched pathways and future targets for investigation. ω-3 PUFA supplementation 
studies that have utilised the 450k arrays have identified multiple DMRs as a result of 
the intervention (Arpón et al., 2017; Perfilyev et al., 2017; Tremblay et al., 2017; 
McMorrow et al., 2018). A large number of pathways where DMRs were found are 
altered by supplementation and these include those that are related to the 
inflammatory and immune response, lipid metabolism, cardiovascular signalling and 
those implicated in type 2 diabetes, amongst others.  
Currently, to the authors knowledge, the following genes have been the only targets 
of methylation analysis in adult supplementation studies: FADS1, FADS2, ELOVL2, 
ELOVL5, CD14, PDK4, CD36, and FFAR3 “Free Fatty Acid Receptor 3”. The 
methylation of FADS1 promotor has been shown to increase as a result of 
supplementation of ω-3 PUFAs compared to a control group in a calorie-restricted 
intervention (do Amaral et al., 2014). However, in separate research by Hoile et al. 
(2014), where supplementation was the only intervention and the intervention was 
carried out in two separate cohorts, no significant changes were observed in FADS1. 
These two studies targeted different CpG sites within the FADS1 gene and this may 
be responsible for the different results obtained. The response of FADS2 methylation 
to either olive oil or ω-3 PUFA supplementation was found to be sex-specific. 
Increases in FADS2 methylation were observed in females post-supplementation at 
four CpG sites, as opposed to males where one site increased and one decreased. 
Hoile et al., (2014) found that olive oil supplementation increased the methylation at 
more CpG sites than ω-3 PUFA supplementation. The same result was observed for 
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ELOVL5 (at fewer CpG sites), and notably the methylation of FADS2 and ELOVL5 
CpG sites was negatively associated with their mRNA transcripts. 
Supplementation studies that have investigated the effect of ω-3 PUFAs on pro-
inflammatory cytokines have reported that the production of cytokines TNFα, IL1b and 
IL6 is reduced post-supplementation (Li et al., 2014; Tan et al., 2018). However, as 
discussed in Chapter 1, the full mechanism through which this is achieved is not 
currently understood. In this chapter, the aim was to investigate the effect of ω-3 PUFA 
supplementation on epigenetic signatures in vivo of the inflammatory cytokine genes 
TNF, IL6 and IL1B.  
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5.2 Methods 
5.2.1 Ethical approval and study requirements 
Due to differences in cell membrane incorporation of ω-3 PUFAs between the sexes 
and because of difficulties fitting the testing schedule within the menstrual cycle, which 
could alter the blood markers being measured, it was decided that the cohort for this 
study would be males. 
Prior to the recruitment of participants ethical clearance for the study was sought from, 
and granted by, the Loughborough University Ethics Approvals (Human Participants) 
Sub-Committee (reference R16-P138). Recruitment was then achieved through word 
of mouth, posters, emails and social media advertisements in the Loughborough area. 
Potential participants attended the National Centre for Sport and Exercise Medicine 
prior to starting the study. During this preliminary session they were fully informed of 
the study requirements and assessed for study suitability prior to providing written 
consent.  Participants then completed a health screening questionnaire, ethnicity 
questionnaire, FFQ and the International Physical Activity Questionnaire (IPAQ). 
In order to be included in the study the participants had to meet the following criteria: 
• Male (see above)  
• Aged between and including 18 to 30 years. 
• Body mass index (BMI; in kg/ m2), between and including 18 to 30. 
• No consumption of vitamin or ω-3 PUFAs supplements in the previous 6 
months. 
• A low habitual oily fish consumption (less than 4 servings per month), however 
this was relaxed when recruitment proved difficult. 
• Non-smoking. 
• No plan to change dietary habits. 
• No significant changes in body weight in the past 6 months. 
• No habitual use of anti-inflammatory drugs. 
• No history of diabetes, heart disease, coagulation/bleeding disorders, 
metabolic disease or serious allergy. 
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• Not known to have blood-borne virus. 
• No receipt of inoculations within 2 months of starting the study or an intention 
to receive any during the duration of the intervention. 
• No donation of or intention to donate blood within 8 weeks of providing the first 
study sample or at any point during the intervention period. 
• Not allergic to fish. 
 Participants 
A total of 39 individuals indicated their interest in the study. Of these 12 did not respond 
to follow up emails and eight did not fit the inclusion criteria. Of the remaining 19 who 
commenced participation, one was unable to complete as he displayed needle phobia 
and another contracted an illness, which although unrelated to the study, prevented 
them from continued participation. A total of 17 males (aged 22.56 ± 2.76 yrs; body 
mass 80.07 ± 9.02 kg, mean ± standard deviation) completed the study.  
5.2.2 Study design 
The study involved five laboratory visits over the course of 28 days. The first visit was 
used to take baseline measurements and samples, the participants then undertook a 
course of ω-3 PUFA supplementation for 28 days, visiting the laboratory on days 7, 
14, 21 and 28, as shown in Figure 5-1. Throughout the course of the study, participants 
were asked to maintain their habitual diet (including where applicable their usual 
consumption of fatty fish), weight and activity levels. 
 
Figure 5-1 Intervention outline for the 28-day supplementation period and five 
laboratory visits. 
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5.2.3 Supplementation 
For 28 days, participants took four ω-3 PUFA capsules (Omega Via, Innovix Pharma 
Inc, USA) which contained a total of 6000mg of fat, including 4420mg total ω-3. The 
ω-3  component comprised 3,120mg EPA, 1,040mg DHA, and 260mg of other ω-3 
PUFAs, Table 5-1. It was recommended that participants took two capsules in the 
morning and two in the evening, each with a meal. 
Table 5-1 Fatty acid composition of the omega-3 polyunsaturated fatty acids (ω-3 
PUFAs) supplements (Omega Via, Innovix Pharma Inc, CA, USA) 
Supplement contents Per capsule (mg) Per four capsules (mg) 
Omega 3 1105 4420 
EPA 780 3120 
DHA 260 1040 
DPA and other ω-3 PUFAs 65 260 
Total capsule (mg) 1500 6000 
Eicosapentaenoic acid (EPA); Docosapentaenoic acid (DPA); Docosahexaenoic acid (DHA). 
 
5.2.4 Study protocol 
A food diary was completed by each participant for the day prior to the first laboratory 
visit, this food diary was then used to replicate the same dietary intake the day before 
each of the subsequent laboratory visits. On laboratory visit days, participants were 
asked to take their supplements after they had visited the laboratory that day. 
Participants were also asked to abstain from the following before attending the 
laboratory: 
• Consumption of food and drink (exc. water) for 12 hours 
• vigorous exercise for 24 hours 
• alcohol for 48 hours 
Laboratory visits lasted 30 minutes and were conducted between 7am and 10am.  
 Anthropometric measurements 
Each visit commenced with a recording of anthropometric measurements. Height was 
measured using a digital stadiometer to the nearest 0.1 centimetre (cm) and weight 
using digital weighing scales to the nearest 0.01 kilogram (kg). Bioelectrical 
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impedance analysis (BIA) was used to estimate body composition (fat, water and 
muscle). Using a measuring tape, waist and hip circumference was measured to the 
nearest 0.1 centimetre (cm) and used to calculate waist-to-hip ratio.  
 Blood pressure 
Using a digital automatic blood pressure monitor the arterial blood pressure was 
measured by placing the cuff on the upper right arm with the arm resting on a pillow 
next to the participant. Participants remained in a Fowler’s position for five minutes 
prior to the first measurement. Three measurements of blood pressure were taken 
with an interval of one minute between each measurement. An average of the three 
measurements was used for analysis. 
 Blood collection and handling 
Participants remained in the Fowler’s position for venous blood samples. Samples 
were collected from the antecubital vein via venepuncture at the end of each laboratory 
visit. A total of 70ml of blood was collected into EDTA coated vacutainers (Becton, 
Dickinson & Company, NJ, USA). The vacutainers were gently inverted eight to 10 
times. Aliquots of blood were taken from one of the vacutainers for a cell count 
(Beckman Coulter Counter, USA); in addition, aliquots of blood were frozen at -80oC 
for DNA extraction (section 5.2.7). Six vacutainers were processed to isolate PBMCs, 
see section 5.2.5 for details. 
5.2.5 PBMC isolation 
PBMCs were isolated for fatty acid composition analysis and in vitro stimulation 
method development (not completed within this thesis, details of the isolation, 
cyroprservation given in Appendix 3). A blood sample was collected at each visit into 
10ml EDTA vacutainers. PBMCs were extracted using density gradient separation and 
resuspended. For fatty acid analysis the cells were resuspended in 250µL PBS per 
10ml blood tube. Cells were counted using a cell counter (Beckman Coulter Counter, 
USA) prior to being stored at -80oC until required for further analysis. 
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5.2.6 Fatty acid measurements 
The fatty acid composition of PBMCs was measured from samples collected at 
baseline (day zero) and each subsequent lab visit. Fatty acid incorporation was 
analysed by GC-MS to profile the fatty acid composition of the participants’ PBMCs. 
Briefly, the PBMCs were homogenised and 100µL of the resulting suspension was 
derivatised as described in section 4.2.3. Fatty acid quantities were determined based 
on the relative abundance to the internal standard. Fatty acids levels were calculated 
as %TFA.  
5.2.7 Sample preparation and DNA extraction 
Prior to the blood samples being frozen, a blood cell count was obtained from each 
sample. Whole blood was used for genomic DNA extraction and subjected to 
bisulphite conversion using EpiTect® Fast LyseAll Bisulphite conversion kit (Qiagen, 
Germany) to the manufacture’s protocol. Briefly, blood samples were lysed and 
proteins denatured, the resulting pellets were re-suspended in PBS and added directly 
into the bisulphite reaction. The DNA was sodium bisulphite-treated and subjected to 
two cycles of denaturing at 95oC for 5 minutes and incubation 60oC for 20 minutes. 
Bisulphite-converted DNA was desulfonated and purified using MinElute spin 
columns. 
5.2.8 DNA methylation analysis 
DNA was extracted from blood and bisulphite-converted using EpiTect LyseAll kit 
(Qiagen, Germany). DNA methylation levels of TNF, IL1B and IL6 were measured by 
pyrosequencing using the PyroMark Q48 Autoprep (Qiagen, Germany) with the 
assays designed and validated in Chapter 3. Data is presented as mean ± standard 
deviation. 
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5.2.9 Statistics 
The one-way repeated ANOVA is sensitive to departures from sphericity, an 
assumption that it is not easily detected in small sample sizes (Maxwell and Delaney, 
2003); consequently, here the Greenhouse-Geisser correction was applied to all 
ANOVA p values reported.  
Analysis was completed both with and without extreme outliers (3 box lengths from 
the edge of the box plot) in the data; where no impact of the outliers on significance 
was observed, then the results, including the outliers, is presented.  
Two participants missed one lab visit each, in order for their data to be included in the 
one-way repeated ANOVA, an average was taken from the data point of each visit 
either side of the missed lab visit. The same method was used for replacing outliers 
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5.3 Results 
5.3.1 Sample demographic 
A total of 17 participants completed the four weeks of supplementation. There were 
no significant differences in participant characteristics between baseline and post-
supplementation at week four, Table 5-2. No change in diastolic blood pressure over 
the 28 days supplementation, Table 5-3, however there was a small non-significant 
decrease in systolic blood pressure over the intervention (130 ± 10 to 125. ± 9). 
Additionally, there was a significant decrease in heart rate from day 7 (60 ± 11) and 
day 14 (59 ± 10) compared to day 28 (55 ± 10). 
 
Table 5-2 Sample demographic pre and post 28-day ω-3 PUFA supplementation 
 Before ω-3 PUFA After ω-3 PUFA p 
(n = 17) (n = 17) 
Weight (kg) 80.1 ± 9.0 80.6 ± 9.3 0.148 
BMI (kg/m2) 24.0 ± 2.3 24.2 ± 2.4 0.170 
Waist circumference (cm) 79.5 ± 5.2 79.6 ± 5.1 0.927 
Hip circumference (cm) 87.5 ± 6.0 87.4 ± 5.4 0.910 
Waist-to-Hip ratio 0.9 ± 0.1 0.9 ± 0.1 0.952 
Skeletal Muscle Mass (kg) 32.9 ± 2.8 33.0 ± 2.6 0.893 
Water weight (L) 47.7 ± 3.8 48.9 ± 4.5 0.122 
Body fat (kg) 17.0 ± 4.3 17.1 ± 4.5 0.687 
Data presented before and after 28-day omega-3 polyunsaturated fatty acid (ω-3 PUFA) supplementation 
Mean ± standard deviation; differences between groups assessed by independent samples t-test. 
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Table 5-3 Blood pressure and heart rate during a four-week supplementation with omega-3 polyunsaturated fatty acid 
Variable Day 0 Day 7 Day 14 Day 21 Day 28 p 
Diastolic blood pressure (mmHG) 69 ± 6 a,b 71 ± 5 a,b 68 ± 7 a,b 69 ± 8 a,b 67 ± 5 a,b 0.237 
Systolic blood pressure (mmHG) 130 ± 10 a,b 130 ± 7 a,b 129 ± 8 a,b 127 ± 9 a,b 125 ± 9 a,b 0.072 
Heart Rate (beats per minute) 57 ± 11 a,b  60 ± 11 b,a 59 ± 10 b,a 58 ± 11 a,b  55 ± 10 a,b 0.022 
n = 16; Data is presented as mean ± standard deviation. Significant difference assessed by ANOVA with Greenhouse-Geisser correction applied. 
Means that do not share a letter (a,b) are significantly different (p < 0.05 ) from each other after correcting for multiple testing (Bonferroni 
correction). 
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5.3.2 Fatty acid profile of peripheral blood mononuclear cells (PBMCs) 
The fatty acid profile of PBMCs was measured at baseline and every seven days of 
the intervention; results are presented in Table 5-4. ω-3 PUFA, EPA significantly 
increased during the first seven days of the supplementation from 0.1 ± 0.1 to 0.5 ± 
0.3 %TFA and continued to increase (not with statistical significance) until day 28 (0.7 
± 0.3 %TFA).  In addition to the EPA increase, DPA significantly increased from day 0 
(0.4 ± 0.2 %TFA) compared to day 7 (0.7 ± 0.2 %TFA) and DHA increased over the 
28 days from 0.5 ± 0.2 to 0.6 ± 0.2 %TFA, not with statistical significance. The result 
of the EPA, DPA and DHA increases is a significant increase in total ω-3 PUFA within 
PBMCs by day 21 (9.4 ± 0.7 %TFA) compared to baseline (8.1 ± 1.1 %TFA). There 
was no change in the levels of the essential fatty acid alpha-linolenic (ALA) over the 
28 days of supplementation. 
During the first 14 days of supplementation there was a significant decrease in the 
levels of ω-6 PUFA adrenic acid from 0.4 ± 0.2 to 0.2 ± 0.1 %TFA. There was a 
significant change in dihomo-γ-linolenic acid (DGLA), which did not remain significant 
after correction for multiple testing. 
5.3.3 CpG methylation of TNF, IL6 and IL1B 
Methylation of TNF, IL6 and IL1B was measured every seven days throughout the 
intervention. No change was observed in any of the three genes across the four weeks 
supplementation. 
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Table 5-4 Peripheral blood mononuclear cell fatty acid levels before ω-3 supplementation and every 7 days for 28 days, 
  Day 0 Day 7 Day 14 Day 21 Day 28 p 
Omega 3 Polyunsaturated Fatty Acids (⍵-3 PUFA)      
18:3ω-3 (ALA, alpha-Linolenic acid) 07.0 ± 0.8 07.3 ± 0.7 07.2 ± 0.7 07.3 ± 0.6 07.0 ± 0.6 0.495 
20:5ω-3 (EPA, Eicosapentaenoic acid) 00.1 ± 0.1 a 00.5 ± 0.3 b 00.6 ± 0.3 b 00.7 ± 0.2 b 00.7 ± 0.3 b <0.001 
22:5ω-3 (DPA, Docosapentaenoic acid) 00.4 ± 0.2 a 00.7 ± 0.2 b 00.7 ± 0.3 a,b 00.8 ± 0.2 b 00.8 ± 0.2 b 0.001 
22:6ω-3 (DHA, Docosahexaenoic acid) 00.5 ± 0.2 00.6 ± 0.2 00.6 ± 0.2 00.6 ± 0.2 00.6 ± 0.3 0.072 
TOTAL ⍵-3 PUFA 08.1 ± 1.1 a 09.1 ± 0.9 a,b 09.0 ± 1.4 a,b 09.4 ± 0.7 b 09.1 ± 1.0 a,b 0.007 
Omega 6 Polyunsaturated Fatty Acids (⍵-6 PUFA)      
18:2ω-6 (LA, Linoleic acid) 02.6 ± 0.9 02.5 ± 0.5 02.5 ± 1.0 02.9 ± 0.7 02.7 ± 0.7 0.490 
18:3ω-6 (GLA, "-Linolenic acid) 00.6 ± 0.3 00.6 ± 0.3 00.6 ± 0.2 00.6 ± 0.2 00.7 ± 0.3 0.794 
20:2ω-6 (Eicosadienoic acid) 00.2 ± 0.1 00.1 ± 0.0 00.1 ± 0.0 00.1 ± 0.0 00.1 ± 0.0 0.160 
20:3ω-6 (DGLA, Dihomo-"-linolenic acid) 00.5 ± 0.2 00.3 ± 0.1 00.3 ± 0.2 00.4 ± 0.1 00.3 ± 0.1 0.047 
20:4ω-6 (AA, Arachidonic acid) 05.8 ± 2.1 05.6 ± 2.0 05.2 ± 2.0 05.9 ± 1.3 05.2 ± 1.3 0.660 
22:4ω-6 (Adrenic Acid) 00.4 ± 0.2 a 00.3 ± 0.2 a,b 00.2 ± 0.1 b 00.2 ± 0.1 b 00.2 ± 0.1 b 0.001 
22:2ω-6 (Docosadienoic acid) 00.4 ± 0.2 00.5 ± 0.2 00.5 ± 0.2 00.4 ± 0.2 00.4 ± 0.1 0.806 
TOTAL ⍵-6 PUFA 10.5 ± 3.0 09.9 ± 2.3 09.5 ± 2.9 10.5 ± 1.7 09.7 ± 1.8 0.589 
Monounsaturated Fatty Acids (MUFA)      
14:1ω-5 (Myristoleic acid) 13.4 ± 5.1 14.1 ± 4.2 14.5 ± 4.4 12.7 ± 3.2 13.3 ± 2.8 0.662 
16:1ω-7 (Palmitoleic acid) 03.4 ± 3.2 03.4 ± 3.0 02.6 ± 0.9 03.1 ± 3.2 02.5 ± 0.5 0.371 
17:1ω-7 (Cis-10-Heptadecenoic acid) 02.2 ± 0.9 02.5 ± 1.1 02.4 ± 0.9 02.0 ± 0.6 02.1 ± 0.6 0.285 
22:1ω-17 (5Z-docosenoic acid) 00.3 ± 0.2 00.4 ± 0.4 00.3 ± 0.2 00.5 ± 0.8 00.4 ± 0.5 0.493 
18:1ω-9 (Oleic acid) 08.3 ± 3.2 08.5 ± 3.2 08.9 ± 2.9 07.7 ± 2.7 08.0 ± 2.4 0.669 
18:1ω-9 (9-octadecenoic acid) 00.4 ± 0.2 00.5 ± 0.2 00.5 ± 0.2 00.4 ± 0.2 00.4 ± 0.1 0.510 
TOTAL MUFA 28.1 ± 10.0 29.4 ± 8.7 29.2 ± 8.7 26.5 ± 7.6 26.7 ± 6.1 0.661 
Saturated Fatty Acids (SFA)       
13:0 (Tridecanoic acid) 01.4 ± 0.3 01.4 ± 0.5 01.6 ± 0.8 01.3 ± 0.4 01.4 ± 0.4 0.362 
14:0 (Myristic acid) 03.8 ± 1.9 03.3 ± 1.5 03.4 ± 1.3 02.9 ± 0.7 03.2 ± 0.8 0.296 
15:0 (Pentadecanoic acid) 02.5 ± 1.2 02.3 ± 1.0 02.2 ± 0.9 01.9 ± 0.5 02.1 ± 0.5 0.333 
16:0 (Palmitic acid) 25.8 ± 4.9 24.8 ± 3.8 25.7 ± 3.3 26.1 ± 3.4 26.6 ± 3.0 0.467 
18:0 (Stearic acid) 19.2 ± 3.7 19.1 ± 3.5 18.8 ± 4.6 20.6 ± 3.2 20.4 ± 2.7 0.433 
20:0 (Arachidic acid) 00.4 ± 0.2 00.5 ± 0.2 00.5 ± 0.2 00.5 ± 0.2 00.5 ± 0.2 0.574 
21:0 (Heneicosylic acid) 00.1 ± 0.0 00.1 ± 0.0 00.1 ± 0.0 00.1 ± 0.0 00.1 ± 0.0 0.095 
22:0 (Behenic acid) 00.2 ± 0.1 00.2 ± 0.1 00.2 ± 0.1 00.2 ± 0.1 00.2 ± 0.1 0.718 
TOTAL SFA 53.4 ± 8.8 51.6 ± 7.2 52.5 ± 5.9 53.6 ± 6.3 54.5 ± 5.5 0.571 
n = 17; Data is presented as Percentage Total Fatty Acids (%TFA), mean ± standard deviation. Significant difference assessed by ANOVA with Greenhouse-Geisser correction applied. Means that 
do not share a letter (a,b) are significantly different from each other after correcting for multiple testing (Bonferroni correction). 
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Figure 5-2 Fatty acid composition of whole blood, n=17. (a) Total omega 3 (ω-3) poly 
unsaturated fatty acid (PUFA) (b) ω-3 PUFA alpha-Linolenic acid, ALA (c) 
ω-3 PUFA Docosahexaenoic acid, DHA Data presented as mean ± 95% 
confidence intervals. * significantly different to day 0.  
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Table 5-5 Percentage DNA methylation during the course of a four-week Omega-3 supplementation 
  Day 0 Day 7 Day 14 Day 21 Day 28 p 
Tumor Necrosis Factor (TNF, %, n = 17)        
CpG1 9.4 ± 2.7 9.1 ± 3.8 8.6 ± 2.5 8.8 ± 1.9 9.1 ± 2.8 0.770 
CpG2 8.0 ± 3.0 7.0 ± 3.3 6.9 ± 2.1 6.9 ± 2.1 7.5 ± 1.8 0.499 
CpG3 8.3 ± 3.2 7.8 ± 2.6 7.3 ± 2.1 7.4 ± 1.7 7.9 ± 2.0 0.485 
CpG4 14.4 ± 4.5 13.1 ± 4.6 13.0 ± 3.3 13.4 ± 2.9 14.8 ± 4.2 0.395 
CpG Average 10.0 ± 3.3 9.3 ± 3.5 8.9 ± 2.4 9.1 ± 1.9 9.8 ± 2.5 0.519 
Interleukin-6 (IL6, %, n = 11)       
CpG1 91.2 ± 2.3 90.4 ± 2.9 91.1 ± 2.8 90.0 ± 2.9 90.4 ± 2.9 0.460 
CpG2 90.8 ± 2.1 91.0 ± 1.4 90.9 ± 1.9 90.6 ± 2.0 91.3 ± 1.4 0.678 
CpG3 91.6 ± 1.8 91.7 ± 1.3 91.1 ± 1.9 92.0 ± 1.9 92.6 ± 1.5 0.248 
CpG4 87.7 ± 2.0 88.0 ± 1.8 87.7 ± 1.9 87.8 ± 2.0 88.9 ± 1.7 0.330 
CpG5 82.8 ± 3.4 83.1 ± 4.0 83.1 ± 2.9 83.1 ± 3.5 82.9 ± 4.1 0.945 
CpG6 88.8 ± 3.0 89.2 ± 2.5 89.4 ± 2.5 89.2 ± 2.0 89.7 ± 2.9 0.693 
CpG Average 88.8 ± 1.8 88.9 ± 1.7 88.9 ± 1.5 88.8 ± 1.9 89.3 ± 1.6 0.659 
Interleukin-1 beta (IL1B, %, n = 17)       
CpG1 92.7 ± 3.4 92.9 ± 3.5 92.7 ± 3.5 91.9 ± 4.5 92.4 ± 4.3 0.460 
CpG2 94.0 ± 1.4 94.4 ± 1.2 94.5 ± 1.7 93.9 ± 2.6 93.9 ± 3.2 0.678 
CpG3 85.8 ± 4.5 87.2 ± 4.1 86.1 ± 4.5 85.9 ± 4.9 85.2 ± 7.2 0.248 
CpG4 90.8 ± 4.5 91.2 ± 4.2 90.4 ± 4.5 90.9 ± 3.2 89.7 ± 5.2 0.330 
CpG5 75.1 ± 2.5 75.6 ± 2.3 75.8 ± 2.5 76.1 ± 3.1 75.2 ± 3.9 0.945 
CpG Average 87.7 ± 2.9 88.3 ± 2.7 87.9 ± 2.9 87.7 ± 2.7 87.3 ± 4.4 0.693 
Data is presented as Percentage methylation, mean ± standard deviation; Significant difference assessed by ANOVA and means that do not share a letter are significantly different after 
correcting for multiple testing (Bonferroni correction) 
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5.4 Discussion 
In a group of young healthy males, this research sought to investigate whether altering 
dietary fatty acid consumption would have an impact upon the promotor methylation 
levels of cytokine genes. Dietary supplementation with a high dose of ω-3 PUFAs, 
EPA and DHA, for a four-week period resulted in significant changes to the levels of 
certain fatty acids incorporated into PBMCs. However, there were no observed 
changes to the methylation levels of TNF, IL6 or IL1B over that intervention period.   
w-3 PUFAs are known to decrease inflammatory cytokine expression and production 
through multiple mechanisms as discussed previously in this thesis. The three 
cytokines investigated here are partly controlled through epigenetic mechanisms. 
Regulation of IL6 expression appears to be predominantly controlled through histone 
modifications, with HDAC and HAT inhibitors reducing or preventing transcription 
respectively (Hu et al., 2017). However, methylation of CpG sites within the promotor 
region of IL6 are associated with gene transcription (Kirchner et al., 2014; Poplutz et 
al., 2014; Ma et al., 2016).  
Elsewhere research undertaken into the effect of ω-3 PUFA supplementation on the 
methylation profile of genes has also utilised 450k arrays. These studies observed 
altered methylation in genes linked to inflammatory pathways when baseline levels 
were compared to those post supplementation (Arpón et al., 2017; Perfilyev et al., 
2017; Tremblay et al., 2017; McMorrow et al., 2018). Specifically methylation changes 
in IL6 and TNF were measured and an increase in methylation was observed as a 
result of supplementation (Perfilyev et al., 2017). It was not possible to confirm these 
findings using the targeted approach reported in this chapter. It is difficult to make 
comparisons between the work reported here and the previous studies carried out 
elsewhere, or indeed to make comparisons between those studies because of 
differences in the interventions. This is an issue that has plagued the field of fatty acid 
research and appears to be responsible for the observed inconsistencies in findings. 
The four studies referred  to above illustrate this problem since they comprised a six 
week supplementation with a high dose ω-3 PUFA (Tremblay et al., 2017), a seven 
week RCT overfeeding with PUFA or SFA included (Perfilyev et al., 2017), an eight 
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week “anti-inflammatory nutrition” intervention which included ω-3 PUFAs (McMorrow 
et al., 2018), and a 5 year Mediterranean diet intervention (Arpón et al., 2017). 
The research reported in Chapter 4 found that methylation of the TNF gene promotor 
was associated with levels of particular fatty acids within whole blood. Specifically, in 
males the ω-3 PUFA DHA and the ω-6 PUFA AA were associated with methylation 
levels of TNF. In this chapter this research aimed to investigat whether altering the 
dietary fatty acid intake of a male cohort affects the fatty acid composition of PBMCs 
and whether this would result in alterations to the methylation signature of the TNF 
gene. Furthermore, it was also investigated whether the increased dietary fatty acid 
intake impacted upon the methylation levels of two other inflammatory cytokine genes, 
IL6 and IL1B. 
Significantly, the intervention undertaken in this chapter did not give rise within PBMCs 
to a change in levels of any of the fatty acids, which were shown in chapter 4 as being 
associated with TNF methylation. Had the intervention caused a change in the levels 
of DHA or AA within PBMCs, then it would have been expected to see corresponding 
changes to the methylation of TNF, however this was not the case and so the fact that 
the intervention did not lead to a change in methylation of TNF is less surprising.    
The intervention described in this chapter was intended to give a large dose of ω-3 
PUFAs that was expected to change the fatty acid composition of the blood. The fatty 
acid levels within PBMCs were measured because these cells play a significant role 
in the immune system and provide a source of DNA for epigenetic analysis. By altering 
the PBMC fatty acid composition, it was intended to alter the environment of these 
cells, and therefore their epigenetic regulation on the specific genes studied.  
Measuring the fatty acid levels of WBC, compared to whole blood or red blood cells 
(RBCs) targets the biologically relevant cell type to inflammation. In addition, the 
incorporation of ω-3 PUFAs into RBC and WBC following ω-3 PUFA supplementation 
occurs at different rates. RBC incorporation occurs in a linear dose-response 
relationship, however the incorporation into WBCs is not linear with lower 
incorporation levels (Witte et al., 2010). 
Incorporation of EPA in PBMCs occurs in a dose-dependent manner (Rees et al., 
2006), therefore the dose used of 4.42g total ω-3 PUFA (3.12g EPA, 1.04g DHA and 
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0.26g other ω-3 PUFA) per day, and to the authors knowledge, higher than any 
previous research that has investigated DNA methylation changes as the result of 
supplementation (as reported in Table 2-2). This dose was achieved using high 
strength capsules that only required the participant to take four capsules per day. The 
incorporation of EPA and DHA into PBMCs reaches near saturation of the PBMCs 
within the first seven days of supplementation (Faber et al., 2011), with further 
supplementation only having a modest effect of the composition (Yaqoob et al., 2000). 
In the current study, EPA and DPA increased significantly from baseline (day 0) to day 
seven, and although continued to increase until day 28, the further increases were not 
statistically significant from the previous measurement; consistent with the studies 
above. The increases observed in DHA levels was small and not statistically 
significant, in agreement with previous research that did not see changes in DHA 
levels over the first two weeks (Yaqoob et al., 2000; Faber et al., 2011)  
The use of a heterogeneous population of cells, such as white blood cells, has 
previously been discussed in Chapter 4. The research conducted within this chapter 
was also conducted using whole blood as the source of DNA and therefore this 
contained a mix of WBCs. Sorting of the cells using flow cytometry would have allowed 
for the analysis of individual sub-populations of WBCs, however this was not available 
within the existing laboratory facilities at Loughborough.  
We did not include a control group within the current study in order to increase the 
number of participants who took the ω-3 PUFA supplement. The participants 
methylation levels at baseline were used to compare the methylation to in subsequent 
weeks. Therefore, this research has not measured if there is any variation within the 
methylation of the genes naturally over time. This could have been measured by 
including multiple baseline samples in order to assess habitual variation and have the 
ability to attribute any changes to the intervention. 
A homogenous population of young males was used for this research in order to 
reduce confounding variables. This, however, limits the ability for these results to be 
generalised to the whole population. Multiple reasons contribute to the decision to 
include only male participants in the study. Firstly, there are significant differences in 
the levels of and the metabolism of fatty acids between males and females. Further to 
this there are differences in fatty acids between pre- and post-menopausal females. 
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Factoring in the menstrual cycle in studying females would have increased the time 
and cost of the present study. The current study has provided preliminary results into 
the investigation of fatty acids on inflammatory cytokine methylation. Secondly, due to 
the findings observed in Chapter 4 there was further justification in including only 
males into this preliminary work. 
The participants included in this study were all healthy, free-living individuals. The lack 
of findings in this research may be due to the lack of inflammation within those 
individuals. Inducing inflammation or having an active inflammatory phenotype (e.g. 
as the result of a chronic disease) might alter the interaction between the fatty acids 
and the inflammatory mechanisms. Repetition of this study in a patient cohort (with for 
example COPD, obesity or diabetes) would provide important information into 
understanding the mechanisms of fatty acids on the epigenome. 
The intervention period of this study was four weeks. It is possible that the failure to 
detect significant results may be related to this and that a longer intervention period, 
would have resulted in the epigenetic changes that this research sought to measure. 
5.5 Conclusion 
We conclude that altering the fatty acid profile of the blood through supplementation 
with ω-3 PUFAs over a four-week period does not impact the DNA methylation levels 
of specific CpG sites within the inflammatory cytokine encoding genes TNF, IL6 and 
IL1B.  
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Chapter 6 The effects of eccentric exercise 
and fatty acid supplementation on the 
inflammatory response 
6.1 Introduction 
In Chapter 4 it was established that there are associations between blood fatty acid 
levels and DNA methylation of the TNF gene which encodes the inflammatory cytokine 
TNFα. Furthermore, it was then investigated whether dietary supplementation could 
influence the methylation profile of TNF and two other inflammatory cytokine genes, 
IL6 and IL1B by changing the fatty acid composition of the blood and it was discovered 
that over a 28-day period of intervention no significant changes could be detected 
(Chapter 5). However, the lack of modification to the methylation profile that was 
observed may be because there were no inflammatory stimuli to activate these 
cytokine genes.  
The research undertaken in this chapter seeks to establish whether the introduction of 
an inflammatory stimulus will provoke a change to gene methylation and hence 
expression, and therefore, it seeks to establish whether dietary supplementation will 
influence the outcome. 
An inflammatory response can be stimulated by eccentric exercise (EE); (Peake, 
Nosaka and Suzuki, 2005). During an eccentric contraction a muscle lengthens, as 
opposed to shortening which occurs during a concentric contraction. The lengthening 
of the muscle under force causes disruption of sarcomeres in the myofibrils (Proske 
and Morgan, 2001). The force of the contraction and the length over which it is 
generated positively relate to the amount of disruption that occurs (Proske and 
Morgan, 2001). The greatest damage to the muscle as a result of eccentric 
contractions occurs during a large range of motion (Fochi et al., 2016). In 
untrained/unaccustomed individuals, the EE induced muscle damage (EEIMD) causes 
increases in protein release from the muscle, local inflammatory response within the 
muscle (swelling, stiffness, infiltration of neutrophils) and a systemic inflammatory 
response evidenced by elevated levels of inflammatory cytokines, including IL6, TNFα, 
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IL1b, and the production of prostaglandins (Brown, Day and Donnelly, 1999; Clarkson 
and Hubal, 2002; Chen et al., 2003). Therefore, EE was used to provide the desired 
inflammatory stimuli. 
The inflammation triggered by EEIMD is known to be modulated by fatty acid 
supplementation (Jouris, McDaniel and Weiss, 2011; Tartibian, Maleki and Abbasi, 
2011). Supplementation with ω-3 PUFAs for just seven days was shown to result in a 
decrease in localised soreness (inflammation) which had been induced by EE (Jouris, 
McDaniel and Weiss, 2011). Additional evidence supporting the influence of ω-3 
PUFA on the inflammatory response is provided by a study in which a low dose ω-3 
PUFA supplementation attenuated TNFα secretion, as well as that of prostaglandin 
E2 and lactate dehydrogenase (LDH). Serum levels of these inflammatory markers 
were seen to be reduced immediately after EE and the effect remained 48 hours later. 
The levels of the inflammatory markers, IL6 and creatin kinase (CK) responded in a 
like manner (Tartibian, Maleki and Abbasi, 2011). 
Research to date has not established whether the inflammatory response to EEIMD 
is controlled through epigenetic mechanisms, such as DNA methylation, neither has it 
been established whether the observed attenuation of that response by ω-3 PUFA is 
the result of an epigenetic interaction with the fatty acid. To establish whether the 
induced inflammatory response is controlled by methylation, methylation levels will be 
measured alongside the cytokine expression of the same genes both before and after 
exercise, with and without ω-3 PUFA supplementation. 
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6.2 Methods 
6.2.1 Ethical clearance 
The local university ethics board approved the experimental procedure prior to 
recruitment. All participants provided written consent (example consent form in 
Appendix 2) after receiving verbal and written details of the experimental procedure, 
the intervention, and the risk involved. 
6.2.2 Participants 
Participants were recruited from the local area by word of mouth, advertisement 
posters, email and social media. Sixteen untrained, healthy, male participants (n=16) 
completed the intervention. In order ensure that only untrained individuals were 
recruited, participants were excluded if they had undertaken resistance training in the 
six months prior to the start of the study. In addition, it was a requirement that 
participants had not taken vitamin or ω-3 PUFAs supplementation during the previous 
six months. Other exclusion criteria included: any habitual use of anti-inflammatory 
drugs, a history of heart disease, coagulation/bleeding disorders or metabolic 
diseases, serious allergies, known blood borne virus, and those with current 
symptoms of general illness. Females were excluded from the study.  
 
 
Figure 6-1 Intervention outline for five laboratory visits including two main experimental 
trial days separated by a 21-day supplementation period 
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Figure 6-2 Study protocol and sampling procedure pre and post a bout of eccentric exercise. (a) muscle biopsies were optional; (b) 
standardised breakfast bar was provided to each participant after the second performance test. Range of motion (ROM), 
Visual analogue scale (VAS). Arrows in grey text  indicate that samples collected but not analysed as part of this thesis. 
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6.2.3 Intervention outline 
The study comprised two main experimental trial days (ETD). These were designated 
as Trial A and Trial B and were separated by three weeks double blind 
supplementation intervention. Participants attended the lab on five occasions; 
Familiarisation, Trial A, Trial A+48 hours, Trial B and Trial B+48 hours (see Figure 
6-1). On each ETD various measurements and samples were taken as described in 
the following sections at these designated time points, see Figure 6-2; 
1. Baseline before performance test one or eccentric exercise (Pre-EE) 
2. After undertaking performance test 1 (Post-PT1) 
3. Immediately after completing eccentric exercise (Post-EE) 
4. After undertaking performance test 2 (Post-PT2) 
5. 30 minutes after completing eccentric exercise (Post-EE+0.5h) 
6. One and a half hours after completing eccentric exercise (Post-EE+1.5h) 
7. Three hours after completing eccentric exercise (Post-EE+3h) 
8. Before undertaking performance test 3 (Pre-PT3) 
9. After undertaking performance test 3 (Post-PT3) 
10. 48 hours after completing eccentric exercise (Post-EE+48h) 
11. Before undertaking performance test 4 (Pre-PT4) 
12. After undertaking performance test 4 (Post-PT4) 
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 Double-blind supplementation 
In order to maintain balanced intervention groups, participants were allocated into one 
of two groups on the basis of age, weight, height and preliminary force measurements. 
The diet of each participant was then supplemented, with either ω-3 PUFAs or with 
extra virgin olive oil (EVOO). Six capsules of either the PUFAs or the EVOO 
supplement were taken for 21 days, as shown in Figure 6-1. Consequently, the 
participants either received 3.0g EPA, 1.2g DHA and 0.9g of other ω-3 PUFAs (Table 
6-1) or 6g of EVOO per day. 
Table 6-1 Fatty acid composition of the omega-3 polyunsaturated fatty acid (ω-3 
PUFA) supplements (Norwegian Premium Omega-3 85%, Norwegian 
Pure-3 AS, Oslo, Norway) 
Supplement contents (mg) Per capsule Per six capsules 
Omega 3  850 5100 
EPA  500 3000 
DHA  200 1200 
DPA and other ω-3 PUFAs 150 900 
Total fat (mg) 1000 6000 
eicosapentaenoic acid (EPA); docosapentaenoic acid (DPA); docosahexaenoic acid (DHA), 
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6.2.4 Familiarisation to experimental procedures 
All participants attended a familiarisation session where they were fully informed of 
the study requirements and assessed for suitability to the study before they provided 
their written consent. Participants then completed a health screen questionnaire and 
an IPAQ questionnaire, before basic anthropometric measurements (height and 
weight) were taken. Further description of the experimental procedures and exercise 
testing were provided to the participants, including a description of all of the equipment 
and testing requirements.  
Participants were individually fitted to the Humac Norm dynamometer (CSMI, 
Massachusetts, USA), and then given the opportunity to practice the movements 
required by completing the performance test described in Section 6.2.6.5. Verbal 
coaching on the required technique was provided as required. 
6.2.5 Pre-trial standardisation 
Participants were asked to refrain from strenuous exercise and the consumption of 
caffeine and alcohol during the 24 hours prior to attending the ETD’s and until after 
they had completed the 48 hours post eccentric exercise lab visit. Starting 24 hours 
before  Trial A, participants were asked to record a 3-day food diary detailing the food 
and drink they consumed during that period and they then used this diary to replicate 
the food consumed prior to and during Trial B. Participants were asked not to change 
their habitual diet or exercise routines for the duration of the study. On the morning of 
the ETD’s, participants attended the lab having fasted for at least 12 hours and having 
consumed 500ml of water before arrival, water was then consumed ad-libitum 
throughout the day. Participants arrived at the lab for Trial A between 7am and 10am 
according to their chosen start time, and same start time was maintained for Trial B.  
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6.2.6 Experimental trial day 
 Anthropometric measurements 
At the beginning of each ETD anthropometric measurements were recorded. Height 
was measured using a digital stadiometer to the nearest 0.1 centimetre (cm) and 
weight using digital weighing scales to the nearest 0.01 kilogram (kg). Body fat was 
estimated using bioelectrical impedance analysis (BIA).  
 Thigh girth and range of motion 
Bilateral thigh girth was measured at the midpoint between the point just proximal to 
the patella and the inguinal crease at the hip. A surgical pen was used to mark the 
midpoint; this provided the measurement point for thigh girth measurements 
throughout the trial day. The measurement of thigh girth was taken whilst the 
participant was standing, relaxed and with all weight on that leg, three measurements 
were taken for each leg and an average recorded. Measurements were taken at four 
time points: Pre-EE, Post-PT2, Pre-PT3 and Pre-PT4. If the participant had consented 
to muscle biopsies (not analysed in this thesis), the measurements for this study were 
taken from the non-biopsied leg, which was always the leg that performed the 
eccentric exercise first.  
Range of motion (ROM) of the hip and knee joints was measured using a Goniometer. 
For hip flexion, the participant lay supine on a firm bed, raised each leg unaided, 
keeping the leg straight and their back flat to the bed, measurements were taken with 
the centre of the Goniometer at the greater trochanter and when the leg reached its 
maximum flexion. Hip extension and knee flexion were measured with the participant 
lying prone. All the movements were voluntary, and no assistance was provided. Each 
leg was measured three times separately and an average of the measurements was 
recorded. Measurements were taken at the following time points: Pre-EE, Post-PT2, 
Pre-PT3 and Pre-PT4. 
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 Muscle soreness 
Participants were asked to indicate the level of muscle soreness using a visual 
analogue scale (VAS), which consisted of a 100mm line ranging from “No pain” to 
“Worst possible pain”. They recorded their pain perception by drawing a line on the 
scale whilst in a seated position with both legs fully extended horizontally in front of 
them. Measurements were taken at the following eight time points: Pre-EE, Post-PT1, 
Post-EE, Post-PT2, Pre-PT3, Post-PT3, Pre-PT4 and Post-PT4. 
 Blood samples 
Venous blood samples were collected Pre-EE, and Post-EE, and then every 30 
minutes for the next 3 hours and an additional sample 48 hours after exercise. To 
facilitate ease of sample collection and minimise the number of venepunctures, a 
catheter (Appleton Woods, Birmingham, UK) was inserted into the antecubital vein of 
the arm prior to exercise to obtain a baseline blood sample and samples throughout 
the trial day. The catheter was continually kept clear with isotonic saline solution (0.9% 
sodium chloride) administered approximately every 30 minutes. Post-EE+48h blood 
sample was taken via venepuncture. The samples used for further analysis were Pre-
EE, Post-EE, Post-EE+0.5h, Post-EE+1.5h, Post-EE+3h and Post-EE+48h. 
 Performance test 
Each performance test started with three (unless the final jump was highest to a 
maximum of five) countermovement jumps. Following this the participant completed a 
set of bilateral voluntary isometric, isokinetic concentric and isokinetic eccentric 
contractions on the dynamometer. Verbal encouragement and feedback were given 
throughout the performance test. Performance test results were not analysed as part 
of this thesis. 
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 Eccentric exercise protocol 
The dynamometer was used for the eccentric exercise protocol which consisted of 20 
sets of maximal eccentric bilateral knee extensions; each set consisted of 10 
repetitions with each set being separated by 1 minute’s rest. The dynamometer lever 
arm was programmed to flex the participant’s knee from a start position of 10° of 
flexion (where 0° is full extension, leg straight in seated position) to 90° of flexion. This 
allowed for an 80° range of motion. The participants began with their leg at the start 
position and were asked to maximally contract their quadriceps against a resistance 
while the lever arm moved to the finish position (90° knee flexion). Once at the finish 
position they were advised to relax their leg and the dynamometer moved them back 
to the start position to avoid a concentric contraction being performed. The lever arm 
moved at a set speed of 60°·s-1. Visual feedback and verbal encouragement were 
provided to all participants to maximise torque output for each contraction. 
 Plasma volume changes 
Changes in plasma were calculated using the method outlined by Dill and Costill 
(1974). Briefly, haematocrit (Hct) and haemoglobin (Hb) measured using a cell counter 
(Beckman Coulter Counter, USA) were used to calculate percentage changes in blood 
volume (BV), red cell volume (CV) and plasma volume (PV) using the following 
formulas: 
BV2 = BV1 (Hb1 / Hb2) 
CV2 = BV2 * Hct2 
PV2 = BV2 - CV2 
BVcorrection =BV2/BV1 
Subscripts 1 denotes Pre-EE blood sample and subscript 2 the Post-EE samples 
requiring plasma volume change. The BVcorrection value was used for subsequent 
plasma volume corrections. 
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6.2.7 Serum cytokines 
At time points Pre-EE, Post-EE, Post-EE+0.5h, Post-EE+3h and Post-EE+48h, 10mL 
of blood was collected into vacutainers (Becton, Dickson & Company, UK) that 
contained no anticoagulant. The blood was allowed to clot at room temperature for 20 
minutes and then centrifuged at 2800 rpm for 15 minutes at 4oC. The resulting serum 
was aliquoted and frozen -80°C for future analysis. Serum levels of IL1b, IL6 and TNFα 
cytokine levels were measured using BD™ Cytometric Bead Array (CBA) Enhanced 
Sensitivity Flex Sets (BD Bioscience, UK) on a flow cytometry platform (BD AccuriTM 
C6 Flow Cytometer, BD Bioscience, UK). Serum was diluted 1:3 with CBA buffer. The 
resulting values were corrected for plasma volume change, calculated in section 
6.2.6.7. 
Table 6-2 Assay statistics for the BD™ Cytometric Bead Array (CBA) Enhanced 
Sensitivity Flex Sets (BD Bioscience, UK) on a flow cytometry platform (BD 
AccuriTM C6 Flow Cytometer, BD Bioscience, UK) 
Assay Normal rages Linear assay (R2) 
Limit of detection 
(pg/ml) 
CV 
Interleukin 1 beta 13-227pg/ml 0.9965 0.68 17.81 
Interleukin 6 13-149pg/ml 1.0000 0.27 10.81 
Tumour necrosis factor 42-203pg/ml 0.9999 0.28 33.44 
# normal ranges from (Sekiyama, Yoshiba and Thomson, 1994).   
 
6.2.8 Gene expression 
RNA was extracted from blood collected at time points Pre-EE, Post-EE, Post-
EE+0.5h, Post-EE+1.5h, Post-EE+3h and Post-EE+48h. Promptly after blood 
collection, an aliquot of blood collected in EDTA-coated vacutainers was diluted 1:1 
with deionised water. 250μL of diluted blood was mixed with TRIzol LS (TRIzol LS™, 
Invitrogen™, Thermo Fisher Scientific, USA) at a ratio of 1:3, mixed vigorously and 
allowed to stand at room temperature for five minutes to lyse the sample before being 
frozen at -20oC. Samples were transferred to storage at -80oC at the end of the ETD 
until purification. 
RNA was extracted from the TRIzol  using the Phenol-Chloroform method. Briefly, 
thawing the sample at room temperature for 10-15 minutes. Once completely thawed, 
200μL of chloroform (pure, Sigma-Aldrich, UK) per 750μL of TRIzol used was mixed 
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with the homogenous sample. After thoroughly mixing the samples, the reaction was 
incubated for 15 minutes at room temperature. Following this, in order to separate out 
the phases, the samples were centrifuged at 12,000 x g for 15 minutes at 4oC. The 
upper aqueous phase containing the RNA was removed to separate RNase free tubes 
and mixed with 2-propanol (pure, Sigma-Aldrich, UK) to precipitate the RNA (500μL 
per 750μL of TRIzol used). After incubating at room temperature for 10 minutes, the 
samples were centrifuged at 12,000 x g for 10 minutes at 4oC. The supernatant was 
removed to leave the RNA pellet, the pellet was then washed with 75% ethanol 
(Sigma-Aldrich, UK) with 1000μL per 750μL of TRIzol used and centrifuged at 7,500 
x g for 5 minutes at 4oC. The excess supernatant was removed, pellet left to air dry for 
10-20 minutes and resuspended in EDTA storage solution (Fisher Scientific, UK). The 
concentrations and purity of the RNA samples were assessed using UV spectroscopy 
(Nanodrop, Fisher Scientific, UK). Samples were considered to have sufficient purity 
when they had a A260/A280 ratio of ³1.7. 
The extracted RNA was reverse transcribed using the High-Capacity RNA-to-cDNA™ 
Kit (Applied Biosystems, USA) according to the manufacturer’s protocol to produce 
complementary DNA (cDNA) which was normalised to 5 ng/µL. Quantitative PCR 
(qPCR) was performed for each target gene using a Viia7 Real-Time PCR system 
(Applied Biosystems, USA). Each reaction contained 5 µL of SybrGreen PrecisionPlus 
qPCR Master Mix (PrimerDesign, UK), 0.5 µL of forward and reverse primer and 4 µL 
of 5 ng/µL cDNA. All samples were run in duplicate using the following cycling 
conditions: initial denaturation at 95oC for 2 minutes, followed by 40 cycles of 95oC for 
15 seconds and 60oC for 60 seconds. Melt curves were visually inspected for a single 
peak indicating the generation of a single product. The relative mRNA expression of 
the genes of interest were calculated using the DDCt formula; relative to the expression 
of GAPDH “Glyceraldehyde-3-phosphate dehydrogenase” and using the average pre-
exercise Ct for Trial A from each supplement group as the second reference. Data is 
presented as fold change mean ± standard deviation. 
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Table 6-3 PCR primer sequences 
Gene ID Primer Sequence 
DNMT1 Forward 5'-TACCTGGACGACCCTGACCTC-3' 
Reverse 5'-CGTTGGCATCAAAGATGGACA-3' 
DNMT3a Forward 5'-TATTGATGAGCGCACAAGAGAGC-3' 
Reverse 5'-GGGTGTTCCAGGGTAACATTGAG-3' 
DNMT3b Forward 5'-GGCAAGTTCTCCGAGGTCTCTG-3' 
Reverse 5'-TGGTACATGGCTTTTCGATAGGA-3' 
PPARGC1A Forward 5'-CAGCCTCTTTGCCCAGATCTT-3' 
Reverse 5'-TCACTGCACCACTTGAGTCCAC-3' 
IL6 Forward 5'-GCAGAAAAAGGCAAAGAATC-3' 
Reverse 5'-CTACATTTGCCGAAGAGC-3' 
TNF Forward 5'-AGGCAGTCAGATCATCTTC-3' 
Reverse 5'- TTATCTCTCAGCTCCACG-3' 
GAPDH Forward 5'- GCCTCAAGATCATCAGCAATGCCT-3' 
Reverse 5'- TGTGGTCATGAGTCCTTCCACGAT-3' 
6.2.9 DNA methylation 
Blood samples were collected into EDTA-coated vacutainers and frozen promptly on 
the trial day at -20oC before being transferred to -80oC for long term storage prior to 
DNA extraction. DNA was extracted from blood and bisulphite-converted using 
EpiTect LyseAll kit (Qiagen, Germany). DNA methylation levels of TNF, IL1B and IL6 
were measured by pyrosequencing using the PyroMark Q48 Autoprep (Qiagen, 
Germany) with the assays designed and validated in Chapter 3. Data is presented as 
mean ± standard deviation. 
6.2.10 Statistics 
Descriptive statistics were calculated prior to the removal of outliers and replacement 
of missing values. Outliers were classed as data points three times the interquartile 
range above the upper quartile and below the lower quartile. These data points were 
removed prior to analysis. Due to the exclusion of cases in a listwise manner during 
analysis of variants (ANOVA), missing values were replaced using the multiple 
imputation method. The effect of variables on each other was unknown at this point 
and therefore all variables (split into two groups, see below) were used in the model. 
Five imputations were pooled to give a variable to use for further analysis. 
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• Anthropometrics, blood measures (Methylation, RNA expression, Protein) 
• VAS, thigh girth, ROM 
A three-way mixed between-within-within (BWW) ANOVA was used to understand the 
effects of supplement (EVOO or ω-3 PUFAs), trial (Trial A and Trial B), and time point 
(including where data available: Pre-EE, Post-EE, Post-EE+0.5h, Post-EE+1.5h, Post-
EE+3h and Post-EE+48h) on each analysed variable. Distribution of the data was 
assessed by Shapiro-Wilk's test, due to violations being observed in only a few 
instances and ANOVAs being considered as fairly robust, violations were noted but 
the tests were performed on non-transformed data. Due to the small sample size, the 
Greenhouse-Geisser correction was used for all ANOVAs performed. 
6.3 Results 
6.3.1 Baseline measurements 
The baseline characteristics of the participants are presented in Table 6-4, and 
comparisons between their baseline blood measurements are shown in  
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Table 6-5. Prior to intervention there were no significant differences between the 
characteristics of the two groups. The baseline blood measurements also indicated 
that there was no significant difference in measured blood variables between the 
groups with the exception of serum IL6 cytokine levels which were higher at baseline 
in the group which was to be supplemented with ω-3 PUFA (p = 0.033). 
The EE performed was designed to cause maximum muscle fatigue and damage 
without injuring the participants. However, there were two instances where the 
participant was not able to complete the eccentric exercise protocol on both legs. One 
participant (in the EVOO group) only completed one leg during Trial B; and one 
participant from the ω-3 PUFA group only completed one leg for both Trial A and B.  
Due to the limited size of the cohort, it was decided that the results of these individuals 
would be included in the analysis.  
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Table 6-4 Participant characteristics as baseline split by intervention group 
Descriptive Leg* EVOO (n = 8) 
ω-3 PUFAs 
(n = 8) p 
Age (years)  28.5 ± 11.2 26.7 ± 7.10 0.703 
IPAQ  2,577 ± 1,874 2,892 ± 2,289 0.768 
Height (cm)  179.5 ± 3.800 180.6 ± 6.500 0.699 
Weight (Kg)  80.5 ± 10.7 83.5 ± 19.5 0.707 
Body Fat (Kg)  16.4 ± 7.50 19.7 ± 12.4 0.520 
Body Fat (%)  19.8 ± 6.90 21.7 ± 9.90 0.657 
Water Weight (%)  58.1 ± 4.80 56.6 ± 6.90 0.635 
BMI (m/kg2)  25.0 ± 3.30 25.5 ± 5.20 0.814 
Pain (VAS, mm)  12 ± 10 10 ± 7 0.675 
Knee Flexion (degrees) First leg 121 ± 6 120 ± 7 0.886 
 Second leg 122 ± 6 121 ± 7 0.740 
Hip Flexion (degrees) First leg 69 ± 9 64 ± 10 0.336 
 Second leg 67 ± 10 68 ± 12 0.804 
Hip Extension (degrees) First leg 22 ± 7 21 ± 5 0.929 
 Second leg 22 ± 7 19 ± 5 0.348 
Thigh Girth (degrees) First leg 55 ± 6 55 ± 6 0.819 
* Leg which performed the eccentric exercise first or second. Data presented mean ± standard deviation. T-test 
probability value comparing Extra virgin olive oil (EVOO) and omega-3 polyunsaturated fatty acids (ω3PUFA) groups. 
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Table 6-5 Baseline blood analysis comparisons between EVOO and ω-3 PUFA groups 
Variable EVOO group (n = 8) 
ω-3 PUFAs group 
(n = 8) p 
White Blood Cell (WBC) Counts (109/L) [range*]   
 Total WBC [3.5-10.0] 4.85 ± 0.99 4.86 ± 0.74 0.973 
 Neutrophils [1.6-7.0] 2.90 ± 1.09 2.46 ± 0.57 0.330 
 Monocytes [0.2-0.8] 0.51 ± 0.15 0.45 ± 0.11 0.345 
 Basophils [0.0-0.2] 0.09 ± 0.04 0.08 ± 0.05 0.554 
 Eosinophils [0.0-0.5] 0.16 ± 0.05 0.18 ± 0.15 0.828 
 Lymphocytes [1.0-3.0] 1.61 ± 0.43 1.71 ± 0.22 0.563 
DNA Methylation (%) - Interleukin 1 beta (IL1B)  
 CpG1 89.5 ± 2.7 90.2 ± 1.1 0.535 
 CpG2 94.4 ± 0.8 94.3 ± 0.7 0.949 
 CpG3 86.2 ± 3.1 87.5 ± 2.2 0.345 
 CpG4 90.4 ± 2.3 91.6 ± 1.9 0.273 
 CpG5 74.6 ± 1.7 74.9 ± 1.5 0.701 
 CpGavg 87.0 ± 2.0 87.7 ± 1.3 0.409 
DNA Methylation (%) - Interleukin 6 (IL6)   
 CpG1 91.5 ± 2.3 90.5 ± 1.3 0.336 
 CpG2 91.8 ± 0.8 92.1 ± 1.6 0.596 
 CpG3 92.3 ± 0.8 93.0 ± 1.6 0.334 
 CpG4 88.8 ± 0.7 88.6 ± 1.2 0.735 
 CpG5 83.9 ± 0.8 83.8 ± 1.7 0.958 
 CpG6 89.6 ± 1.3 89.9 ± 0.8 0.575 
 CpGavg 89.7 ± 0.6 89.7 ± 1.0 0.905 
DNA Methylation (%) - Tumor necrosis factor (TNF)  
 CpG1 8.4 ± 1.6 7.9 ± 1.0 0.464 
 CpG2 5.9 ± 1.9 6.8 ± 1.0 0.242 
 CpG3 6.7 ± 2.3 6.9 ± 0.8 0.853 
 CpG4 11.2 ± 3.1 11.5 ± 1.5 0.864 
 CpGavg 8.1 ± 2.1 8.2 ± 1.0 0.836 
Serum Cytokines (pg/ml)    
 Tumor necrosis factor alpha (TNFa) 195.7 ± 163.0 271.7 ± 223.9 0.451 
 Interleukin 6 (IL6) 551.2 ± 223.0 294.5 ± 218.8 0.036 
Muscle Damage Markers (U/l)    
 Lactate dehydrogenase (LDH) 254.9 ± 130.6 261.2 ± 77.3 0.909 
 Creatin kinase (CK) 147.6 ± 27.1 169.9 ± 30.3 0.143 
 Myoglobin 34.7 ± 9.7 44.2 ± 21.8 0.285 
Data presented mean ± standard deviation. T-test probability value comparing Extra virgin olive oil (EVOO) and omega-3 polyunsaturated 
fatty acids (ω-3 PUFA) groups. *normal range quoted from the coulter counter data sheet. 
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6.3.2 Perception of pain (visual analogue scale) 
The participant’s perception of pain in both their legs was assessed using a VAS scale. 
The results are summarised in Table 6-6 and are depicted graphically in Figure 6-3. It 
was found that the level of pain perceived by the participants increased significantly 
after completing the EE. Their perceived level of pain remained elevated after EE until 
at least 48 hours later when the last measurement was recorded for the trial. 
There was no statistically significant three-way interaction between the two trials, time 
and supplements (trial x time x supplement), F (3.953,55.345) = 1.388, p = 0.250, 
partial h2 = 0.090.  
The two-way interaction (trial x time) was marginally not significant in the olive oil group 
F(3.486,24.403) = 2.332, p = 0.091, partial h2 = 0.250, with the tendency for lower 
perceived pain after EVOO supplementation. There was no two-way interaction (trial 
x time) in the ω-3 PUFA group. 
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Table 6-6 Perception of pain measured using a visual analogue scale (VAS). 
Supplement Trial Pre-EE  Post-PT1 
 Post-EE  Post-PT2 
 Pre-PT3  Post-PT3 
 Pre-PT4  Post-PT4   
p simple 
interaction $ 
p two-
way # 
p three-
way § 
EVOO A 12 ± 10 a 25 ± 11 a,b 66 ± 25 b,c 54 ± 17 b,c 41 ± 13 a,b,c 52 ± 19 b,c 59 ± 22 c 58 ± 18 c <0.001 0.091 
0.250  B 7 ± 6 
a,c 17 ± 9 a,b 55 ± 29 a,c,d 55 ± 28 c,d 35 ± 18 a,c,d 38 ± 17 b,d 47 ± 22 d 41 ± 21 a,c,d 0.001 
ω3PUFA A 10 ± 7 a 26 ± 14 a,b 57 ± 24 c 60 ± 20 C 48 ± 23 b,c 60 ± 18 c 55 ± 35 a,c 58 ± 23 c <0.001 0.471 
  B 8 ± 6 a 20 ± 8 a 62 ± 20 b 64 ± 16 B 52 ± 19 b 60 ± 16 b 58 ± 26 b 58 ± 23 b <0.001 
Pre and post eccentric exercise (EE) completed before (Trial A) and after (Trial B) 21 days of either extra virgin olive oil (EVOO) or omega-3 polyunsaturated fatty acid (ω-3 PUFA) supplementation. Data presented 
in millimetres (mm) as mean ± standard deviation. Means (within trial) not sharing a letter (a,b,c,d) are significantly different for simple interactions of time (p<0.05) after Bonferroni correction for multiple testing.             
§ Three-way mixed ANOVA (time x trial x supplement). # Two-way repeated measures ANOVA (time x trial). $ One-way repeated measures ANOVA (time, within trial). 
 
Figure 6-3 Perception of pain measured using a visual analogue scale (VAS) pre and post eccentric exercise (EE) completed before 
(Trial A) and after (Trial B) 21 days of either extra virgin olive oil (EVOO) or omega-3 polyunsaturated fatty acid (ω-3 PUFA) 
supplementation. Data presented as mean ± 95% confidence intervals.
0
10
20
30
40
50
60
70
80
90
Pre-EE Post-PT1 Post-EE Post-PT2 Pre-PT3 Post-PT3 Pre-PT4 Post-PT4
Pe
rc
ep
tio
n 
of
 P
ai
n 
(V
isu
al
 A
na
lo
gu
e 
Sc
al
e,
 m
m
)
EVOO (Trial A) EVOO (Trial B) ω3PUFA (Trial A) ω3PUFA (Trial B)
  136 
6.3.3 Swelling (thigh girth) 
Changes in thigh girth, used as an indicator of swelling, were not detected. The results 
are presented graphically in Figure 6-4. There was no difference over time between 
trials (two-way interaction: time x trial, within supplementation group) or between 
supplementation group (three-way interaction: time x trial x supplementation). There 
was a small increase in thigh girth of the ω-3 PUFA group during Trial B between Pre-
EE and the Post-EE+48h (56.0 ± 6.3 vs. 56.4 ± 6.3, p = 0.029) after correction for 
multiple testing. 
 
 
 
Figure 6-4 Thigh girth measurements pre and post eccentric exercise (EE) completed 
before (Trial A) and after (Trial B) 21 days of either extra virgin olive oil 
(EVOO) or omega-3 polyunsaturated fatty acid (ω-3 PUFA) 
supplementation. Data presented as mean ± 95% confidence intervals. 
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6.3.4 Range of motion (knee and hip joints) 
We found that the ROM around hip joint for the first leg undertaking the EE was 
reduced following the exercise but that this reduction became less apparent over time 
such that it had mostly returned to baseline values 48 hours after the exercise, as 
shown in Figure 6-5. This was the case in both groups with no effect seen as the result 
of the intervention, see Table 6-7. This trend was not as pronounced in the leg that 
had performed the EE second.  
In Trial A it was found that the knee flexion ROM for the first leg undertaking the EE 
was reduced following the exercise, with no recovery to pre-exercise levels within the 
48 hours after exercise. However, after supplementation (i.e. Trial B) no significant 
decreases in ROM were observed. The interaction (time x trial) was calculated and 
found to be significant within the EVOO group (F(2.144,15.009) = 6.808, p = 0.007, 
partial h2 = 0.493) but not in the ω-3 PUFA group. The results for the second leg 
undertaking the exercise displayed the same trend as the first leg but again were not 
as pronounced. 
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Table 6-7 Range of motion around the hip and knee joints before and after an intense bout of eccentric exercise and the effect of 
EVOO or ω3 PUFA supplementation 
Movement Leg * Supplement Trial Pre EE Post EE+1h Post EE+2.5h Post EE+48h 
p simple 
interaction $ 
p two-way 
# 
p three-way 
§ 
Hip Flexion First EVOO A 69 ± 9  a 58 ± 10 b 59 ± 9 b 59 ± 11 b 0.001 0.432 
0.687 
   B 64 ± 11 a 55 ± 16 a,b 56 ± 10 b 59 ± 16 a,b 0.096 
  ω3PUFA A 64 ± 10 a 48 ± 12 b 54 ± 13 b 53 ± 18 a,b 0.002 0.106    B 63 ± 13 a,c 47 ± 18 b 51 ± 17 b,c 58 ± 18 c 0.001 
 Second EVOO A 67 ± 10 a 60 ± 11 a,b 58 ± 9 b 57 ± 13 a,b 0.022 0.175 
0.141 
   B 62 ± 14  55 ± 18  57 ± 13  57 ± 15  0.002 
  ω3PUFA A 68 ± 12 a 51 ± 10 b 57 ± 12 b 58 ± 16 a,b 0.169 0.119    B 62 ± 13 a 54 ± 14 b 53 ± 12 b 60 ± 13 a,b <0.001 
Hip 
Extension 
First EVOO A 22 ± 7 a 18 ± 7 a,b 18 ± 5 b 19 ± 7 a,b 0.008 0.262 
0.864 
  B 19 ± 6  17 ± 7  17 ± 6  16 ± 6  0.152 
  ω3PUFA A 21 ± 5  17 ± 5  18 ± 7  19 ± 6  0.116 0.671    B 19 ± 6  17 ± 6  17 ± 5  17 ± 6  0.191 
 Second EVOO A 22 ± 7 a 18 ± 7 a,b 17 ± 6 b 18 ± 8 a,b 0.008 0.283 
0.370 
   B 20 ± 7 a 17 ± 8 a,b 16 ± 7 b 18 ± 7 a 0.306 
  ω3PUFA A 19 ± 5  19 ± 4  18 ± 7  17 ± 6  0.008 0.226    B 19 ± 5  16 ± 6  16 ± 6  18 ± 5  0.125 
Knee 
Extension 
First EVOO A 121 ± 6 a 116 ± 5 b 115 ± 4 b 113 ± 8 b <0.001 0.007 
0.729 
  B 121 ± 5  115 ± 6  116 ± 5  118 ± 7  0.158 
  ω3PUFA A 120 ± 7 a 114 ± 9 b 112 ± 8 b 112 ± 17 a,b 0.006 0.481    B 118 ± 7  114 ± 4  114 ± 7  115 ± 9  0.123 
 Second EVOO A 122 ± 6 a 118 ± 5 b 118 ± 4 a,b 117 ± 6 a,b 0.035 0.836 
0.611 
   B 121 ± 6  117 ± 6  118 ± 5  117 ± 8  0.157 
  ω3PUFA A 121 ± 7  116 ± 6  118 ± 5  117 ± 8  0.088 0.496 
      B 119 ± 7   116 ± 7   117 ± 7   118 ± 8   0.301 
Measurements taken pre and post eccentric exercise (EE) completed before (Trial A) and after (Trial B) 21 days of either extra virgin olive oil (EVOO) or omega-3 polyunsaturated fatty 
acid (ω-3 PUFA) supplementation. * Leg which performed the eccentric exercise first or second. Data presented in degrees as mean ± standard deviation. Means not sharing a letter 
(a,b,c) are significantly different for simple interactions of time (p<0.05) after Bonferroni correction for multiple testing. § Three-way mixed ANOVA (time x trial x supplement). # Two-way 
repeated measures ANOVA (time x trial). $ One-way repeated measures ANOVA (time, within trial).  
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a)  
 
b) 
 
c) 
 
Figure 6-5 Range of motion for hip flexion (a), hip extension (b), knee flexion (c) pre- 
and post -eccentric exercise (EE) completed before (Trial A) and after (Trial 
B) 21 days of either extra virgin olive oil (EVOO) or omega-3 
polyunsaturated fatty acid (ω-3 PUFA) supplementation. For the first leg to 
perform the EE. Data presented as mean ± 95% confidence intervals. 
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6.3.5 Muscle damage-related inflammatory markers in the serum 
The results for the 3 serum muscle damage markers, creatin kinase (CK), lactate 
dehydrogenase (LDH) and myoglobin (Mb) that were measured are depicted in Table 
6-8 and Figure 6-6. Note that the x axis in the graphical representations (Figure 6-6 a) 
are not to scale and so the rate of changes apparent here are not representative. 
During Trial A the levels of CK were seen to increase between baseline and post-EE 
and then to continue to rise. The differences between time points were statistically 
significant for both groups (p<0.002), which at this this point had not received 
supplemention and therefore effectively homogenous. Post-supplementation (Trial B), 
the levels of CK were also seen to increase as a result of the EE and to continue to 
rise thereafter. Statistical analysis confirms that the visualised trend was significant for 
both EVOO and ω-3 PUFA (p<0.006). The Pre-EE levels of Trial B were similar to 
those of pre-supplementation (Trial A) but the observed increase was less than Trial 
A. This difference in trend pre- and post-supplementation was significant for both 
EVOO and ω-3 PUFA (p<0.062), however, as discussed below, this may not have 
been the result of the supplementation itself. The three-way ANOVA indicated that 
there was no significant interaction between supplement type, trial day and time point 
(p = 0.781). 
No statistically significant changes were observed in the levels of LDH in either group 
prior to supplementation, i.e. during the first trial day (p=>0.155). Neither were there 
any significant changes observed for levels of this marker in the EVOO supplemented 
group post-supplementation (p=>0.521). However, there was a statistically significant, 
but small, increase in the levels of LDH during Trial B for the group which had been 
supplemented with ω-3 PUFA. In neither group was there an interaction between pre 
and post supplementation (p=>0.565). The levels of Mb pre-EE were consistent 
between the groups and on both trial days during which, for both groups, in response 
to EE the levels of this marker increased over the following 3 hours but had returned 
to pre-exercise levels when measured 48 hours later. This observed trend was 
significant (p =<0.015). Post-supplementation the increase in levels of Mb were not as 
pronounced but the trend was the same, with levels increasing after exercise and 
having returned to pre-exercise levels 48 hours later. There was no statistical 
interaction between the supplementation groups (p=0.497). 
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Table 6-8 Muscle damage markers in serum 
  Pre-EE  Post-EE  Post-EE+0.5h  Post-EE+3h  Post-EE+48h  
p simple 
interaction 
$ 
p two-
way # 
p three-
way § 
CK EVOO Trial A 147.6 ± 27.1 a 214.1 ± 59.1 b 275.3 ± 90.1 c 618.2 ± 370.9 a,b,c,d 616.5 ± 275.0 d 0.002 0.009 
0.781   Trial B 173.6 ± 58.2 
a 213.6 ± 66.5 a 243.6 ± 68.1 a 348.9 ± 106.4 B 351.3 ± 135.7 a,b 0.006 
 ω3PUFA Trial A 169.9 ± 30.3 a 300.2 ± 93.6 a,b,c 324.7 ± 69.3 b,d 652.0 ± 276.4 c,d 818.3 ± 352.2 d <0.001 0.062 
  Trial B 178.9 ± 69.2 a 236.8 ± 73.7 b 252.2 ± 34.8 a,b,c 428.2 ± 173.3 c,d 507.6 ± 175.0 d <0.001 
LDH EVOO Trial A 254.9 ± 130.6 
 
255.9 ± 61.5 
 
258.4 ± 73.0 
 
306.9 ± 81.2 
 
258.7 ± 52.1 
 
0.365 0.579 
0.497   Trial B 271.8 ± 169.2 
a,b 231.2 ± 61.6 a 260.0 ± 58.7 a,b 271.8 ± 68.5 B 265.6 ± 64.7 b 0.521 
 ω3PUFA Trial A 261.2 ± 77.3 
 
270.4 ± 66.9 
 
281.8 ± 59.8 
 
294.6 ± 67.0 
 
328.9 ± 100.2 
 
0.155 0.565 
  Trial B 246.6 ± 68.8 a,c 252.8 ± 73.1 a 261.2 ± 81.0 a,c 288.3 ± 78.1 B 289.0 ± 90.4 b,c <0.001 
Mb EVOO Trial A 34.7 ± 9.7 a 200.0 ± 116.5 b 342.1 ± 226.3 a,b 498.8 ± 412.8 a,b 63.1 ± 54.4 a,b 0.015 0.038 
0.497   Trial B 33.0 ± 10.5 
a 96.1 ± 41.8 b 151.3 ± 69.0 c,d 168.3 ± 76.3 D 36.0 ± 11.4 a <0.001 
 ω3PUFA Trial A 44.2 ± 21.8 a 247.1 ± 142.3 b 401.4 ± 288.7 a,b 446.8 ± 345.3 a,b 53.6 ± 15.2 a,b 0.008 0.023 
  Trial B 36.8 ± 10.8 a 118.0 ± 54.7 b 197.5 ± 108.0 c 220.7 ± 124.4 b,c 39.7 ± 10.5 a 0.002 
Serum creatin kinase (CK), lactate dehydrogenase (LDH) and myoglobin (Mb) (U/l) measurements from pre- and post-eccentric exercise (EE) completed before (Trial A) and after (Trial B) 21 days of either extra 
virgin olive oil (EVOO) or omega-3 polyunsaturated fatty acid (ω-3 PUFA) supplementation. Data presented as mean ± standard deviation. Means not sharing a letter (a,b,c,d) are significantly different for simple 
interactions of time (p<0.05) after Bonferroni correction for multiple testing. § Three-way mixed ANOVA (time x trial x supplement). # Two-way repeated measures ANOVA (time x trial). $ One-way repeated 
measures ANOVA (time, within trial).  
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a) 
 
b) 
 
c) 
 
Figure 6-6 Serum muscle damage markers: Creatin kinase (a), Lactate 
dehydrogenase (b), Myoglobin (c) pre- and post-eccentric exercise (EE) 
completed before (Trial A) and after (Trial B) 21 days of either extra virgin 
olive oil (EVOO) or omega-3 polyunsaturated fatty acid (ω-3 PUFA). Data 
presented as mean ± 95% confidence intervals. 
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6.3.6 Serum cytokines 
Measurements of the serum cytokines IL6 and TNFα are summarised in Table 6-9 and 
discussed below.  
The pre-supplementation Trial A results showed that serum IL6 cytokine levels 
increased after EE, with the highest measurement occurring at the Post EE+0.5hr time 
point. The results for the ω-3 PUFA group were significant (p=0.004) whilst those for 
the EVOO were not (p=0.069). There was a large range in data values and this was 
responsible for the failure to show significance. However, at the time of Trial A the 
supplementation intervention had not yet taken place and therefore it is also valid to 
consider the cohorts as a single population. The combined results show that the 
increase in IL6 after EE was indeed significant (F(3.017,45.249)=9.559,p<0.001). 
In respect of the group who had received the EVOO supplement the post-
supplementation Trial B IL6 measurements displayed a similar but non-significant 
(p=0.102) and a less pronounced trend to that observed pre-supplementation. The 
results for the group supplemented with ω-3 PUFA also displayed a similar less 
pronounced trend post-supplementation and this was also not significant (p=0.062). 
There was no interaction between the two supplementation groups with respect to 
time points and trials (p=0.890). 
The pre-supplementation Trial A results showed that serum TNFα cytokine levels did 
not increase immediately following EE but did subsequently rise and the highest 
values recorded were at the Post-EE+3h time point and that they had fallen but not 
fully returned to Pre-EE levels after 48 hours. The results for the two groups both 
showed this trend but only the results for the EVOO designated group were significant 
(p=0.027). The combined results however did confirm that the increase was significant 
F(2.479,37.034)=5.742, p=0.004. Post-supplementation results showed similar trends 
for both groups but due to the small sample sizes and large variation in levels between 
participants the results were not significant (p=0.85 for EVOO and p=0.29 for ω-3 
PUFA). Again, there was no interaction between the two supplementation groups with 
respect to time points and trials (p=0.540). 
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Table 6-9 Serum cytokine levels in response to eccentric exercise 
 
 
 
Serum 
Cytokine Supplement Trial Pre-EE 
 Post-EE  Post-EE+0.5h  Post-EE+3h  Post-EE+48h   
p simple 
interaction $ 
p two-
way # 
p three-
way § 
IL6 (pg/ml) EVOO A 551.2±223.0  2,198.2±1,548.7  2,959.0±2,368.4  2,552.9±2,585.5  1,361.6±1,366.1  0.069 0.645 
0.890  B 568.5±198.4  1,762.2±1,538.7  1,846.6±2,152.7  2,346.1±1,680.5  887.2±762.2  0.102 
ω3PUFA A 294.5±218.8 a 2,851.1±2,148.6 a,b 3,238.4±1,436.1 b 2,539.2±1,884.8 a,b 912.3±1,039.4 a,b 0.004 0.343 
 B 326.4±330.3 a 1,762.3±1,844.7 a,b 1,842.7±926.2 b 1,895.9±1,140.7 a,b 635.7±651.4 a,b 0.062 
TNFα 
(pg/ml) 
  
EVOO A 195.7±163.0  264.6±121.2  232.2±94.1  496.5±248.3  272.0±138.1  0.027 0.104 
0.540  B 230.7±155.6  276.8±190.9  289.6±239.6  253.7±128.0  241.3±64.9  0.850 
ω3PUFA A 271.7±223.9  266.9±179.3  218.6±110.2  456.3±216.9  346.6±145.7  0.192 0.536 
  B 293.4±256.9  174.4±91.9  166.1±100.0  324.6±196.6  309.9±307.1  0.290 
Serum interleukin-6 (IL6) and tumor necrosis factor alpha (TNFa) cytokine levels pre and post-eccentric exercise (EE) completed before (Trial A) and after (Trial B) 21 days of either extra virgin olive oil 
(EVOO) or omega-3 polyunsaturated fatty acid (ω-3 PUFA) supplementation. Data presented as mean ± standard deviation. Means not sharing a letter (a,b) are significantly different for simple interactions 
of time (p<0.05) after Bonferroni correction for multiple testing. § Three-way mixed ANOVA (time x trial x supplement). # Two-way repeated measures ANOVA (time x trial). $ One-way repeated measures 
ANOVA (time, within trial). 
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a) 
 
 
b) 
  
Figure 6-7 Serum cytokine levels: Interleukin-6 (a), Tumor necrosis factor alpha (b) -
pre and post-eccentric exercise (EE) completed before (Trial A) and after 
(Trial B) 21 days of either extra virgin olive oil (EVOO) or omega-3 
polyunsaturated fatty acid (ω-3 PUFA). Data presented as mean ± 95% 
confidence intervals. 
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6.3.7 Gene expression 
The results of gene expression have been presented as fold increase and are set out 
in Table 6-10. The expression of seven genes was measured. Following EE before 
supplementation (Trial A) results for the combined groups showed that the expression 
of COX2 was seen to increase, and that of DNMT3b, IL6 and TNF to decrease. The 
differential expressions across the time points of Trial A for these genes were 
significant (one-way repeated measures ANOVA). The changes observed in COX2, 
and IL6 expression were not significant after correction for multiple testing. Expression 
of DNMT3b was significantly lower at post-EE+1.5h and +3h (p=<0.014). The 
expression of TNF post-EE+0.5h was significantly lower than immediately after the 
exercise (p=0.036). 
After supplementation, Trial B, the two groups are considered separately. No any 
significant results were evident after correction for multiple testing except as regards 
DNMT3b and IL1B in the group that had been supplemented with ω-3 PUFA. 
Expression of DNMT3b was observed to decrease after EE and expression of IL1B 
was observed to increase after EE. 
As regards to the expression of DNMT3b, a significant three-way interaction (time x 
trial x supplementation) F(3.723,52.128)=3.299, p=0.02 was observed. Furthermore, 
the two-way interaction (time x trial) for the ω-3 PUFA group was significant (p=0.021) 
as a result of a small decrease in expression immediately after EE in Trial B compared 
to the increase observed in Trial A. 
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Table 6-10 Gene expression 
Gene Supplement Trial Pre-EE Post-EE Post-EE+0.5h Post-EE+1.5h Post-EE+3h Post-EE+48h p simple interaction $ 
p two-
way # 
p three-
way § 
COX2 EVOO A 1.1 ± 0.5  1.5 ± 0.8  1.5 ± 0.8  1.2 ± 0.3  1.3 ± 0.7  1.1 ± 0.7   0.183 0.380 
0.673 
  B 0.7 ± 0.4  1.5 ± 0.7  1.5 ± 0.9  1.4 ± 0.6  1.3 ± 0.6  0.9 ± 0.3  0.030 
 ω3PUFA A 1.1 ± 0.5  1.6 ± 0.8  1.3 ± 0.6  1.1 ± 0.6  1.3 ± 0.5  1.3 ± 0.6  0.148 0.237   B 0.8 ± 0.1  1.3 ± 0.7  1.7 ± 1.0  1.3 ± 0.5  1.6 ± 1.2  1.0 ± 0.4  0.104 
DNMT3a EVOO A 0.8 ± 0.3  0.9 ± 0.2  0.7 ± 0.3  0.8 ± 0.2  0.9 ± 0.3  0.9 ± 0.4  0.198 0.569 
0.539 
  B 0.7 ± 0.3  0.7 ± 0.3  0.7 ± 0.3  0.8 ± 0.3  0.9 ± 0.4  0.8 ± 0.3  0.375 
 ω3PUFA A 1.1 ± 0.4  1.3 ± 0.6  1.0 ± 0.5  1.1 ± 0.3  1.2 ± 0.5  1.3 ± 0.7  0.336 0.356   B 1.0 ± 0.4  1.1 ± 0.4  1.0 ± 0.3  1.1 ± 0.4  0.9 ± 0.3  1.0 ± 0.1  0.777 
DNMT3b EVOO A 0.9 ± 0.5 a,b 0.7 ± 0.3 a 0.4 ± 0.2 a,b 0.5 ± 0.2 b 0.5 ± 0.2 b 0.6 ± 0.3 a,b 0.021 0.141 
0.020 
  B 0.7 ± 0.5  0.5 ± 0.2  0.5 ± 0.1  0.5 ± 0.3  0.6 ± 0.2  0.6 ± 0.4  0.494 
 ω3PUFA A 1.1 ± 0.5  1.3 ± 0.5  1.0 ± 0.4  0.7 ± 0.3  0.8 ± 0.4  1.3 ± 0.6  0.011 0.021   B 1.2 ± 0.6 a,b 0.8 ± 0.2 a,b 1.0 ± 0.4 a 0.9 ± 0.3 a 0.7 ± 0.3 b 1.2 ± 0.6 a,b 0.018 
IL1B EVOO A 1.3 ± 1.0  1.7 ± 1.3  1.2 ± 1.1  1.7 ± 1.0  1.5 ± 0.8  1.5 ± 0.9  0.388 0.294 
0.761 
  B 1.1 ± 0.8  1.3 ± 0.9  1.3 ± 1.1  1.7 ± 1.0  1.5 ± 0.9  1.0 ± 0.4  0.028 
 ω3PUFA A 1.1 ± 0.5  1.6 ± 0.7  1.4 ± 0.8  1.3 ± 0.6  1.6 ± 1.0  1.4 ± 0.5  0.321 0.411   B 1.0 ± 0.6 a 1.2 ± 0.8 a,b 1.6 ± 0.8 a,b 1.6 ± 0.5 b 1.6 ± 0.8 a,b 1.3 ± 0.6 a,b 0.079 
IL6 EVOO A 0.6 ± 0.2  0.6 ± 0.2  0.5 ± 0.2  0.4 ± 0.2  0.5 ± 0.3  0.6 ± 0.4  0.415 0.460 
0.169 
  B 0.6 ± 0.2  0.4 ± 0.1  0.5 ± 0.3  0.5 ± 0.2  0.5 ± 0.3  0.6 ± 0.3  0.364 
 ω3PUFA A 0.9 ± 0.4  0.8 ± 0.2  1.1 ± 0.6  0.7 ± 0.2  0.7 ± 0.2  1.6 ± 0.9  0.030 0.119   B 1.3 ± 0.8  0.7 ± 0.2  1.3 ± 0.5  0.8 ± 0.2  0.9 ± 0.6  1.0 ± 0.4  0.048 
PGC1a EVOO A 0.8 ± 0.5  1.4 ± 1.3  0.5 ± 0.5  0.8 ± 0.3  0.8 ± 0.5  0.9 ± 0.7  0.231 0.224 
0.375 
  B 0.8 ± 0.3  0.6 ± 0.1  0.7 ± 0.4  1.2 ± 1.3  1.0 ± 0.6  0.7 ± 0.6  0.338 
 ω3PUFA A 1.5 ± 1.5  1.6 ± 1.1  1.1 ± 0.4  1.2 ± 0.9  1.2 ± 0.9  2.4 ± 2.4  0.195 0.085   B 0.8 ± 0.5  0.8 ± 0.7  0.6 ± 0.6  1.8 ± 1.7  1.3 ± 1.1  0.7 ± 0.4  0.159 
TNFα EVOO A 1.0 ± 0.6 a,b 1.2 ± 0.6 a,b 0.6 ± 0.4 a 0.8 ± 0.2 a,b 1.2 ± 0.4 b 1.2 ± 0.6 a,b 0.089 0.169 
0.581 
  B 1.0 ± 0.5  1.1 ± 0.5  0.7 ± 0.4  0.9 ± 0.2  0.8 ± 0.5  0.9 ± 0.7  0.447 
 ω3PUFA A 1.1 ± 0.5  1.2 ± 0.2  0.9 ± 0.3  1.0 ± 0.2  1.1 ± 0.8  1.2 ± 0.5  0.401 0.341     B 1.0 ± 0.5   1.1 ± 0.4   1.3 ± 0.7   1.0 ± 0.2   0.9 ± 0.4   1.3 ± 0.6   0.296 
Gene expression of COX2, DNMT3a, DNMT3b, IL1B, interleukin-6 (IL6), PGC1a and tumor necrosis factor alpha (TNFa) cytokine levels pre and post eccentric exercise (EE) completed before 
(Trial A) and after (Trial B) 21 days of either extra virgin olive oil (EVOO) or omega-3 polyunsaturated fatty acid (ω-3 PUFA) supplementation. Data presented as 2-(DDCt) fold change (relative to 
GAPDH expression and mean baseline value for each trial day) mean ± standard deviation. Means not sharing a letter (a,b)are significantly different for simple interactions of time (p<0.05) after 
Bonferroni correction for multiple testing. § Three-way mixed ANOVA (time x trial x supplement). # Two-way repeated measures ANOVA (time x trial). $ One-way repeated measures ANOVA (time, 
within trial). 
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Figure 6-8 Gene expression of a) COX2, b) PGC1a, c) DNMT3a, d) DNMT3b, e) TNFa 
f) IL6, g) IL1b pre and post eccentric exercise (EE) completed before (Trial 
A) and after (Trial B) 21 days of either extra virgin olive oil (EVOO) or 
omega-3 polyunsaturated fatty acid (ω-3 PUFA). Data presented as 2-(DDCt) 
fold change (relative to GAPDH expression and mean baseline value for 
each trial day) mean ± 95% confidence intervals. 
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6.3.8 DNA methylation 
We measured the percentage of methylated CpG sites of interest in three genes, TNF, 
IL1B and IL6.  
 Tumor necrosis factor (TNF) 
The percentage methylation values of four CpG sites in TNF were measured and the 
results are presented together with the average methylation of the four sites in Table 
6-11. Low methylation levels of TNF (<15%) were observed at all the CpG sites 
measured.  
Analysis of the results for all participants during Trial A shown in Figure 6-9 indicate 
that the methylation of TNF decreased following EE and had returned to pre-exercise 
levels 48 hours later (CpGavg F(3.254,48.803)=8.841, p<0.001). In general, the same 
trend was seen across the measured time points at each site and for each trial 
regardless of the supplementation.  
The results of the two way ANOVA (time x trial) indicated that there were no significant 
interactions in methylation of TNF between Trial A and Trial B and there were no 
significant three-way interactions between time, trial and supplement either, visualised 
for CpG2 in Figure 6-10. 
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Figure 6-9 Average DNA methylation of four CpG sites (CpGavg) within Tumor 
necrosis factor (TNF) exon1 pre- and post-eccentric exercise (EE). Data 
presented as mean and ±95% confidence intervals for CpGavg. 
 
 
Figure 6-10 DNA methylation CpG2 within the Tumor necrosis factor (TNF) exon1 pre- 
and post-eccentric exercise (EE) completed before (Trial A) and after (Trial 
B) 21 days of either extra virgin olive oil (EVOO) or omega-3 
polyunsaturated fatty acid (ω-3 PUFA) supplementation. Data presented as 
mean ±95% confidence intervals. 
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Table 6-11 Tumor Necrosis Factor (TNF) exon 1 methylation levels 
CpG Site Supplement Trial Pre-EE   Post-EE   Post-EE+1.5h Post-EE+3h   Post-EE+48h 
p simple 
interaction $ 
p two-
way # 
p three-
way § 
CpG1 EVOO A 8.4 ± 1.6   7.4 ± 0.9   7.2 ± 1.2   7.1 ± 1.8   8.2 ± 1.1  0.176 0.202 
0.212   B 8.6 ± 1.2 a,b 10.0 ± 2.0 a 6.9 ± 1.2 b 7.7 ± 2.4 a,b 8.9 ± 1.3 a,b 0.020  ω3PUFA A 7.9 ± 1.0  7.8 ± 1.0  7.0 ± 1.2  6.3 ± 1.3  8.7 ± 1.8  0.034 0.642   B 9.2 ± 1.1  8.1 ± 1.9  7.6 ± 1.7  7.5 ± 1.9  8.6 ± 0.6  0.145 
CpG2 EVOO A 5.9 ± 1.9 a,b 5.1 ± 0.6 a 4.6 ± 0.5 a 4.6 ± 1.3 a 6.8 ± 0.8 a,b 0.011 0.099 
0.176   B 7.0 ± 1.8  7.4 ± 1.6  5.2 ± 0.8  5.3 ± 2.1  6.2 ± 1.3  0.021  ω3PUFA A 6.8 ± 1.0 a,b 6.1 ± 0.9 a 4.6 ± 1.0 b,c 4.5 ± 0.8 c 6.7 ± 1.4 a,b,c 0.001 0.303   B 7.5 ± 1.3 a 6.0 ± 1.4 b 5.8 ± 1.2 a,b 5.0 ± 1.5 b 6.2 ± 0.9 a,b 0.016 
CpG3 EVOO A 6.7 ± 2.3  6.0 ± 0.8  5.6 ± 1.4  5.2 ± 1.1  6.4 ± 1.3  0.214 0.470 
0.549   B 7.4 ± 1.0  7.8 ± 1.1  5.9 ± 1.1  5.8 ± 2.2  6.4 ± 0.9  0.030  ω3PUFA A 6.9 ± 0.8 a 6.2 ± 1.1 a,b 5.7 ± 1.5 a,b 4.7 ± 0.6 b 7.3 ± 1.5 a,b 0.007 0.799   B 7.8 ± 0.8  6.4 ± 1.1  6.2 ± 1.7  5.7 ± 1.7  7.7 ± 0.8  0.017 
CpG4 EVOO A 11.2 ± 3.1 a,b 10.2 ± 1.0 a,b 9.7 ± 2.2 a 8.8 ± 2.1 a 12.1 ± 1.6 b 0.031 0.156 
0.539   B 12.6 ± 1.8 a 12.4 ± 2.0 a 8.8 ± 1.6 b 9.8 ± 2.5 a,b 11.4 ± 1.7 b 0.001  ω3PUFA A 11.5 ± 1.5 a 10.5 ± 0.9 a,b 9.4 ± 2.1 a,b 8.5 ± 1.2 b 12.1 ± 2.0 a,b 0.004 0.777   B 13.0 ± 2.1 a,b 11.6 ± 1.7 a,b 10.5 ± 2.2 a,b 9.5 ± 2.0 a 12.2 ± 1.3 b 0.028 
CpGavg EVOO A 8.1 ± 2.1 a,b 7.2 ± 0.6 a,b 6.8 ± 1.6 a 6.6 ± 1.5 a,b 8.3 ± 1.0 b 0.068 0.255 
0.454   B 8.9 ± 1.3 a,b 9.4 ± 1.6 a,b 6.8 ± 1.3 a 7.2 ± 2.2 a,b 8.2 ± 1.2 b 0.014 
 ω3PUFA A 8.2 ± 1.0  7.7 ± 0.9  6.8 ± 1.6  6.0 ± 0.9  8.7 ± 1.6  0.006 0.734     B 9.4 ± 1.3   8.0 ± 1.4   7.5 ± 1.6   6.9 ± 1.7   8.7 ± 0.8   0.024 
DNA methylation of TNF pre- and post-eccentric exercise (EE) completed before (Trial A) and after (Trial B) 21 days of either extra virgin olive oil (EVOO) or omega-3 polyunsaturated fatty acid (ω-3 
PUFA) supplementation. Data presented as mean ± standard deviation. Means not sharing a letter (a,b,c) are significantly different for simple interactions of time (p<0.05) after Bonferroni correction 
for multiple testing. § Three-way mixed ANOVA (time x trial x supplement). # Two-way repeated measures ANOVA (time x trial). $ One-way repeated measures ANOVA (time, within trial). 
  152 
 Interleukin 1beta (IL1B) 
The percentage methylation of five CpG sites in IL1B were measured, the results are 
shown in Table 6-12. High methylation levels of IL1B (>70%) were observed, 
compared to TNF. The methylation level of CpG5 was less than that observed for the 
other IL1B sites. 
Analysis of the results for all participants during Trial A shown in Figure 6-11 indicate 
that the methylation of IL1B was significantly altered after EE (CpGavg: 
F(2.618,39.272)=8.418, p<0.001. Methylation was seen to increase following the 
exercise and had returned to pre-exercise levels 48 hours later. 
The changes in recorded methylation at CpG3 (Figure 6-12 A) were significant in both 
Trail A and Trial B for both supplementation groups, although no significant 
interactions were shown between pre- and post-supplementation results or 
supplementation type. 
The results for CpG5 (Figure 6-12 B) of IL1B were interesting in that all measurements 
for this site showed that it was generally less methylated than the other sites measured 
for this gene. It also appeared that there were slight increases to the methylation levels 
following EE and that these returned to pre-exercise levels 48 hours later but the 
statistical significance of this effect was not clear. The results of the three-way ANOVA 
indicate that there was an interaction between the supplement and trials for each time 
point.  
The EVOO supplemented group saw and increase in methylation at CpG5 as a result 
of EE before supplementation; however, after taking the EVOO supplement, there was 
no change in methylation levels following EE. In contrast, the ω-3 PUFA group did 
show changes to the level of methylation of CpG5 following EE both before (not 
significantly) and after supplementation. The interaction between Trial A and Trial B 
for the ω-3 PUFA group was significant (p=0.013), which is the result of the 
methylation level of the 48-hour measurement after supplementation being 
significantly lower (p=0.027) than the pre-exercise level. At CpG5 the difference in 
response to exercise between the supplement groups at Trial B results in a significant 
three-way interaction (time x trial x supplement, F(2.893,40.498)=3.368, p=0.029).  
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Figure 6-11 Average DNA methylation of five CpG sites (CpGavg) within Interleukin 
1B (IL1B) promotor pre and post-eccentric exercise (EE). Data presented 
as mean and ±95% confidence intervals for CpGavg 
A) 
 
B) 
 
Figure 6-12 DNA methylation A) CpG2 B) CpG5 within the Interleukin 1beta (IL1B) 
promotor pre- and post-eccentric exercise (EE) completed before (Trial A) 
and after (Trial B) 21 days of either extra virgin olive oil (EVOO) or omega-
3 polyunsaturated fatty acid (ω-3 PUFA) supplementation. Data presented 
as mean ±95% confidence intervals. 
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Table 6-12 Interleukin 1 beta (IL1B) methylation levels 
CpG Site Supplement Trial Pre-EE   Post-EE   Post-EE+1.5h Post-EE+3h   Post-EE+48h 
p simple 
interaction $ 
p two-
way # 
p three-
way § 
CpG1 EVOO A 89.5 ± 2.7 a,b 91.1 ± 2.2 a,b 90.7 ± 2.4 a,b 91.8 ± 1.8 a 89.6 ± 1.7 b 0.047 0.614 
0.559   B 90.1 ± 3.2 a,b 90.9 ± 3.4 a,b 91.6 ± 2.7 a,b 92.1 ± 1.9 a 88.5 ± 2.4 b 0.097  ω3PUFA A 90.2 ± 1.1  89.8 ± 1.4  90.1 ± 1.1  89.2 ± 0.5  89.2 ± 1.3  0.219 0.197   B 89.1 ± 2.2 a,b 89.7 ± 2.2 a,b 89.8 ± 2.8 a,b 90.6 ± 1.6 a 87.7 ± 1.6 b 0.077 
CpG2 EVOO A 94.4 ± 0.8  94.6 ± 0.4  94.7 ± 0.9  94.8 ± 0.5  94.3 ± 0.7  0.485 0.495 
0.945   B 93.5 ± 0.9 a 94.4 ± 1.0 a,b 94.1 ± 0.8 a,b 95.0 ± 0.7 b 93.9 ± 0.8 a,b 0.030  ω3PUFA A 94.3 ± 0.7  94.3 ± 0.4  94.8 ± 0.9  94.6 ± 0.8  94.4 ± 0.9  0.442 0.366   B 93.6 ± 1.2  94.4 ± 0.9  94.0 ± 0.7  94.6 ± 0.6  94.1 ± 0.5  0.237 
CpG3 EVOO A 86.2 ± 3.1 a,b 89.1 ± 2.0 a 88.6 ± 2.0 a,b 89.4 ± 1.4 a 85.5 ± 1.8 b 0.004 0.983 
0.523   B 86.1 ± 2.2 a,c 88.6 ± 2.2 b,c 88.1 ± 2.4 a,b,c 89.3 ± 1.8 a,b 84.8 ± 1.5 c 0.006  ω3PUFA A 87.5 ± 2.2 a,b 88.5 ± 1.4 a 88.7 ± 1.2 a,b 87.9 ± 1.9 a,b 86.0 ± 1.5 b 0.031 0.187   B 86.6 ± 1.3 a,b 88.5 ± 2.0 a,b 86.8 ± 3.0 a,b 89.6 ± 1.6 a 85.3 ± 1.7 b 0.012 
CpG4 EVOO A 90.4 ± 2.3  93.0 ± 1.5  91.7 ± 2.3  92.6 ± 1.5  90.6 ± 2.1  0.012 0.610 
0.378   B 90.1 ± 2.4 a,b 91.8 ± 2.0 a,b 92.2 ± 2.6 a,b 92.6 ± 1.9 a 89.7 ± 1.9 b 0.027  ω3PUFA A 91.6 ± 1.9 a,b 92.2 ± 1.2 a,b 92.6 ± 1.5 a 91.9 ± 1.6 a,b 90.6 ± 1.1 b 0.125 0.365   B 91.2 ± 1.4 a,b 92.2 ± 1.5 a 90.8 ± 3.0 a,b 92.2 ± 1.4 a 89.3 ± 1.4 b 0.066 
CpG5 EVOO A 74.6 ± 1.7 a,b 76.2 ± 1.2 a,b 76.3 ± 0.6 a 76.4 ± 1.4 a,b 74.2 ± 0.8 b 0.003 0.484 
0.029   B 75.1 ± 1.3  75.4 ± 1.9  75.6 ± 1.3  75.7 ± 1.6  74.6 ± 0.9  0.530  ω3PUFA A 74.9 ± 1.5 a,b 74.6 ± 0.5 a,b 75.7 ± 0.5 a 74.7 ± 0.8 b 74.5 ± 0.9 a,b 0.165 0.013   B 74.7 ± 1.2 a,b 74.5 ± 1.5 a,b,c 74.1 ± 1.1 a,c 76.1 ± 0.8 b 72.7 ± 1.0 c 0.002 
CpGavg EVOO A 87.0 ± 2.0 a,b 88.9 ± 1.2 a 88.4 ± 1.4 a 89.1 ± 1.1 a 86.7 ± 1.0 b 0.003 0.936 
0.331   B 87.0 ± 1.6 a,c 88.3 ± 1.8 b,c 88.3 ± 1.9 a,b,c 88.9 ± 1.1 a,b 86.3 ± 1.3 c 0.036 
 ω3PUFA A 87.7 ± 1.3 a,b 88.0 ± 0.8 a 88.4 ± 0.8 a,b 87.7 ± 0.9 a,b 86.9 ± 0.8 b 0.056 0.111     B 87.1 ± 0.9 a,b 87.8 ± 1.3 a,b 86.9 ± 2.0 a,b 88.6 ± 0.9 a 85.9 ± 1.0 b 0.015 
DNA methylation of IL1B pre- and post-eccentric exercise (EE) completed before (Trial A) and after (Trial B) 21 days of either extra virgin olive oil (EVOO) or omega-3 polyunsaturated fatty acid (ω-3 
PUFA) supplementation. Data presented as mean ± standard deviation. Means not sharing a letter (a,b,c) are significantly different for simple interactions of time (p<0.05) after Bonferroni correction 
for multiple testing. § Three-way mixed ANOVA (time x trial x supplement). # Two-way repeated measures ANOVA (time x trial). $ One-way repeated measures ANOVA (time, within trial). 
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 Interleukin 6 (IL6) 
The percentage methylation of six CpG sites in IL6 were measured, the results are 
shown in Table 6-13. As with IL1B, the levels of methylation at all the CpG sites within 
the region of IL6 that were studied were high (>80%). 
The combined results for methylation of IL6 promotor during Trial A, shown in Figure 
6-13, showed no significant response to EE, with the exception of CpG1 and CpG6. 
The significant change in CpG6 methylation over the time points measured 
F(3.289,49.276)=3.832, p=0.013 remained significant after correction for multiple 
testing with a decrease (89.7% vs. 88.3%, p=0.007) of 1.4% at 3 hours post EE. The 
change in methylation at CpG1 was not significant after correction for multiple testing. 
When comparing resting methylation levels before and after supplementation, IL6 
CpG1 methylation had increased in the ω-3 PUFA group (90.5 ± 1.3 vs. 91.2 ± 1.2) 
compared to a decrease in the EVOO group (91.5 ± 2.3 vs. 90.6 ± 2.0), with the 
interaction almost reaching statistical significance (p=0.055). 
After supplementation, other than at CpG2 for the EVOO supplemented group, no 
significant changes were seen to methylation levels of any of the CpG sites measured 
in IL6. After supplementation with EVOO, the methylation of CpG2 was significantly 
higher three hours after EE compared to Trial B Pre-EE values (90.7% vs. 92.4%, 
p=0.015). 
There were no significant two-way (time x trial) or three-way (time x trial x supplement) 
interactions observed for IL6 methylation. 
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Figure 6-13 Average DNA methylation of six CpG sites (CpGavg) within Interleukin 6 
(IL6) promotor pre- and post-eccentric exercise (EE). Data presented as 
mean and ±95% confidence intervals for CpGavg during Trial A (n=16). 
 
Figure 6-14 DNA methylation CpG average (CpGavg) within the Interleukin 6 (IL6) 
promotor pre- and post-eccentric exercise (EE) completed before (Trial A) 
and after (Trial B) 21 days of either extra virgin olive oil (EVOO) or omega-
3 polyunsaturated fatty acid (ω-3 PUFA) supplementation. Data presented 
as mean ±95% confidence intervals 
 
 
80
82
84
86
88
90
92
94
Pre EE Post EE Post EE+0.5hr Post EE+1.5hr Post EE+3hr Post EE+48hr
IL
6 
Pr
om
ot
or
 M
et
hy
la
tio
n 
(%
)
CpG1 CpG2 CpG3 CpG4 CpG5 CpG6 CpGavg
85
86
87
88
89
90
91
92
Pre EE Post EE Post EE+0.5hr Post EE+1.5hr Post EE+3hr Post EE+48hr
IL
6 
Cp
Ga
vg
 m
et
hy
la
tio
n 
(%
)
EVOO (Trial A) EVOO (Trial B) ω3PUFA (Trial A) ω3PUFA (Trial B)
  157 
Table 6-13 Interleukin 6 (IL6) promotor methylation levels 
CpG Site Supplement Trial Pre-EE   Post-EE   Post-EE+0.5h Post-EE+1.5h Post-EE+3h   Post-EE+48h 
p simple 
interaction 
$ 
p two-
way # 
p 
three-
way § 
CpG1 EVOO A 91.5 ± 2.3   90.9 ± 2.0   91.5 ± 2.7   92.0 ± 2.4   92.3 ± 2.6   89.9 ± 2.2   0.072 0.534 
0.496   B 90.6 ± 2.0  90.8 ± 2.5  91.2 ± 1.8  91.3 ± 0.9  91.6 ± 1.4  90.7 ± 2.1  0.532  ω3PUFA A 90.5 ± 1.3  90.0 ± 1.0  90.6 ± 1.5  91.1 ± 1.4  91.1 ± 1.1  90.4 ± 1.3  0.368 0.638   B 91.2 ± 1.2  90.1 ± 1.7  90.9 ± 1.7  90.5 ± 0.8  91.7 ± 1.0  90.4 ± 1.4  0.243 
CpG2 EVOO A 91.8 ± 0.8  92.1 ± 1.1  92.1 ± 1.0  91.7 ± 1.5  92.2 ± 0.7  91.4 ± 1.0  0.411 0.455 
0.948   B 90.7 ± 1.2 a 91.8 ± 1.2 a,b 91.6 ± 0.8 a,b 91.6 ± 0.5 a,b 92.4 ± 0.6 b 90.9 ± 1.1 a,b 0.018  ω3PUFA A 92.1 ± 1.6  91.5 ± 1.0  91.7 ± 0.7  91.6 ± 1.3  91.6 ± 0.8  91.4 ± 1.0  0.565 0.263   B 91.0 ± 1.2  91.5 ± 1.6  91.6 ± 1.2  91.5 ± 0.6  92.4 ± 0.8  91.5 ± 1.0  0.269 
CpG3 EVOO A 92.3 ± 0.8  92.7 ± 1.8  92.3 ± 1.8  92.3 ± 2.2  92.6 ± 1.6  92.2 ± 1.4  0.822 0.478 
0.850   B 92.0 ± 1.2 a,b 92.3 ± 1.8 a,b 91.9 ± 1.8 a,b 91.3 ± 1.6 a 92.7 ± 1.4 b 91.8 ± 1.0 a,b 0.242  ω3PUFA A 93.0 ± 1.6  91.2 ± 2.6  91.7 ± 2.1  92.0 ± 1.8  92.2 ± 0.4  91.3 ± 2.3  0.254 0.834   B 92.5 ± 1.4  91.5 ± 1.8  92.0 ± 2.7  91.8 ± 2.1  92.3 ± 2.2  91.9 ± 1.3  0.760 
CpG4 EVOO A 88.8 ± 0.7  87.8 ± 1.9  88.1 ± 0.9  88.3 ± 1.4  88.2 ± 1.0  88.6 ± 0.7  0.541 0.791 
0.526   B 88.5 ± 1.5  87.6 ± 1.5  88.4 ± 1.4  88.3 ± 0.9  88.9 ± 0.9  88.4 ± 1.2  0.434  ω3PUFA A 88.6 ± 1.2  89.2 ± 1.1  88.2 ± 0.8  88.8 ± 0.8  88.7 ± 0.9  89.2 ± 1.7  0.255 0.112   B 89.6 ± 2.3  88.1 ± 1.9  88.5 ± 1.7  88.9 ± 0.9  89.7 ± 1.5  88.4 ± 1.2  0.174 
CpG5 EVOO A 83.9 ± 0.8  84.2 ± 1.8  83.2 ± 2.6  83.8 ± 1.3  84.1 ± 1.4  83.8 ± 2.0  0.670 0.416 
0.846   B 84.0 ± 1.5  83.0 ± 2.2  83.6 ± 1.9  82.8 ± 0.9  84.1 ± 1.8  83.5 ± 1.0  0.414  ω3PUFA A 83.8 ± 1.7  81.7 ± 3.3  82.1 ± 2.5  82.8 ± 1.6  82.2 ± 2.7  81.9 ± 4.5  0.248 0.718   B 83.5 ± 1.2  81.5 ± 1.7  82.7 ± 2.3  82.5 ± 1.9  82.7 ± 1.9  82.4 ± 2.8  0.153 
CpG6 EVOO A 89.6 ± 1.3  89.8 ± 1.6  89.9 ± 2.4  89.0 ± 1.4  88.8 ± 1.0  89.3 ± 1.6  0.323 0.332 
0.346   B 90.3 ± 1.5 a,b 90.3 ± 1.4 a 89.1 ± 1.4 a,b 88.8 ± 0.9 b 89.7 ± 1.4 a,b 89.6 ± 0.5 a,b 0.123  ω3PUFA A 89.9 ± 0.8 a 88.0 ± 1.9 a,b 88.9 ± 1.9 a,b 88.1 ± 1.5 a,b 87.8 ± 1.3 b 87.8 ± 2.5 a,b 0.031 0.138   B 88.9 ± 2.0  89.0 ± 1.0  88.2 ± 1.4  88.3 ± 0.8  88.3 ± 1.2  88.5 ± 0.7  0.418 
CpGavg EVOO A 89.7 ± 0.6  89.6 ± 1.2  89.5 ± 1.4  89.5 ± 1.3  89.7 ± 0.9  89.2 ± 1.0  0.635 0.663 
0.960   B 89.3 ± 0.9 a,b 89.3 ± 1.4 a,b 89.3 ± 1.0 a,b 89.0 ± 0.5 a 89.9 ± 0.6 b 89.2 ± 0.7 a,b 0.326 
 ω3PUFA A 89.7 ± 1.0  88.6 ± 1.4  88.8 ± 1.3  89.0 ± 0.9  88.9 ± 0.7  88.7 ± 1.5  0.181 0.634     B 89.5 ± 0.9   88.6 ± 1.0   89.0 ± 1.2   89.0 ± 0.8   89.5 ± 0.7   88.8 ± 1.0   0.199 
DNA methylation of IL6 pre- and post-eccentric exercise (EE) completed before (Trial A) and after (Trial B) 21 days of either extra virgin olive oil (EVOO) or omega-3 polyunsaturated fatty acid (ω-3 
PUFA) supplementation. Data presented as mean ± standard deviation. Means not sharing a letter (a,b,c) are significantly different for simple interactions of time (p<0.05) after Bonferroni correction for 
multiple testing. § Three-way mixed ANOVA (time x trial x supplement). # Two-way repeated measures ANOVA (time x trial). $ One-way repeated measures ANOVA (time, within trial). 
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6.3.9 Associations between DNA methylation and gene expression 
The associations between the methylation status of the CpG sites that were studied 
and other variables measured (anthropometric measurements, gene expression, 
proteins and methylation of the other sites) before supplementation is depicted in the 
form of a ‘heat map’ in Figure 6-15.  
Negative associations are shown in red and positive associations in green, with the 
shade of colour representing the strength of the association. A large number of 
associations are shown between individual sites and these are not commented upon 
in detail, however attention is drawn to the obvious apparent associations below. 
Baseline associations, which depict the position before muscle damage, are displayed 
in the first three columns. There is a negative association between the studied 
methylation status of each of the four CpG sites in TNF and five of the six CpG sites 
in IL1B. The exception being that CpG2 of IL1B showed no association with any of the 
TNF sites. Immediately after the muscle damaging exercise the negative association 
described above between TNF and IL1B had substantially disappeared and both at 
three and 48 hours after the completion of the exercise the initial association remained 
absent.  
In contrast to the association described above between TNF and IL1B, very little 
association was observed between the methylation status of IL6 and IL1B at baseline 
but immediately after the muscle damaging exercise a positive association was 
observed between four of the IL6 sites and five of the IL1B sites and a new negative 
association was observed between two sites in TNF and three in IL6. At three hours 
after the exercise the positive association between the methylation status of the IL6 
and IL1B sites appeared to be less but this was slightly stronger after 48 hours. 
Methylation of the TNF gene was negatively associated with TNFα mRNA levels. 
As regards the anthropometric measurements negative association between body fat 
percentage and TNF methylation of three of the studied CpG sites were observed 
before muscle damage and supplementation, but this was not observed at any point 
thereafter. The methylation of CpG2 was also negatively associated with BMI and 
positively associated with water weight.
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Figure 6-15 Correlations between blood DNA methylation of Interleukin 6 (IL6), Interleukin 1beta (IL1B) and Tumor necrosis factor (TNF) with each 
other , gene expression and serum protein levels. Data values in Appendix 4.
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6.4 Discussion 
The aim of the research presented in this chapter was to investigate whether the 
methylation profiles of three cytokine genes would change in the presence of an 
inflammatory stimulus. The three genes studied were TNF, IL6 and IL1B, and an 
intense bout of exercise was used to provide the inflammatory stimulus. This research 
also sought to investigate if the observed results would be different dependent upon 
whether the cohort was supplemented with either ω-3 PUFAs or EVOO. 
It has previously been established that individuals who are unaccustomed to EE suffer 
varying degrees of muscle damage as a result of the eccentric contractions and that 
a similar response is not observed as a result of concentric contractions (Brown, Day 
and Donnelly, 1999). Therefore, the chosen inflammatory stimulus was EE. To 
establish whether EE had successfully provided this stimulus, the participant’s 
perception of pain, their range of movement around affected joints and muscle swelling 
were measured. All of this information was recorded at baseline and after EE and then 
again after the supplementation intervention and a second bout of the exercise. 
Eccentric exercise results in the release of CK, LDH and Mb when muscle fibres are 
damaged leading to increased levels within serum (Brown, Day and Donnelly, 1999). 
Therefore, in addition to the perceived pain and physical measurements,  biochemical 
measurements of these three muscle damage markers from the participant’s blood in 
order to establish whether muscle damage had occurred. 
The data collected regarding pain perception confirmed that the participants felt 
increased muscle discomfort following the EE and that this discomfort was still 
apparent after 48 hours. The ROM around the affected joints decreased indicating that 
flexibility within the muscles was reduced after EE, but measurements of thigh girth 
were unable to detect signs of swelling. As regards the measurement of muscle 
damage markers in the blood, it was found that levels of CK and Mb increased after 
EE and that they remained elevated 48 hours after the exercise had been performed. 
However,  the expected increase in LDH levels were not observed, only a trend can 
be seen towards elevated levels, but these were not statistically significant. 
Nevertheless, taken together, all of these results do indicate that the EE undertaken 
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had achieved the desired effect of damaging muscle fibres and thus stimulating an 
inflammatory response. 
The intention of providing the inflammatory stimulus was to see whether it would alter 
the methylation levels of three genes which encode proteins known to be involved in 
inflammation. Eccentric exercise was not found to have any effect on the levels of 
methylation within the IL6 promotor region, with the exception of a small decrease at 
CpG6, however it was established that EE induced demethylation of four CpG sites 
within the first exon of the TNF gene and that it induced increased methylation at three 
sites in the promotor of IL1B.  
In response to EE, a small but significant decrease in the methylation of a single CpG 
(CpG6, -1057) in IL6 was observed, but no significant changes were detected at any 
of the other sites measured. The observed decrease corresponded with an increase 
in serum levels of the IL6 cytokine after EE, however whilst cytokine levels returned 
towards baseline levels by the 48-hour time point, methylation levels had not. Previous 
research investigating the methylation of IL6 has detailed the importance of 
methylation upstream of the promotor in the control of IL6 expression (Poplutz et al., 
2014). When PBMCs were stimulated with LPS, the methylation of the CpG -1099bp 
from the TSS was found to be significantly lower in those with increased mRNA (Nile 
et al., 2008). Here there was no change in IL6 mRNA observed. The control of IL6 
expression through DNA methylation does not just involve these CpG sites where, as 
observed here and in other research, the methylation levels are very high (Na et al., 
2015). The findings here, which are in agreement with the literature (Nile et al., 2008; 
Na et al., 2015), indicate that decreased methylation of sites 1000bp from the TSS are 
involved with the epigenetic control of IL6 cytokine levels. Further research, not 
restricted to the number of sites that can be measured, would provide additional 
understanding of the effects of exercise  on IL6 expression through other CpG sites 
which have been shown to control expression in health and disease (Kirchner et al., 
2014; Poplutz et al., 2014; Ma et al., 2016). 
The decrease in methylation seen in the TNF gene was much clearer than that 
observed in IL6, where it was observed at all four CpG sites measured. The lowest 
levels of methylation at these sites were measured three hours after EE; with levels 
having returned to baseline values 48 hours later. Serum TNFa has previously been 
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shown to negatively correlate with methylation levels in the promotor (Zhang et al., 
2017) and exon 1 (Hermsdorff et al., 2013) of the TNF gene. Therefore, the 
demethylation of TNF which was observed would be expected to increase the gene 
expression and lead to increased serum levels of TNFa. Unexpectedly, a decrease in 
gene expression was observed even though there was no expected increase in TNFa 
levels. Whilst it is possible that the expression of TNF could have been transient, and 
that the time points where an increase had occurred were not measured, the regulation 
of TNFa cytokine production during an inflammatory response is known to be a tightly 
regulated process in which both transcriptional and post-transcriptional mechanisms 
are involved (Aslam and Zaheer, 2011). Hence it is possible that the observed 
reduction in TNF mRNA was the result of degradation by factors such as adenylate-
uridylate-rich element and zinc finger protein 36 (Dean et al., 2003). Whilst this may 
explain why this research failed to observe the expected results, it is also possible that 
issues in the collection of RNA from blood samples, as discussed in detail in Section 
7.3.2, were the cause. 
In contrast to the decreased methylation of TNF, three CpG sites within the promotor 
of IL1B displayed increased levels of methylation after EE. Methylation at these sites 
had also returned to baseline levels 48 hours after exercise had ceased. These 
observed methylation changes were not accompanied by any change in expression 
levels of IL1B transcript, and unfortunately due to experimental issues with the bead 
array kit, levels of serum IL1b could not be detected. Previous research into the effects 
of resistance exercise on the expression of IL1B from chondrocytes in females with 
and without rheumatoid arthritis has found decreased levels of IL1b cytokine after the 
exercise (Pereira Nunes Pinto et al., 2017). In relation to the observed increase in 
methylation, theoretically this would reduce the expression of IL1B and therefore it 
would have expected to see a decrease in IL1b serum levels; as there was a lack of 
detection at baseline with the bead array kits, the reduction may have been even 
further out of the kits range of detection. DNA methylations proximal to the TSS in of 
IL1B have also been shown to have transcriptional control of the gene’s expression 
(Hashimoto et al., 2009, 2013). DNA methylation of the IL1B promotor may be one of 
the ways in which this response is controlled however, this research was unable to 
confirm this. 
  163 
In order to understand how the changes in DNA methylation observed could potentially 
be controlled, the measurement of DNMT3a and DNMT3b gene expression was 
included. Interestingly, there was a decrease in the expression of DNMT3b as a result 
of the EE. In contrast, no changes in the levels of DNMT3a were observed. Previous 
research into the effects of exercise on the levels of DNMT enzymes has found that 
exercise reduces expression (Laye and Pedersen, 2010; Horsburgh et al., 2015). 
These DNMT enzymes are responsible for de novo methylation of the genome. A 
decrease in the DNMT3b enzyme is in accordance with the decrease in methylation 
of TNF and IL6, however it does not account for the small increase in methylation of 
IL1B. Future investigation into the activity of the enzymes, rather than just the 
expression, would elucidate the mechanisms behind the observed changes in 
methylation. In addition, the measurement of enzymes involved in active removal of 
methyl groups should be included to understand how the decreases in methylation 
occur as a result of exercise (Wu and Zhang, 2014).  
As described above, the decrease in levels of TNF methylation and the increase in 
levels of IL1B methylation which was observed to take place after EE had returned to 
base line 48 hours after the end of the exercise. To the authors knowledge, this study 
is the first to document these acute reversible changes to the methylation levels of 
these genes as a result of EE. The decrease in methylation of IL6 at CpG6 which were 
observed in response to EE is also not documented elsewhere. Having established 
that the EE induced a change in the methylation levels of the candidate genes, this 
research was able to investigate whether supplementation with fatty acids interacted 
with these changes in any way.  
Methylation levels for CpG1 (-1099) of IL6 increased following ω-3 PUFA 
supplementation and decreased following EVOO supplementation, although the 
interaction did not reach significance (p=0.05). Methylation of a separate CpG closer 
to the TSS within the IL6 genes has previously been associated with ω-3 PUFA in the 
blood (Ma et al., 2016). Having regard to the aforementioned studies, and the changes 
seen in this research, the methylation of this particular site appears to be closely 
implicated in the expression of this gene and that expression appears to be influenced 
by levels of ω-3 PUFAs in the blood. There were no observed interactions at the CpG 
sites of IL6 between the supplements and methylation levels after exercise. These 
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observations were similar as regards TNF, where the decrease in methylation 
observed when analysing all participants together remained once split by supplement 
group and after supplementation. The inability to detect changes in the methylation as 
a result of the fatty acids supplementations is likely to be affected by the small group 
sizes once split by supplement.  
Within the IL1B gene, the methylation of CpG5 (-1009) was lower 1.5 hours and 48 
hours after EE in the ω-3 PUFA group compared to EVOO group. In addition, the IL1B 
expression levels were increased 1.5 hours after the EE. This is in contrast to  previous 
research which has observed decreases in IL1b as a result of ω-3 PUFA 
supplementation (Dangardt et al., 2010). This, therefore, warrants future investigation 
to gain a better understanding of the interaction between the ω-3 PUFAs and IL1B 
methylation.  
At Trial B, the participants were no longer unaccustomed to the EE as they had 
performed an intense bout during Trial A three weeks earlier. As expected, due to the 
repeated bout effect, although there was still an increase in CK and LDH during Trial 
B this was not of the same magnitude as that measured during Trial A. The repeated 
bout effect has been observed in individuals repeating the exercise at least six months 
apart (Nosaka et al., 2001). Having regard to the repeated bout effect it is hard to 
delineate if the decrease in cytokine levels (IL6 and TNFa) which were observed in 
both groups after supplementation were  as a result of the repeated exercise or of the 
supplementation.  
Splitting the cohort into supplementation groups permitted comparison between those 
groups according to type of fatty acid. Previous supplementation research has found 
less elevation in the levels of Mb, LDH and CK in those supplemented with ω-3 PUFA 
compared to a placebo (SFA) and a control group (Tartibian, Maleki and Abbasi, 
2011). No difference in Mb, CK and LDH release into the serum between the two 
supplements was observed in the current study. In comparison to the research design 
used here, where the participants complete two main ETDs, Tartibian et al. (2011) 
only required the participants perform the EE once at the end of the intervention and 
therefore as the participants were unaccustomed to the EE no repeated bout effect 
was observed. 
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The relationships between the methylation levels of the candidate genes and other 
measurements were assessed at Trial A by combining both supplement groups. 
Methylation levels of TNF exon 1 were negatively associated with the body fat of the 
participants at the start of the study. Previous research in a separate cohort of normal-
weight young females, found that women with lower truncal fat had higher levels of 
methylation in the same CpG sites (Hermsdorff et al., 2013). In addition, these CpG 
sites within the TNF gene have been used to predict response to weight loss 
intervention (Campión et al., 2009). Furthermore, it was found that methylation of the 
TNF gene was negatively associated with TNF mRNA transcripts, a result which has 
previously been reported (Hermsdorff et al., 2013; Marques-Rocha et al., 2016). 
Interestingly, there was a strong negative association between all TNF CpG sites 
measured and four of the IL1B CpG sites at baseline. This association did not remain 
after exercise, when IL1B methylation then switched to a positive association with IL6 
methylation. The pathways for each of these cytokines are complex and in fine 
balance. It is possible that these associations observed are a manifestation of this 
regulatory network. 
6.4.1 Conclusion 
In conclusion, it was found that methylation levels of specific sites within three 
inflammatory genes are altered by an intense bout of eccentric exercise with no effect 
of supplementation with either w-3 PUFA or EVOO fatty acids.  
  166 
Chapter 7 General Discussion 
7.1 Summary of the research 
The overall aim of this research was to increase knowledge and understanding of 
interactions between fatty acids and certain genes known to be associated with 
inflammation through the study of DNA methylation, an important epigenetic marker. 
This research also aimed to investigate whether it is possible to alter the methylation 
profile of selected inflammatory cytokine genes in order to promote a pro-resolution 
environment for inflammation.  
In Chapter 1 the modern interpretation of the term epigenetics was explained and how 
expression of DNA can change in response to the environment. DNA methylation was 
introduced as one way in which the underlying DNA can remain unaltered whilst gene 
expression itself is changed and attention was drawn to evidence linking epigenetic 
changes to many diseases which are themselves associated with inflammation. Diet 
was identified as an important environmental factor and it was noted that there are 
popular dietary supplements, such as fish oil (w-3 fatty acids), that could have 
epigenetic effects on inflammation. 
The nature and importance of fatty acids was considered in Chapter 2, where it was 
also discussed what is meant by methylation. It was noted that methylation changes 
are a normal part of cell processes but that they can also be associated with disease 
and inflammation, which were considered in more detail. Current research into the 
epigenetic effects of fatty acids was reviewed with particular reference to the different 
ways in which methylation has been associated with fatty acid intake on a genome 
wide and candidate gene level. The research aims were then set out, which in the 
broadest sense were to study methylation of specific regions of genes known to be 
associated with inflammation and to see whether their methylation and expression 
would be altered in response to changes in the w-3 fatty acid environment. 
The experimental methodology for measuring the chosen epigenetic marker, DNA 
methylation, was detailed in Chapter 3 where it was discussed how methylation would 
be measured using bisulphite conversion and pyrosequencing. Assays were designed 
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and tested to enable measurement of methylation at biologically relevant sites in the 
chosen target genes and theses were used as the primary investigative tool. 
The first piece of experimental research, which was reported and discussed in Chapter 
4, was a cross sectional analysis of TNF methylation and associations with levels of 
fatty acids in the blood. This research particularly focused on whether methylation at 
exon-1 of this gene would be affected by the amount of fatty acids within the blood 
with a particular interest in w-3 fatty acids. It was found that there are indeed significant 
relationships between levels of specific blood fatty acids and DNA methylation at the 
four CpG sites studied. Although methylation levels were not shown to be associated 
with most of the fatty acids measured, dependent upon the fatty acid group, some 
positive and some negative associations were observed, and it was also found that 
the amplitude and direction of associations differed according to sex.  
These relationships were investigated further in Chapter 5 where it was considered 
whether changes to methylation could be provoked by supplementation altering the 
fatty acids profile of the blood. Having regard to the results of the previous study where 
it was found that more relationships between fatty acids and the methylation in males 
than females, and that the levels of w-3 PUFA DHA were associated with TNF 
methylation, this second study had a cohort limited to males. The scope of the 
research was broadened by considering not just the TNF gene but two other genes, 
IL6 and IL1B, both of which are also known to be associated with inflammation. 
However, this research was unable to detect any significant change to methylation 
over the four-week supplementation period and it was speculated that this might be 
because the healthy disease-free cohort had no inflammatory stimulus. 
How an inflammatory stimulus might be provoked was considered at the beginning of 
Chapter 6. This final study set out to establish whether muscle damaging exercise 
would provoke a change in methylation levels of the candidate genes and whether 
there would be an increase in systemic inflammation. The results of various 
measurements of muscle damage and cytokine levels indicated that an inflammatory 
stimulus had been provided. Levels of methylation after the exercise were increased 
for IL1B and decreased for IL6 and TNF. No effect of the supplementation was 
observed on the methylation of IL1B and TNF, whilst a small increase in IL6 
methylation was observed after exercise. Interactions between methylation levels after 
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exercise and supplementation were hard to detect and should be considered in future 
research. 
To summarise, the following has been achieved in this thesis: 
1. Designed and implemented robust assays for the measurement of DNA 
methylation of genes involved in inflammation (Chapter 3). 
2. Determined that there was a relationship between DNA methylation of cytokine 
gene TNF and certain fatty acids found within the blood, with a difference in the 
relationship between males and females (Chapter 4). 
3. Investigated the effect of a 28-day w-3 PUFA supplement on the DNA 
methylation of cytokine the genes TNF, IL6 and IL1B, finding no changes 
across the intervention (Chapter 5). 
4. Profiled the DNA methylation levels of the cytokine genes TNF, IL6 and IL1B 
before and after an intense bout of muscle damage inducing eccentric exercise, 
with an investigation into the interaction of fatty acid supplementation (Chapter 
6). 
  
  169 
7.2 Biological significance of findings 
If this research is to be meaningful, understanding the broader biological significance 
of the findings is of great importance. The methylation of just 15 CpG sites within three 
genes was measured, out of the 28.3 million CpG sites in the human genome (Luo, 
Lu and Xie, 2014). A full understanding of the biological significance of these sites 
requires consideration of their biological relevance in the context of the small but 
statistically significant results that were observed and must be supported by 
phenotypic data such as gene expression and protein profiles. Although there were 
associations found between fatty acids and gene methylation as well as associations 
between methylation and gene expression, this research lacked mechanistic studies 
that could have delineated the direct effect. 
The 15 CpG sites measured are a very small part of a larger and complex epigenetic 
network of mechanisms that fine tune the inflammatory response. Therefore, it is 
postulated that it is when the subtleties and fine tuning of this network fail that 
disruptions occur to the acute inflammatory response and result in a chronic 
inflammatory phenotype. A more comprehensive understanding of these sites and 
how they interact with their environment could eventually provide a means for 
therapeutic intervention. 
7.2.1 Methylation of TNF 
The findings of this research fit within the existing literature as regards the methylation 
of TNF, the associations with circulating fatty acids and TNF gene expression. 
Previously reported research, and the research that has been presented here 
indicates that some of these interactions are site specific, whilst others involve the 
methylation of multiple sites. Previous research had specifically found that two out of 
20 CpG sites studied had a significant difference between high and low truncal fat and 
that the same sites were associated with gene expression. The assay used in this 
thesis measured four of the CpG sites from the aforementioned research. When 
analysing the relationship between circulating fatty acids and the methylation of these 
four sites (Chapter 4) the associations were not site specific; however consistent with 
previously reported results Hermsdorff et al. (2013), the methylation of CpG2 was the 
only site studied in this research to show association with  anthropometric 
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measurements of body fat and BMI (Chapter 6). This site specifically, as noted by 
Hermsdorff et al. (2013), lies within the sequence RCGTG, which is the core binding 
motif for Hypoxia inducible factor (HIF-1), as shown below: 
TNF exon 1: 5’-CCGGGACGTGGAGCTGGCCGAGGAGGCGCT-3’ 
Therefore, altered methylation at this site could influence the binding of the HIF-1 
transcription factor, thus influencing the expression of the gene. Methylation of this 
motif within the erythropoietin gene has been shown to prevent the binding of HIF-1 
(Wenger et al., 1998). However, it must be noted that, chromatin immunoprecipitation 
couple to next-generation high throughput sequencing (CHIP-seq) data investigating 
the binding sites of HIF-1 throughout the genome did not identify TNF as a target gene 
(Schodel et al., 2011). Despite this, this individual CpG site (CpG2) has been found to 
be associated with measurements of obesity in both this research and that of 
Hermsdorff et al. (2013). Furthermore, methylation of the promotor and the first exon 
of TNF have been implicated in diseases such as cancer, where methylation of these 
regions is significantly associated with the suppression of TNF in tumours (Zhang et 
al., 2009; Ganapathi et al., 2014). Whilst there was no influence of w-3 PUFA 
supplementation on the methylation of the four sites, the demethylation as a result of 
the exercise is an interesting discovery and investigating the impact of multiple bouts 
of exercise, such as an exercise training intervention, on the resting methylation levels 
of these sites warrants further investigation.  
7.2.2 Methylation of IL1B 
Our research has added to the limited research of the IL1B promotor. Although 
methylation of the IL1B gene was not altered as a result of w-3 PUFA supplementation, 
EE induced an increase in the methylation of the sites studied. The methylation within 
the promotor of the IL1B gene is sparse, with no CpG island. Methylation of the IL1B 
promotor has been found to have a direct suppressive effect on expression of the gene 
in chondrocytes (Hashimoto et al., 2013; Tekpli et al., 2013; Kirchner et al., 2014). The 
available research has predominantly focused on the methylation levels of the CpG 
sites located proximal to the TSS (-299bp) compared the region studied within this 
thesis, circa. -1000bp from the TSS. As explained in Chapter 3 this research was 
unable to validate an assay that would reliably measure the methylation of CpG site -
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299bp from the TSS. The methylation of IL1B in chondrocytes is of particular relevance 
in rheumatoid arthritis, which is characterised by overexpression of IL1B. As is the 
case with TNF, it would be interesting to see if repeated bouts of exercise, particularly 
those at a lower intensity than someone suffering from rheumatoid arthritis could 
manage, would alter the methylation of the IL1B to provide a therapeutic effect. 
7.2.3 Methylation of IL6 
Previous research into the epigenetic regulation of the IL6 gene has indicated the 
importance of methylation in the regulation of its gene transcription (Poplutz et al., 
2014). The sites studied in this thesis are located in a region that remains closed and 
methylated during LPS stimulation. However, these sites have been associated with 
obesity and altered by zinc deficiency (Na et al., 2015; Wong, Rinaldi and Ho, 2015). 
The methylation of other CpG sites within the promotor of IL6 have been investigated 
in relation to diseases such as rheumatoid arthritis and asthma (Nile et al., 2008; 
Baccarelli et al., 2012).  
7.2.4 Regulation of gene transcription 
It is important to understand the scale of the interactions between genes, 
transcriptional regulation (pre-, during and post-), interactions between proteins and 
feedback loops. For example, the cytokines themselves have an effect on the levels 
of methylation within the genome, such as IL1β and TNFα decreasing the expression 
and activity of the TET enzyme and leading to a decrease in 5-hmC throughout the 
genome (Haseeb, Makki and Haqqi, 2014) and IL6 affecting the activity of DNMT1 
(Hodge et al., 2007). It was not within the scope of this research to measure any other 
epigenetic markers than DNA methylation. However the transcriptional regulation of 
the genes studied  is not solely controlled through the methylation of these specific 
sites, or DNA methylation across the gene, but rather a combination of multiple factors 
including histone modifications (Sullivan et al., 2007; Lee, Sahoo and Im, 2009; Yoza 
and McCall, 2011; Poplutz et al., 2014).  
Considering DNA methylation alone, there are multiple modifications in the chemistry 
of cytosine other than that of the heavily studied methylcytosine, these include 
hydroxymethylcytosine, formylcytosine and carboxycytosine. Analysis of these 
alternative modifications cannot currently be resolved through the bisulphite 
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sequencing methods. Methods to quantify these other cytosine modifications are 
being developed but currently not concordant with each other or available for whole 
genome use (Lauschke, Ivanov and Ingelman-Sundberg, 2017).  
It would be interesting to investigate the effects of similar interventions to the ones 
used within this thesis on other epigenetic modifications such as these cytosine 
modifications, histone modifications and micro RNAs. 
7.2.5 Responders and non-responders 
Previously in this thesis, the issue of responders and non-responders was briefly 
mentioned in Chapter 1 in relation to how epigenetic pharmacogenomics uses the 
genome of an individual in order to establish if they are responders or non-responders 
to particular drugs and to establish what dosage is appropriate. The implication for 
research is that within any cohort there may be individuals that respond to an 
intervention and there may be others that do not.  
In Chapter 2 conditionally essential fatty acids were mentioned. At the level of dietary 
intake that may be essential to one person, may not be to another and therefore the 
effect of this supplementation may for example be seen in one person but not in 
another. 5 
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7.3 Thesis Limitations 
7.3.1 Target tissue 
There are a number of issues that require careful consideration in the design and 
implementation of epigenetic analysis of candidate genes. Identification of the 
candidate gene and the biologically significant region within it presents the first hurdle. 
To elucidate pathways in detail requires careful study of the baseline position and 
measurements to be made at precise CpG sites before analysing many potential 
induced effects. When associations are observed these need to be carefully 
considered and verified before there can be confidence to say that a pathway has 
been established.  
For practical, and sometimes ethical reasons, it is not always possible to directly 
sample the tissue which would be the most interesting to study. This is problematic 
because alternative tissues must be used and an attempt to relate the results to the 
tissue of interest. This is not easily done because, as pointed out earlier in the thesis, 
methylation is specific to tissue type and responses to environmental changes differ 
according to cell type, so measurement of changes in one cell type may not be 
representative of the changes taking place in another cell type. Circulating blood 
comprises a heterogeneous cell population and this presents a barrier to interpretation 
of results. Different cell types within the blood complicate the position as they may 
have different methylation levels and may respond differently to intervention. It is 
recognised that tissue composition must be accounted for and that changes to tissue 
composition as a result of an intervention may lead to critical results being masked or 
exaggerated without specificity to one cell type or adjustment for any change (Jenke 
et al., 2013).  
In part this problem was addressed by performing a cell count for each sample 
collected which enabled the use of statistical correction to the methylation values to 
address the potential confounding factor of changes to tissue composition which arose 
from the inflammatory stimulus and resulted in a non-uniform increase in the different 
white blood cells. However, the white blood cells themselves comprise different cell 
types and future investigations would benefit from collecting a homogenous cell 
population; for example, by utilising the fluorescence-activated cell sorting (FACS) 
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method to obtain individual sub-populations of blood mononuclear cells. The use of 
FACS however also has its limitations and its use is restricted in studies such those 
carried out in this thesis because it would require a larger volume of blood to separate 
out the cells, and so sampling at a number of time points would not be possible.  
7.3.2 Gene expression data 
Many of the nutri-epigenetics studies are deficient in that they lack gene expression 
and protein measurement data and so make it difficult to investigate the biological 
significance of changes to DNA methylation. In Chapter 6 the methylation data was 
bilt upon by measuring mRNA expression and protein levels alongside the levels of 
methylation. 
Unfortunately, due to the quality of the mRNA extracted from whole blood, the gene 
expression data proved difficult to analyse. In light of this, a more suitable approach 
for the collection of samples for RNA extraction would be collection of the buffy coat 
and preservation in TRIzol, rather than the whole blood. By using whole blood very 
few cells that contained RNA were captured within the sample, whereas the buffy coat 
would have concentrated the cells containing the RNA into the same volume of TRIzol. 
During design and implementation of the exercise protocol, it was considered that 
additional sample handling would not have been possible due to the pressure of the 
sampling schedule. In hindsight, it would have been better to reduce the number of 
samples collected (not all timepoints were analysed in this thesis) and to subject the 
smaller number of samples to additional processing in order to collect the buffy coat. 
7.3.3 Cohort size and selection – power to detect changes 
A common theme amongst intervention studies is the small size of the cohort 
population. This issue partly arises as a result of recruitment issues but the high costs 
of running the experiments and analysing results is also a major factor. Some 
epigenetic responses are sex-specific and this adds to the problem of obtaining a 
sufficiently large cohort to allow for stratification by sex. 
The cohort size in Chapter 6 was halved for the second part of the research due to the 
split of participants by supplement type. Ideally, a larger cohort would have been used 
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so that after splitting the effect of any missed data points or outliers would not have 
impacted on the study. 
7.3.4 Supplementation length 
The supplementation periods in the second two studies were relatively short and no 
significant effects were seen. Longer periods of supplementation have their own 
issues as regards cohort recruitment, compliance and cost, however before it can be 
concluded with certainty that supplementation has no effect then longer interventions, 
even those that span generations are required. 
7.4 Future directions 
This research has proved promising in identifying changes to DNA methylation of 
candidate inflammatory genes. Future research is required to interrogate the observed 
changes in DNA methylation as the result of exercise and whether multiple bouts of 
reduced intensity exercise could provide a long-term beneficial change to DNA 
methylation profile of the genes. Furthermore, the relationship between fatty acids and 
DNA methylation could be interrogated further by using a different method of 
stimulation. As part of the research within Chapter 5, PBMCs were extracted before, 
during and after the w-3 PUFA supplementation for ex vivo stimulation of the cells. 
Unfortunately, due to time pressures the method development for the ex vivo 
stimulation was not complete for inclusion in this thesis. It will be interesting to see if 
the methylation profiles of the cytokine genes respond to ex vivo stimulation in the 
same manner as the in vivo stimulation induced by EE. 
This research did not show that increasing the dietary intake of EPA and DHA had any 
significant effect on the methylation of specific CpG sites within three cytokine genes. 
However, it did demonstrate that high intensity eccentric exercise altered methylation 
levels within these genes. The research here cannot be taken to indicate that changing 
dietary w-3 PUFA has no effect on methylation throughout the genome, since at other 
CpG sites in other genes it may well have had an effect.   
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Appendix 1: Data values for Figure 4-2 Spearman correlation coefficients heat map between 
the DNA methylation of four Cytosine-Guanine dinucleotides (CpG) sites located in 
exon 1 of the Tumor Necrosis Factor (TNF) gene and dried blood spot fatty acid levels 
measured as a percentage of total (spearman correlation coefficients) 
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Omega 3 Polyunsaturated Fatty Acids (⍵-3 PUFA)
20:5n-3 (EPA, Eicosapentaenoic acid) -0.01 0.04 -0.01 -0.02 0.00 -0.01 0.03 0.01 -0.02 0.00 0.20 0.23 -0.06 0.06 0.11 0.25 0.31 -0.03 0.21 0.21 -0.10 -0.04 0.00 -0.06 -0.05 -0.12 -0.05 0.03 -0.08 -0.06
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18:2n-6 (Linoelaidic acid) -0.08 -0.18 -0.04 -0.16 -0.12 -0.12 -0.18 -0.08 -0.18 -0.14 -0.14 -0.11 -0.02 -0.13 -0.06 -0.03 0.00 0.06 0.04 0.04 -0.07 -0.22 -0.07 -0.19 -0.15 -0.17 -0.23 -0.14 -0.26 -0.21
20:4n-6 (AA, Arachidonic acid) 0.16 0.24 0.28 0.18 0.23 0.10 0.20 0.26 0.13 0.19 0.37 0.47 0.33 0.38 0.44 0.45 0.57 0.35 0.46 0.49 0.04 0.10 0.23 0.07 0.11 -0.06 0.03 0.19 -0.01 0.04
20:3n-6 (DGLA, Dihomo-!-linolenic acid)-0.11 -0.04 0.03 -0.04 -0.05 -0.20 -0.06 -0.01 -0.08 -0.09 -0.18 -0.12 -0.14 -0.02 -0.13 -0.19 -0.11 -0.10 -0.01 -0.13 -0.07 0.05 0.15 -0.04 0.01 -0.18 0.05 0.11 -0.09 -0.05
20:2n-6 (Eicosadienoic acid) 0.12 0.12 0.16 0.18 0.16 0.15 0.16 0.19 0.23 0.22 0.02 -0.03 0.02 0.17 0.09 -0.07 -0.11 -0.09 0.12 0.01 0.18 0.22 0.27 0.21 0.24 0.22 0.31 0.34 0.27 0.30
22:2n-6 (Docosadienoic acid) -0.07 -0.11 -0.05 -0.02 -0.07 0.00 -0.03 0.01 0.10 0.03 -0.06 -0.11 0.02 0.08 -0.08 -0.06 -0.15 -0.04 0.06 -0.08 -0.10 -0.15 -0.11 -0.12 -0.13 0.02 -0.08 -0.04 0.03 -0.03
22:4n-6 (Adrenic Acid) 0.23 0.24 0.31 0.25 0.28 0.13 0.17 0.25 0.15 0.20 0.21 0.32 0.28 0.35 0.31 0.24 0.28 0.24 0.33 0.30 0.25 0.22 0.34 0.22 0.28 0.15 0.13 0.28 0.14 0.20
TOTAL ⍵-6 PUFA 0.03 0.02 0.12 0.02 0.05 0.00 0.01 0.09 0.00 0.04 0.15 0.24 0.20 0.21 0.25 0.26 0.35 0.24 0.36 0.34 -0.03 -0.09 0.06 -0.10 -0.05 -0.11 -0.11 0.03 -0.15 -0.09
Monounsaturated Fatty Acids (MUFA)
14:1n-5 (Myristoleic acid) -0.14 -0.23 -0.20 -0.13 -0.18 -0.14 -0.20 -0.21 -0.09 -0.18 -0.45 -0.50 -0.37 -0.38 -0.48 -0.35 -0.47 -0.30 -0.35 -0.42 0.04 -0.05 -0.06 0.04 0.00 -0.04 -0.09 -0.19 0.01 -0.09
16:1n-7 (Palmitoleic acid) 0.04 -0.05 -0.09 0.05 -0.02 0.11 0.04 -0.06 0.09 0.06 -0.26 -0.36 -0.31 -0.26 -0.33 -0.16 -0.28 -0.23 -0.16 -0.20 0.14 0.13 0.01 0.18 0.13 0.22 0.18 0.04 0.23 0.19
17:1n-7 (Cis-10-Heptadecenoic acid) -0.05 -0.06 0.01 0.01 -0.02 -0.06 -0.05 0.04 0.01 -0.02 -0.39 -0.34 -0.21 -0.26 -0.35 -0.37 -0.34 -0.17 -0.31 -0.36 0.13 0.09 0.16 0.18 0.16 0.06 0.03 0.10 0.13 0.09
22:1n-17 (5Z-docosenoic acid) 0.10 0.07 0.12 0.17 0.12 0.01 0.02 0.07 0.11 0.05 -0.16 -0.24 -0.01 -0.04 -0.12 -0.18 -0.34 -0.08 -0.13 -0.20 0.21 0.23 0.20 0.28 0.23 0.12 0.15 0.11 0.18 0.14
18:1n-9 (Oleic acid) 0.04 0.06 0.03 0.06 0.05 0.07 0.13 0.08 0.09 0.09 -0.19 -0.23 -0.05 -0.22 -0.20 -0.14 -0.14 0.08 -0.25 -0.15 0.18 0.24 0.09 0.25 0.21 0.16 0.25 0.05 0.26 0.21
18:1n-9 (9-octadecenoic acid) -0.07 -0.08 -0.12 -0.12 -0.09 -0.02 -0.03 -0.09 -0.05 -0.03 0.19 0.17 -0.01 0.07 0.12 0.18 0.23 0.02 0.14 0.16 -0.21 -0.24 -0.17 -0.26 -0.23 -0.11 -0.13 -0.08 -0.13 -0.13
20:1n-9 (Gondoic acid) 0.15 0.02 0.06 0.11 0.09 0.10 0.01 0.03 0.07 0.03 0.05 -0.07 0.04 0.04 0.02 0.04 -0.15 -0.01 -0.04 -0.03 0.22 0.11 0.09 0.18 0.15 0.19 0.07 0.04 0.13 0.11
TOTAL MUFA -0.08 -0.14 -0.13 -0.07 -0.11 -0.06 -0.09 -0.12 -0.02 -0.08 -0.46 -0.50 -0.32 -0.38 -0.47 -0.40 -0.46 -0.23 -0.40 -0.43 0.14 0.09 0.03 0.15 0.12 0.10 0.07 -0.06 0.15 0.08
Saturated Fatty Acids (SFA)
13:0 (Tridecanoic acid) 0.11 0.17 0.11 0.09 0.12 0.17 0.21 0.18 0.11 0.19 0.07 0.05 0.06 -0.05 0.01 0.09 0.09 0.11 -0.10 0.03 0.10 0.22 0.09 0.16 0.15 0.18 0.27 0.20 0.19 0.25
14:0 (Myristic acid) -0.14 -0.10 -0.15 -0.18 -0.16 -0.09 -0.05 -0.07 -0.15 -0.10 -0.21 -0.19 -0.19 -0.25 -0.26 -0.17 -0.05 -0.03 -0.21 -0.17 -0.12 -0.08 -0.15 -0.15 -0.12 -0.05 0.02 -0.07 -0.09 -0.06
15:0 (Pentadecanoic acid) -0.14 -0.03 -0.02 -0.05 -0.06 -0.16 -0.03 0.00 -0.09 -0.07 -0.28 -0.14 -0.01 -0.21 -0.16 -0.31 -0.13 0.03 -0.26 -0.23 -0.05 0.03 -0.04 0.06 0.01 -0.05 0.06 0.00 0.05 0.02
16:0 (Palmitic acid) 0.01 0.00 -0.04 -0.01 -0.02 0.03 -0.05 -0.05 0.00 -0.03 0.34 0.25 0.16 0.27 0.27 0.21 0.03 -0.03 0.13 0.14 -0.14 -0.14 -0.14 -0.17 -0.17 -0.07 -0.15 -0.09 -0.12 -0.15
18:0 (Stearic acid) 0.13 0.14 0.09 0.14 0.13 0.13 0.09 0.05 0.13 0.10 0.42 0.34 0.27 0.36 0.39 0.32 0.13 0.06 0.29 0.28 0.01 0.05 0.02 0.02 0.01 0.07 0.05 0.06 0.07 0.06
20:0 (Arachidic acid) 0.10 0.15 0.10 0.08 0.12 0.06 0.08 0.05 0.01 0.06 0.15 0.21 0.11 0.04 0.16 0.14 0.17 0.10 0.12 0.16 0.07 0.10 0.04 0.08 0.08 0.07 0.04 0.05 0.06 0.10
22:0 (Behenic acid) 0.13 0.18 0.13 0.14 0.16 0.08 0.10 0.07 0.07 0.10 0.20 0.22 0.17 0.17 0.24 0.17 0.17 0.08 0.25 0.25 0.07 0.13 0.06 0.10 0.10 0.06 0.03 0.05 0.06 0.09
TOTAL SFA -0.01 0.04 -0.06 -0.02 -0.02 0.04 0.01 -0.04 0.00 -0.01 0.36 0.28 0.20 0.25 0.29 0.22 0.06 0.04 0.10 0.15 -0.18 -0.06 -0.19 -0.16 -0.17 -0.04 -0.03 -0.07 -0.06 -0.06
Fatty Acid Ratios
MUFA : SFA -0.08 -0.13 -0.08 -0.04 -0.08 -0.09 -0.08 -0.07 -0.02 -0.07 -0.51 -0.51 -0.32 -0.39 -0.48 -0.38 -0.40 -0.18 -0.33 -0.38 0.14 0.08 0.08 0.17 0.14 0.05 0.05 -0.04 0.12 0.06
PUFA : SFA 0.03 0.03 0.11 0.04 0.06 0.00 0.05 0.10 0.02 0.06 -0.02 0.09 0.06 0.04 0.06 0.12 0.29 0.18 0.24 0.20 0.05 0.00 0.14 0.04 0.07 -0.05 0.01 0.09 -0.03 0.01
MUFA&PUFA : SFA 0.01 -0.04 0.06 0.02 0.02 -0.04 -0.01 0.04 0.00 0.01 -0.36 -0.28 -0.20 -0.25 -0.29 -0.21 -0.06 -0.04 -0.10 -0.15 0.18 0.06 0.19 0.16 0.17 0.04 0.03 0.07 0.06 0.06⍵-6 PUFA : ⍵-3 PUFA 0.08 0.00 0.09 0.08 0.07 0.08 -0.02 0.07 0.08 0.05 0.10 0.18 0.28 0.29 0.25 0.12 0.07 0.19 0.25 0.20 0.08 -0.09 -0.02 -0.03 -0.03 0.13 -0.10 -0.01 -0.01 -0.02
Significant (p<0.05) Spearman's correlation coefficients between the four cytosine-guanine dinucleotide (CpG) sites (+197, +202, +214 and +222 base pairs from Transcription Start Site) of TNF gene and fatty acids detected in blood; average methylation of the 
four sites (CpGavg). Bold values indicate significant correlation (p<0.05). # CpG methylation percentage adjusted for white blood cell population. 
All Males Females
Raw (n=88) Adjusted# (n=85) Raw (n=30) Adjusted# (n=29) Raw (n=58) Adjusted# (n=56)
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Appendix 2: Example Participant Consent Form 
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Appendix 3: PBMC cryopreservation 
8.1.1 Sample Collection and Cell Separation 
Cells used for this chapter were collected in Chapter 5, an additional four 10 mL tubes 
of blood were collected for this work. Whole blood samples were collected in EDTA 
coated vacutainers and stored at room temperature prior to processing, which 
occurred within a few hours of sample collection. Processing of blood was carried out 
in a class II microbiological flow hood under aseptic conditions PBMCs were extracted 
from the whole blood sample using Ficoll Plaque density gradient centrifugation, as 
described in section 5.2.5. After extraction, PBMCs were washed twice in hanks salt 
solution.  
8.1.2 Cryopreservation 
Extracted PBMCs were stored in media [Iscove’s Modified Eagle Media (IMEM) 
supplemented with 10% (v/v) fetal bovine serum (FBS) and 100 U/ml of penicillin and 
10 µg/ml of streptomycin (PS)]. Each sample was stored with 10% Dimethyl sulfoxide 
(DMSO) in cryopreservation vials and frozen overnight in a “Mr Frosty” (Fisher 
Scientific, Loughborough, UK) at 1oC/minute to -80oC before being transferred to liquid 
nitrogen for cryopreservation until required. 
8.1.3 Cell Culture and Treatments - Viability 
Samples were rapidly thawed and suspended in Iscove’s Modified Eagle Media 
(IMEM) (10% FBS and 1% PS) within a flask. To isolate the adherent cells within the 
sample, the flask was incubated at 37oC at 5% CO2 for 2 hours.  
Non-adherent cells were removed with the media suspension. The adhered cells were 
released from the flask using Accutase (approx. 2mL) and washed with IMEM media 
(10% FBS and 1% PS) (2 x accutase volume). Cells were pelleted, and supernatant 
removed. The pelleted cells were re-suspended in 100uL IMEM media (10% FBS and 
1% PS). Cell count completed using 1:1 Trypan Blue using a haemocytometer. Cells 
were seeded to a density of 100,000 cells per well in a 6 well plate lined with a collagen 
matrix. Collagen matrix was made up of 85% collagen, 10% MEM media and 5% cell 
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suspension; the collagen was neutralised with sodium hydroxide prior to the addition 
of the cell suspension. 300uL of collagen was set in the bottom of each well. 
Cells maintained at 37oC in 5% CO2 with IMEM media (10% FBS and 1% PS) within 
a thermally regulated incubator. 
 Cell viability 
The cell viability was measured by assessing the metabolic activity of the adhered 
cells and the dissociated cells using alamar Blue every 24 hours (approx.). A solution 
of alamar Blue (1:10) to IMEM media was used. Media removed from each well was 
kept and spun down to allow for analysis of the metabolic activity of the dissociated 
cells. The alamar Blue solution was added to each well and cell pellet. Cell incubated 
for 4 hours prior to fluorescence imaging. 
 Imaging 
After collecting of cell viability data, cell density was capture using a light microscope. 
Cells per frame were quantified. 
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Appendix 4: Data values for Figure 6-15 (spearman correlation coefficients) 
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Interleukin 6 (IL6 ) methylation (%)
CpG1 -0.07 -0.53 -0.66 -0.49 -0.51 -0.44 -0.16 -0.51 -0.55 -0.44 -0.09 -0.25 -0.36 -0.38 -0.27 0.16 0.18 0.39 0.06 0.20
CpG2 0.14 0.01 -0.20 0.00 -0.04 0.01 -0.36 -0.56 -0.63 -0.47 0.06 -0.07 -0.12 -0.11 0.04 0.16 0.10 0.24 0.17 0.16
CpG3 -0.09 0.02 -0.13 -0.08 -0.08 -0.29 -0.58 -0.39 -0.24 -0.40 0.18 -0.01 0.17 0.00 0.13 -0.22 -0.19 -0.02 0.03 -0.08
CpG4 0.16 0.12 0.09 -0.09 0.02 0.47 0.34 -0.09 -0.10 0.06 0.17 -0.05 -0.05 0.05 0.03 0.80 0.54 0.48 0.58 0.63
CpG5 0.39 0.12 -0.15 0.14 0.10 -0.49 -0.67 -0.39 -0.48 -0.51 0.26 0.20 0.00 0.02 0.17 -0.24 -0.38 -0.14 -0.01 -0.13
CpG6 0.49 0.33 0.15 0.51 0.37 -0.37 -0.49 -0.42 -0.50 -0.44 0.42 0.20 0.15 0.10 0.24 -0.19 -0.28 -0.16 0.04 -0.11
CpGavg 0.38 0.13 -0.15 0.13 0.09 -0.35 -0.48 -0.61 -0.69 -0.58 0.31 0.11 -0.10 -0.01 0.12 -0.02 -0.10 0.10 0.15 0.06
Interleukin beta (IL1B) methylation (%)
CpG1 -0.55 -0.53 -0.66 -0.62 -0.66 0.21 -0.13 -0.37 -0.44 -0.20 0.26 0.07 0.17 0.03 0.15 0.04 -0.18 -0.04 -0.16 -0.10
CpG2 -0.34 -0.38 -0.38 -0.37 -0.40 0.05 -0.23 -0.34 -0.52 -0.28 -0.07 -0.31 -0.15 -0.21 -0.33 0.19 0.26 -0.15 0.14 0.03
CpG3 -0.65 -0.57 -0.71 -0.81 -0.76 0.22 0.06 -0.28 -0.50 -0.16 0.12 -0.19 -0.21 -0.13 -0.20 0.46 0.37 0.13 0.28 0.28
CpG4 -0.65 -0.47 -0.55 -0.80 -0.69 0.17 0.02 -0.29 -0.43 -0.17 0.02 -0.25 -0.20 -0.15 -0.28 -0.04 0.01 -0.43 -0.30 -0.27
CpG5 -0.59 -0.66 -0.59 -0.75 -0.70 0.11 -0.45 0.05 -0.17 -0.08 0.24 0.25 0.24 0.11 0.22 0.18 0.16 0.32 0.28 0.26
CpGavg -0.70 -0.63 -0.73 -0.83 -0.80 0.28 0.01 -0.18 -0.40 -0.07 0.20 -0.02 0.00 0.02 0.02 0.15 0.11 -0.13 0.00 -0.03
Gene Expression
COX2 -0.45 -0.39 -0.30 -0.33 -0.38 -0.20 0.07 -0.27 -0.29 -0.20 -0.20 -0.18 -0.29 -0.32 -0.14 -0.24 -0.29 -0.19 -0.38 -0.34
DNMT3a -0.13 -0.07 -0.15 -0.15 -0.12 -0.02 -0.05 -0.28 -0.03 -0.22 0.13 0.24 0.12 0.04 0.18 -0.27 -0.16 -0.07 -0.08 -0.17
DNMT3b -0.08 0.00 0.05 -0.08 -0.02 0.13 0.26 -0.17 0.21 0.00 -0.04 0.06 -0.04 -0.05 0.05 -0.02 -0.15 0.07 0.00 0.01
IL1B -0.55 -0.40 -0.19 -0.39 -0.36 -0.22 -0.22 -0.39 -0.30 -0.38 0.06 0.19 -0.01 0.07 0.03 -0.50 -0.54 -0.32 -0.42 -0.48
IL6 -0.25 -0.03 0.08 0.04 -0.02 0.13 0.24 -0.35 -0.29 -0.14 0.02 -0.07 -0.12 -0.07 -0.04 0.01 -0.06 0.24 0.23 0.14
PPARGC1A 0.09 0.09 0.10 0.00 0.07 -0.28 -0.24 -0.64 -0.30 -0.51 0.38 0.41 0.19 0.39 0.37 -0.26 -0.09 -0.09 -0.09 -0.16
TNF -0.37 -0.65 -0.63 -0.56 -0.64 0.01 -0.03 -0.02 0.02 -0.07 0.22 0.24 0.28 0.07 0.17 -0.15 0.01 -0.04 0.06 -0.10
Serum Proteins
TNFa -0.39 -0.36 -0.18 -0.26 -0.27 -0.28 -0.05 0.06 -0.07 -0.10 -0.18 -0.14 -0.36 -0.26 -0.10 0.59 0.62 0.37 0.32 0.43
IL6 0.26 -0.09 -0.22 0.19 0.04 -0.09 0.23 -0.21 -0.16 -0.06 -0.35 -0.15 -0.28 -0.13 -0.20 0.01 0.02 -0.17 -0.15 -0.14
LDH 0.00 0.13 -0.05 0.09 0.07 0.21 0.18 -0.12 -0.19 -0.02 -0.52 -0.49 -0.23 -0.30 -0.28 -0.10 -0.20 0.11 -0.05 -0.04
CK 0.31 0.84 0.63 0.46 0.60 0.00 0.04 -0.18 -0.08 -0.16 -0.41 -0.09 -0.15 -0.03 -0.07 -0.12 -0.19 0.04 -0.10 -0.18
Myoglobin -0.43 -0.08 -0.03 -0.19 -0.16 0.05 0.14 0.01 -0.14 0.02 -0.37 -0.16 -0.14 -0.11 -0.11 -0.04 -0.21 0.18 -0.02 -0.05
Anthropometrics
Weight (Kg) -0.25 -0.35 -0.09 -0.26 -0.23 -0.15 -0.32 -0.32 -0.17 -0.27 0.47 0.54 0.37 0.54 0.42 -0.38 -0.34 -0.29 -0.30 -0.35
Body Fat (Kg) -0.48 -0.55 -0.28 -0.46 -0.46 -0.17 -0.12 -0.24 -0.11 -0.17 0.42 0.51 0.30 0.52 0.33 -0.43 -0.35 -0.27 -0.42 -0.39
Body Fat (%) -0.59 -0.58 -0.32 -0.53 -0.54 -0.11 0.03 -0.17 -0.02 -0.07 0.37 0.47 0.23 0.45 0.27 -0.40 -0.33 -0.21 -0.40 -0.34
Water weight (%) 0.49 0.59 0.30 0.47 0.49 0.17 -0.01 0.25 0.14 0.15 -0.42 -0.46 -0.19 -0.41 -0.24 0.34 0.28 0.26 0.37 0.33
BMI (m/kg2) -0.38 -0.51 -0.22 -0.38 -0.38 -0.09 -0.15 -0.20 -0.11 -0.13 0.47 0.52 0.34 0.54 0.37 -0.41 -0.32 -0.32 -0.41 -0.38
Significant (p<0.05) Spearman's correlation coefficients shown in bold. Methylation of cytosine-guanine dinucleotide (CpG) sites for TNF; average methylation of the four 
sites (CpGavg) Before (Pre), and after (Post-EE, Post-EE+3h and Post-EE+48h) Eccentric Exercise (EE). 
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Interleukin beta (IL1B) methylation (%)
CpG1 0.22 0.69 0.71 0.23 0.05 0.09 0.45 0.50 0.88 0.39 0.34 0.30 0.62 0.72 0.60 0.42 0.50 -0.01 0.34 0.39 0.52 0.61 0.72 0.54 0.12 0.43 0.34 0.70
CpG2 0.00 0.38 0.47 -0.11 0.01 -0.04 0.20 0.57 0.77 0.32 0.22 0.52 0.75 0.78 0.37 -0.02 0.20 0.50 -0.22 0.00 0.07 0.22 0.54 0.19 -0.01 0.22 0.35 0.41
CpG3 0.35 0.36 0.39 0.16 -0.05 -0.17 0.19 0.45 0.75 0.02 0.50 0.18 0.46 0.58 0.50 0.48 0.34 0.21 -0.07 0.04 0.24 0.46 0.66 0.27 0.17 0.32 0.33 0.52
CpG4 0.33 0.11 0.16 0.32 -0.21 -0.28 -0.02 0.51 0.69 0.10 0.40 0.19 0.54 0.58 0.48 0.24 0.38 0.28 -0.07 0.05 0.21 0.26 0.21 -0.08 -0.11 0.05 0.12 0.08
CpG5 0.28 -0.03 0.02 -0.09 -0.18 -0.34 -0.10 -0.02 0.36 0.05 -0.13 0.17 0.16 0.13 0.12 0.21 0.20 -0.35 0.31 0.03 0.15 0.39 0.75 0.63 -0.20 0.44 0.33 0.66
CpGavg 0.32 0.29 0.34 0.10 -0.12 -0.19 0.12 0.47 0.74 0.09 0.40 0.21 0.53 0.58 0.62 0.49 0.40 0.13 0.14 0.18 0.41 0.51 0.72 0.43 -0.05 0.38 0.37 0.61
Gene Expression
COX2 -0.12 -0.16 0.06 -0.12 -0.38 -0.31 -0.41 0.16 0.22 -0.27 0.10 0.10 -0.14 0.10 -0.15 0.07 0.02 -0.03 0.13 -0.08 0.04 -0.01 0.15 0.07 -0.06 -0.09 -0.24 0.02
DNMT3a 0.05 0.13 0.18 0.01 0.18 0.02 0.09 -0.31 0.24 0.00 0.46 -0.24 -0.32 -0.11 -0.36 -0.27 0.09 -0.13 0.12 0.02 0.00 -0.49 -0.42 -0.14 -0.06 -0.23 -0.31 -0.31
DNMT3b -0.08 -0.02 -0.01 -0.09 -0.02 -0.25 -0.13 -0.36 -0.04 -0.05 0.39 -0.42 -0.46 -0.29 -0.28 -0.31 0.24 -0.06 0.14 0.03 0.01 -0.45 -0.33 -0.30 0.15 -0.11 -0.23 -0.33
IL1B -0.11 -0.31 -0.13 -0.19 -0.43 -0.43 -0.57 -0.02 0.26 -0.05 0.03 0.08 -0.01 0.17 -0.31 0.05 -0.25 -0.23 -0.16 -0.45 -0.21 -0.35 -0.24 0.10 -0.08 0.06 -0.06 -0.06
IL6 -0.49 0.13 0.25 -0.14 -0.29 -0.05 -0.17 0.42 0.48 -0.17 0.42 -0.03 0.20 0.35 -0.44 -0.30 -0.04 0.18 -0.05 0.19 -0.10 -0.49 -0.28 -0.19 0.24 -0.03 -0.17 -0.17
PPARGC1A 0.13 0.23 0.15 0.46 0.01 0.09 0.15 0.00 0.34 0.44 0.22 -0.04 0.10 0.28 -0.19 -0.12 0.00 0.27 0.10 0.13 0.22 -0.42 -0.30 -0.17 -0.17 -0.27 -0.37 -0.30
TNF 0.47 0.04 -0.17 0.00 0.20 -0.15 0.12 -0.65 -0.02 -0.14 0.32 -0.33 -0.42 -0.32 -0.19 0.00 0.22 -0.10 -0.01 0.03 -0.01 -0.49 -0.44 -0.15 -0.01 -0.24 -0.19 -0.26
Serum Proteins
TNFa -0.20 -0.19 0.04 -0.39 -0.48 -0.10 -0.40 -0.11 -0.34 -0.35 -0.07 0.03 -0.11 -0.13 0.01 0.02 -0.19 -0.09 0.22 0.04 0.09 0.11 -0.12 -0.50 0.50 -0.67 -0.68 -0.50
IL6 0.28 0.54 0.32 -0.08 0.22 0.57 0.50 0.23 0.11 0.11 -0.19 -0.09 0.00 0.10 0.09 0.07 -0.48 -0.05 -0.08 -0.37 -0.06 -0.16 0.05 -0.01 0.09 -0.34 -0.37 -0.15
LDH -0.19 0.36 0.35 -0.08 0.10 0.11 0.28 0.10 0.32 -0.03 0.43 0.02 0.07 0.22 0.27 0.22 0.18 -0.10 0.10 -0.02 0.12 0.25 -0.07 -0.02 0.04 0.10 0.13 0.04
CK -0.45 -0.03 0.09 0.29 0.01 0.17 0.09 -0.11 0.14 -0.06 0.43 -0.10 -0.32 -0.11 -0.28 -0.09 -0.53 -0.37 -0.03 -0.45 -0.27 -0.15 0.00 0.02 0.12 -0.04 -0.11 0.05
Myoglobin -0.16 -0.46 -0.32 -0.50 -0.21 -0.63 -0.55 0.00 0.13 -0.17 -0.03 -0.10 -0.25 -0.08 -0.19 0.16 -0.43 -0.27 -0.11 -0.39 -0.20 0.12 0.25 0.02 0.19 0.26 0.23 0.30
Anthropometrics
Weight (Kg) 0.01 -0.01 0.11 0.25 -0.23 -0.45 -0.18 0.20 0.35 0.49 0.02 0.25 0.27 0.43 -0.28 0.13 -0.17 -0.25 0.09 -0.11 -0.04 -0.04 0.16 0.17 -0.22 0.11 0.12 0.16
Body Fat (Kg) 0.08 -0.10 -0.01 0.18 -0.27 -0.41 -0.26 0.22 0.11 0.36 -0.11 0.12 0.17 0.32 -0.23 0.04 -0.25 -0.14 -0.03 -0.22 -0.10 0.09 0.10 0.00 -0.32 -0.07 -0.09 0.00
Body Fat (%) 0.03 -0.08 0.08 0.20 -0.31 -0.41 -0.29 0.13 0.02 0.21 -0.09 -0.04 0.00 0.17 -0.32 0.02 -0.28 -0.12 -0.14 -0.33 -0.20 0.01 0.01 -0.08 -0.25 -0.19 -0.24 -0.11
Water weight (%) -0.04 0.00 -0.13 -0.22 0.26 0.34 0.20 -0.22 -0.11 -0.26 0.05 -0.03 -0.13 -0.28 0.20 -0.11 0.28 0.05 0.10 0.26 0.12 0.00 -0.06 0.09 0.21 0.15 0.16 0.06
BMI (m/kg2) 0.06 -0.03 0.01 0.14 -0.24 -0.41 -0.21 0.16 0.18 0.46 -0.07 0.16 0.23 0.36 -0.19 0.20 -0.13 -0.19 -0.01 -0.19 -0.07 0.04 0.05 -0.01 -0.32 -0.09 -0.07 -0.04
Significant (p<0.05) Spearman's correlation coefficients shown in bold. Methylation of cytosine-guanine dinucleotide (CpG) sites for IL6 ; average methylation of the four sites (CpGavg) Before (Pre), and after (Post-EE, Post-
EE+3h and Post-EE+48h) Eccentric Exercise (EE). 
Pre-EE Post-EE Post-EE+3h Post-EE+48h
Interleukin 6 (IL6 ) methylation (%)
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Gene Expression
COX2 0.18 0.03 0.21 0.22 0.04 0.25 -0.06 -0.04 0.01 -0.13 -0.19 -0.08 -0.02 -0.14 -0.10 -0.05 0.28 -0.04 0.26 -0.11 -0.15 0.05 0.00 0.00
DNMT3a 0.09 -0.19 0.14 0.06 -0.20 0.07 -0.04 -0.16 -0.09 -0.15 -0.20 -0.19 -0.22 -0.26 -0.33 -0.26 -0.03 -0.34 -0.40 -0.33 -0.56 -0.37 -0.30 -0.49
DNMT3b -0.03 -0.21 -0.01 -0.02 -0.20 -0.06 -0.15 -0.30 -0.20 -0.27 -0.43 -0.34 -0.34 -0.23 -0.34 -0.23 -0.23 -0.40 -0.35 -0.28 -0.23 -0.34 -0.07 -0.34
IL1B 0.10 0.06 0.22 0.34 0.18 0.27 0.06 0.13 0.11 -0.01 0.15 -0.04 -0.02 -0.01 0.09 0.10 0.35 0.10 0.02 -0.41 -0.60 -0.23 -0.38 -0.40
IL6 0.15 -0.12 -0.07 -0.15 -0.28 -0.07 0.55 0.49 0.56 0.51 -0.10 0.47 -0.58 -0.39 -0.48 -0.45 -0.41 -0.63 -0.35 -0.22 -0.32 -0.46 -0.04 -0.39
PPARGC1A -0.02 -0.52 -0.05 0.05 -0.43 -0.15 0.20 0.02 -0.06 -0.04 -0.32 -0.14 -0.11 -0.09 -0.14 0.00 -0.14 -0.01 -0.44 -0.15 -0.37 -0.15 -0.03 -0.31
TNF 0.35 0.12 0.39 0.31 0.39 0.41 -0.27 -0.19 -0.14 -0.25 -0.09 -0.26 0.06 -0.10 -0.06 -0.05 0.18 0.02 -0.39 -0.28 -0.55 -0.40 -0.40 -0.50
Serum Proteins
TNFa 0.12 0.37 0.33 0.24 0.50 0.36 -0.48 -0.10 -0.06 -0.05 -0.21 -0.13 -0.27 -0.49 -0.34 -0.53 -0.05 -0.38 -0.26 0.03 0.14 0.11 -0.02 -0.06
IL6 0.28 0.08 -0.03 -0.19 -0.13 -0.04 0.19 -0.11 -0.13 -0.19 0.00 -0.15 -0.27 -0.19 -0.20 -0.21 -0.13 -0.13 0.11 -0.03 -0.22 -0.19 0.06 -0.13
LDH 0.25 0.19 0.21 0.05 0.05 0.19 0.29 0.44 0.59 0.54 -0.13 0.51 -0.03 -0.05 -0.08 -0.10 -0.14 -0.06 0.01 0.10 0.11 0.15 -0.20 0.16
CK -0.31 -0.31 -0.26 -0.11 -0.36 -0.31 -0.11 -0.14 -0.05 -0.12 -0.25 -0.13 -0.40 -0.48 -0.51 -0.50 0.05 -0.41 0.16 -0.24 -0.27 -0.41 -0.03 -0.25
Myoglobin -0.26 -0.26 -0.15 -0.15 0.00 -0.15 0.05 -0.11 -0.13 -0.29 0.21 -0.14 -0.16 -0.30 -0.28 -0.24 0.08 -0.14 0.38 -0.05 -0.06 -0.19 0.01 -0.08
Anthropometrics
Weight (Kg) 0.11 -0.16 -0.12 -0.09 0.00 -0.11 0.29 0.14 -0.03 -0.06 0.13 0.02 -0.05 -0.24 -0.03 -0.10 0.41 0.03 0.28 0.05 -0.27 -0.26 0.01 -0.13
Body Fat (Kg) 0.22 -0.06 0.07 0.13 0.21 0.11 0.14 -0.03 -0.16 -0.18 -0.01 -0.13 -0.05 -0.06 0.06 0.08 0.33 0.13 0.23 -0.02 -0.28 -0.13 -0.03 -0.14
Body Fat (%) 0.30 0.03 0.17 0.23 0.24 0.22 0.04 -0.18 -0.25 -0.28 -0.08 -0.23 -0.10 -0.02 0.07 0.13 0.30 0.11 0.14 -0.12 -0.38 -0.18 -0.07 -0.24
Water weight (%) -0.32 -0.10 -0.16 -0.18 -0.26 -0.20 -0.15 0.05 0.12 0.14 0.05 0.11 0.04 -0.04 -0.17 -0.18 -0.31 -0.18 -0.20 -0.02 0.28 0.08 0.10 0.14
BMI (m/kg2) 0.22 -0.01 0.03 0.06 0.17 0.07 0.22 0.05 -0.10 -0.14 0.05 -0.06 -0.01 -0.10 0.12 0.09 0.32 0.17 0.17 0.03 -0.28 -0.11 -0.08 -0.14
Post-EE+3h Post-EE+48h
Interleukin beta (IL1B ) methylation (%)
Significant (p<0.05) Spearman's correlation coefficients shown in bold. Methylation of cytosine-guanine dinucleotide (CpG) sites for IL1B ; average methylation of the four sites (CpGavg) Before 
(Pre), and after (Post-EE, Post-EE+3h and Post-EE+48h) Eccentric Exercise (EE). 
Pre-EE Post-EE
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Appendix 5: Fatty acid profile in whole blood (Chapter 4) 
vs. peripheral blood mononuclear cells (Chapter 5) 
The fatty acid profile of whole blood which was measured from dried blood spots in 
Chapter 4 was compared to the fatty acid profile at baseline of the white blood cells. 
The percentage total fatty acids differed for all bar a few fatty acids.  
Table 8-1 Comparison of fatty acid profile in whole blood (from dried blood spots) and 
white blood cells. 
  Whole Blood n = 30 
White Blood Cells 
n = 17 p 
Omega 3 Polyunsaturated Fatty Acids (⍵-3 PUFA)   
18:3ω-3 (ALA, alpha-Linolenic acid) 05.31 ± 1.13 07.04 ± 0.84 < 0.001 
20:5ω-3 (EPA, Eicosapentaenoic acid) 00.47 ± 0.22 00.09 ± 0.05 < 0.001 
22:5ω-3 (DPA, Docosapentaenoic acid) 00.63 ± 0.14 00.43 ± 0.18 < 0.001 
22:6ω-3 (DHA, Docosahexaenoic acid) 01.22 ± 0.47 00.51 ± 0.18 < 0.001 
TOTAL ⍵-3 PUFA 07.63 ± 1.36 08.06 ± 1.08 0.268 
Omega 6 Polyunsaturated Fatty Acids (⍵-6 PUFA)   
18:2ω-6 (LA, Linoleic acid) 13.69 ± 1.62 02.64 ± 0.87 < 0.001 
18:3ω-6 (GLA, "-Linolenic acid) 01.09 ± 0.42 00.61 ± 0.29 < 0.001 
20:2ω-6 (Eicosadienoic acid) 00.79 ± 0.24 00.45 ± 0.21 < 0.001 
20:3ω-6 (DGLA, Dihomo-"-linolenic acid) 06.54 ± 1.49 05.78 ± 2.07 0.155 
20:4ω-6 (AA, Arachidonic acid) 00.43 ± 0.13 00.39 ± 0.15 0.343 
22:4ω-6 (Adrenic Acid) 00.14 ± 0.06 00.15 ± 0.07 0.828 
22:2ω-6 (Docosadienoic acid) 00.10 ± 0.03 00.44 ± 0.15 < 0.001 
TOTAL ⍵-6 PUFA 22.79 ± 2.79 10.45 ± 3.00 < 0.001 
Monounsaturated Fatty Acids (MUFA)   
14:1ω-5 (Myristoleic acid) 14.06 ± 2.42 13.36 ± 5.09 0.601 
16:1ω-7 (Palmitoleic acid) 01.05 ± 0.23 03.43 ± 3.21 0.008 
17:1ω-7 (Cis-10-Heptadecenoic acid) 02.33 ± 0.86 02.24 ± 0.91 0.742 
22:1ω-17 (5Z-docosenoic acid) 00.60 ± 0.12 00.32 ± 0.15 < 0.001 
18:1ω-9 (Oleic acid) 02.87 ± 0.99 08.29 ± 3.16 < 0.001 
18:1ω-9 (9-octadecenoic acid) 00.71 ± 0.36 00.43 ± 0.22 0.002 
TOTAL MUFA 22.00 ± 3.53 28.08 ± 9.97 0.026 
Saturated Fatty Acids (SFA)    
13:0 (Tridecanoic acid) 00.08 ± 0.04 01.38 ± 0.32 < 0.001 
14:0 (Myristic acid) 03.25 ± 1.22 03.83 ± 1.85 0.199 
15:0 (Pentadecanoic acid) 00.95 ± 0.33 02.52 ± 1.18 < 0.001 
16:0 (Palmitic acid) 23.01 ± 2.00 25.77 ± 4.85 0.037 
18:0 (Stearic acid) 19.44 ± 1.36 19.20 ± 3.73 0.801 
20:0 (Arachidic acid) 00.45 ± 0.28 00.44 ± 0.21 0.970 
22:0 (Behenic acid) 00.41 ± 0.13 00.20 ± 0.06 < 0.001 
TOTAL SFA 47.59 ± 2.70 53.41 ± 8.84 0.017 
Fatty Acid Ratios    
MUFA / SFA 00.47 ± 0.09 00.57 ± 0.31 0.188 
PUFA / SFA 00.64 ± 0.09 00.35 ± 0.08 < 0.001 
(MUFA+PUFA) / SFA 01.11 ± 0.12 00.92 ± 0.34 0.043 
ω-3 PUFA / ω-3 PUFA 03.06 ± 0.56 01.28 ± 0.28 < 0.001 
AA / EPA 16.28 ± 7.73 14.95 ± 14.08 0.677 
Data is presented as Percentage Total Fatty Acids (%TFA), mean ± standard deviation. Significant difference 
assessed by t-tests, significant difference if p<0.05. 
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